EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 127

Results Generated From:
Embase <1980 to 2025 Week 19>
Embase Weekly Updates (updates since 2025-05-02)

<1>
Accession Number
2038495809
Title
Diagnosis, management, and outcome of heart failure in congenitally
corrected transposition of the great arteries (ccTGA)-a narrative review.
Source
Cardiovascular Diagnosis and Therapy. 15(2) (pp 500-508), 2025. Date of
Publication: 30 Apr 2025.
Author
Komori M.; Benesch Vidal M.L.; Imai K.; Tominaga Y.; Shibagaki K.;
Kutsuzawa R.; Kawai S.; Hayashi K.; Kurosaki K.; Ohuchi H.; Toda K.; Saiki
Y.; Sinning C.; Iwai S.
Institution
(Komori, Imai, Tominaga, Shibagaki, Kutsuzawa, Kawai, Hayashi, Iwai)
Department of Paediatric Cardiovascular Surgery, National Cerebral and
Cardiovascular Centre, Osaka, Japan
(Benesch Vidal, Sinning) Department of Cardiology, University Heart and
Vascular Centre Hamburg, Hamburg, Germany
(Kurosaki, Ohuchi) Departments of Paediatric Cardiology, National Cerebral
and Cardiovascular Centre, Osaka, Japan
(Toda) Department of Cardiovascular Surgery, Dokkyo Medical University,
Saitama Medical Centre, Saitama, Japan
(Saiki) Department of Cardiovascular Surgery, Tohoku University, Graduate
School of Medicine, Sendai, Japan
Publisher
AME Publishing Company
Abstract
Background and Objective: Congenitally corrected transposition of the
great arteries (ccTGA) remains a rare congenital disorder with a wide
range of manifestations. The management of heart failure (HF) of the
systemic right ventricle (RV), arrhythmias, heart block, and acquired
cardiac conditions require a complex and multi-faceted approach. The
objective of this manuscript is to present the current evidence regarding
diagnostic, treatment, and management strategies for HF in ccTGA,
including ventricular assist device (VAD) therapy and heart
transplantation. <br/>Method(s): A systematic review of the literature was
conducted using PubMed, covering the period between 2010 and 2024. The
search terms included "heart failure", "ccTGA", "VAD", "heart
transplantation", and "systemic RV failure". Two clinical cases were
included for illustrative purposes. Key Content and Findings: HF is a
common occurrence in the context of ccTGA, primarily driven by progressive
pressure and volume overload of the systemic RV, regurgitation of the
systemic atrio-ventricular (AV) valve, and the development of arrhythmias,
including complete heart block and (supra-)ventricular tachycardia. The
use of HF medication is indicated for symptomatic patients, however, data
on the efficacy of standardized HF medication remains limited. Timing of
AV-valve replacement is essential to prevent further progression of HF.
<br/>Conclusion(s): In ccTGA, the timing of surgery and interventional
treatment approaches, the effect of pharmacological treatment in the
context of HF, as well as the timing of initiation of a mechanical
circulatory support, VAD and heart transplantation, are based on
individualised consensus-level decisions. Optimal management remains a
topic of debate due to the scarcity of outcome data. Future investigations
should focus on identifying surrogate parameters for guiding
treatment.<br/>Copyright &#xa9; AME Publishing Company.

<2>
Accession Number
2038270805
Title
Left Main Spontaneous Coronary Artery Dissection: Clinical Features,
Management, and Outcomes.
Source
JACC: Cardiovascular Interventions. 18(8) (pp 975-983), 2025. Date of
Publication: 28 Apr 2025.
Author
Morosato M.; Gaspardone C.; Romagnolo D.; Pagnesi M.; Baldetti L.; Dormio
S.; Federico F.; Scandroglio A.M.; Chieffo A.; Godino C.; Margonato A.;
Adamo M.; Metra M.; Tchetche D.; Dumonteil N.; Tweet M.S.; Saw J.;
Beneduce A.
Institution
(Morosato, Dormio, Federico, Chieffo, Margonato) Vita-Salute San Raffaele
University, Milan, Italy
(Gaspardone, Godino, Margonato) Cardiology Unit, IRCCS San Raffaele
Scientific Institute, Milan, Italy
(Romagnolo) Cardiac Intensive Care Unit, IRCCS Humanitas Research
Hospital, Rozzano, Italy
(Pagnesi, Adamo, Metra) ASST Spedali Civili di Brescia and Department of
Medical and Surgical Specialties, Radiological Sciences, and Public
Health, University of Brescia, Brescia, Italy
(Baldetti, Scandroglio) Cardiac Intensive Care Unit, IRCCS San Raffaele
Scientific Institute, Milan, Italy
(Chieffo) Interventional Cardiology Unit, IRCCS San Raffaele Scientific
Institute, Milan, Italy
(Tchetche, Dumonteil, Beneduce) Groupe Cardio-Vasculaire lnterventionnel,
Cinique Pasteur, Toulouse, France
(Tweet) Department of Cardiovascular Diseases, Mayo Clinic College of
Medicine, Rochester, MN, United States
(Saw) Division of Cardiology, Vancouver General Hospital, Vancouver, BC,
Canada
(Beneduce) Heart Valve Center, IRCCS San Raffaele Scientific Institute,
Milan, Italy
Publisher
Elsevier Inc.
Abstract
Background: Spontaneous coronary artery dissection (SCAD) is an uncommon
cause of acute myocardial infarction (MI) and is associated with
substantial adverse events. SCAD involving the left main coronary artery
(LM) is a rare but potentially life-threatening condition. Currently,
minimal data on LM SCAD have been reported. <br/>Objective(s): The aim of
this study was to investigate clinical features, contemporary management,
and clinical outcomes of patients with LM SCAD. <br/>Method(s): A
systematic review and pooled analysis of published case reports was
conducted using "left main" and "dissection" as keywords. The authors
screened 1,106 papers in MEDLINE and Embase published between 1990 and
2023. <br/>Result(s): The final analysis included 132 patients (mean age
40 +/- 11 years, 80% women) diagnosed with LM SCAD. Remarkably, 36% of
cases occurred during pregnancy, and 95% presented with acute coronary
syndrome, 22% with cardiogenic shock, and 8% with ventricular arrhythmias.
At 120-day median follow-up, all-cause death occurred in 9%, left
ventricular assist device implantation or heart transplantation in 4%,
recurrent MI in 13%, and urgent myocardial revascularization (MR) in 21%.
Compared with conservative management, early revascularization by
percutaneous coronary intervention or coronary artery bypass grafting
significantly reduced the composite endpoint of all-cause death, left
ventricular assist device implantation or heart transplantation, recurrent
MI, and urgent MR (adjusted HR: 0.37; 95% CI: 0.20-0.69; P < 0.001).
<br/>Conclusion(s): LM SCAD carried significant acute morbidity and
mortality. Early revascularization (percutaneous coronary intervention or
coronary artery bypass graft) was associated with a lower incidence of
early adverse outcomes compared with conservative management, driven
largely by reduction in recurrent MI and urgent MR. These
hypothesis-generating data should be confirmed in future prospective
registries and clinical trials.<br/>Copyright &#xa9; 2025 American College
of Cardiology Foundation

<3>
Accession Number
2038501831
Title
Health Care Resource Utilization for Patients With Suspected Myocardial
Infarction A Secondary Analysis of the RACE-IT Randomized Clinical Trial.
Source
JAMA Network Open. 8(4) (no pagination), 2025. Article Number: e256930.
Date of Publication: 25 Apr 2025.
Author
Miller J.; Cook B.; Gunaga S.; Fadel R.; Gandolfo C.; Emakhu J.; Mills
N.L.; Mahler S.; Levy P.; Parikh S.; Krupp S.; Hawatian K.; Nour K.;
Klausner H.; Gindi R.; Hudson M.; Perrotta G.; Zweig B.; Lanfear D.; Kim
H.; Danagoulian S.; Keerie C.; Nassereddine H.; Morton T.; Affas Z.;
Husain A.; McCord J.
Institution
(Miller, Gunaga, Emakhu, Krupp, Hawatian, Klausner, Perrotta, Morton,
Husain) Department of Emergency Medicine, Henry Ford Health + Michigan
State University Health Sciences, Detroit, United States
(Cook) Department of Pathology, Henry Ford Health + Michigan State
University Health Sciences, Detroit, United States
(Fadel, Gandolfo, Parikh, Nour, Gindi, Hudson, Zweig, Lanfear, Kim,
McCord) Heart and Vascular Institute, Henry Ford Health + Michigan State
University Health Sciences, Detroit, United States
(Mills) British Heart Foundation Center for Cardiovascular Science, The
University of Edinburgh, Edinburgh, United Kingdom
(Mahler) Department of Emergency Medicine, Wake Forest University School
of Medicine, Winston-Salem, NC, United States
(Levy) Department of Emergency Medicine, Wayne State University, Detroit,
MI, United States
(Danagoulian) College of Liberal Arts and Sciences, Wayne State
University, Detroit, MI, United States
(Keerie) College of Medicine and Veterinary Medicine, The University of
Edinburgh, Edinburgh, United Kingdom
(Nassereddine) Department of Emergency Medicine, Corewell Health Beaumont
Hospital, Royal Oak, MI, United States
(Affas) Department of Cardiology, Ascension Providence, Southfield, MI,
United States
Publisher
American Medical Association
Abstract
IMPORTANCE Evaluation for myocardial infarction (MI) in emergency
departments (EDs) is a common, resource-intensive process.
High-sensitivity cardiac troponin I (hs-cTnI) assays have become a key
tool in rapidly ruling out MI, with the potential to reduce health care
resource utilization. OBJECTIVE To determine whether a 0-hour and 1-hour
(hereafter referred to as 0/1-hour) hs-cTnI accelerated protocol reduces
health care resource utilization compared with a traditional 0/3-hour
standard care protocol for MI exclusion in the ED. DESIGN, SETTING, AND
PARTICIPANTS This is a prespecified secondary analysis of the RACE-IT
trial, a stepped-wedge randomized clinical implementation trial conducted
across 9 EDs in Michigan. The trial enrolled 32 608 consecutive ED
patients evaluated for suspected MI between July 8, 2020, and April 3,
2021. Statistical analysis was conducted from July 10 to September 5,
2024. INTERVENTIONS The 0/1-hour hs-cTnI accelerated protocol for MI
exclusion was compared with the traditional 0/3-hour standard care
protocol. MAIN OUTCOMES AND MEASURES Main outcomes were ED discharge to
home, ED length of stay, rates of cardiac stress testing, cardiology
consultation, left heart catheterization, and cardiac revascularization
within 30 days. RESULTS A total of 32 608 patients (median age, 59 years
[IQR, 45-71 years]; 18 705 women [57.4%]) were included in the analysis.
The rate of ED discharge to home was 58.0% for the accelerated protocol
group (11 082 of 19 103) and 59.8% for the standard care group (8070 of 13
505) (adjusted odds ratio [AOR], 1.05; 95% CI, 0.95-1.15). The accelerated
protocol group showed significant reductions in the odds of cardiac stress
testing (3.3% [623 of 19 103] vs 3.9% [526 of 13 505]; AOR, 0.62; 95% CI,
0.49-0.78), cardiology consultations (8.6% [1640 of 19 103] vs 12.2% [1651
of 13 505]; AOR, 0.57; 95% CI, 0.49-0.67), and left heart catheterization
rates (1.0% [198 of 19 103] vs 1.2% [167 of 13 505]; AOR, 0.65; 95% CI,
0.43-0.99) compared with the standard protocol group. The median ED length
of stay decreased by 20 minutes (IQR, 18-24 minutes) in the accelerated
protocol group, with no significant change in revascularization rates.
CONCLUSIONS AND RELEVANCE This secondary analysis of a randomized clinical
trial of a 0/1-hour hs-cTnI protocol to rule out MI in the ED found that
there was a reduction in cardiac evaluations and ED length of stay without
increasing revascularization rates compared with the standard 0/3-hour
hs-cTnI protocol. This approach could optimize health care resources in
EDs.<br/>Copyright &#xa9; 2025 Miller J et al.

<4>
Accession Number
2034293615
Title
Imaging based risk factors for heart failure death in childhood dilated
cardiomyopathy: a systematic review and meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 12 (no pagination), 2025. Article
Number: 1568494. Date of Publication: 2025.
Author
Street-de Palma C.; Lim Z.; Field E.; Kaski J.P.; Norrish G.
Institution
(Street-de Palma, Lim, Field, Kaski, Norrish) Centre for Paediatric
Inherited & Rare Cardiovascular Disease, Institute of Cardiovascular
Science, London, United Kingdom
(Lim, Field, Kaski, Norrish) Centre for Inherited Cardiovascular Diseases,
Great Ormond Street Hospital, London, United Kingdom
Publisher
Frontiers Media SA
Abstract
Background and aim: Dilated cardiomyopathy (DCM) is the most common heart
muscle disease presenting in childhood and is associated with an increased
risk of heart failure related death. In adult cohorts, imaging
characteristics such as increased left ventricular dimensions or the
presence of fibrosis on cardiac magnetic resonance imaging (MRI) have been
shown to be associated with adverse outcomes. In contrast, the prognostic
relevance of imaging characteristics in childhood cohorts remains unclear
and predicting disease progression is challenging. The aim of this study
was to perform a systematic literature review and meta-analysis of imaging
characteristics associated with adverse outcomes in childhood DCM.
<br/>Method(s): PubMed, Embase, and Scopus databases were searched for
original articles published in English from 1946 to July 2024 that
included patients under 21 years with a confirmed diagnosis of DCM and
primary or secondary end-points of heart failure death or equivalent event
(heart transplantation or ventricular assist device implantation). Studies
were excluded if imaging characteristics were not described.
<br/>Result(s): Thirteen studies (1,348 patients) met the inclusion
criteria. All but one study was retrospective and only one had a patient
cohort of more than 100 patients. We identified four imaging risk factors
that were evaluated in at least four studies and significantly associated
with a heart failure end point in at least two; left ventricular
end-diastolic diameter Z score (LVEDD) [pooled hazard ratio [HR] 1.43, 95%
confidence interval [CI] 1.13-1.81, p = 0.003], left ventricular ejection
fraction (LVEF) (pooled HR 0.8, 95% CI: 0.65-0.99, p = 0.04), LV
fractional shortening (LVFS) and severe mitral regurgitation (MR) [pooled
odds ratio (OR) 5.12, 95% CI: 1.18-22.19, p = 0.004]. Two small studies
investigated the role of fibrosis on CMRI and did not report an
association with adverse outcomes. <br/>Conclusion(s): A systematic review
and meta-analysis of imaging risk factors predicting heart failure adverse
events in childhood DCM was performed identifying three "major" risk
factors; higher LVEDD, lower LVEF or LVFS and severe MR. The findings
highlight a significant need for well-designed multicentre studies to
investigate the role of imaging characteristics in predicting outcome in
the paediatric population.<br/>Copyright 2025 Street-de Palma, Lim, Field,
Kaski and Norrish.

<5>
Accession Number
2036442734
Title
The novel balloon-expandable Myval transcatheter heart valve: systematic
review of aortic, mitral, tricuspid and pulmonary indications.
Source
Revista Espanola de Cardiologia. 78(5) (pp 447-464), 2025. Date of
Publication: 01 May 2025.
Author
Garcia-Gomez M.; Fernandez-Cordon C.; Gonzalez-Gutierrez J.C.; Serrador
A.; Campo A.; Cortes Villar C.; Blasco Turrion S.; Aristizabal C.; Peral
Oliveira J.; Stepanenko A.; Gonzalez Arribas M.; Scorpiglione L.; Jain A.;
Carnicero Martinez D.; San Roman J.A.; Amat-Santos I.J.
Institution
(Garcia-Gomez, Fernandez-Cordon, Gonzalez-Gutierrez, Serrador, Campo,
Cortes Villar, Blasco Turrion, Aristizabal, Peral Oliveira, Stepanenko,
Gonzalez Arribas, Scorpiglione, Jain, Carnicero Martinez, San Roman,
Amat-Santos) Instituto de Ciencias del Corazon (ICICOR), Hospital Clinico
Universitario, Valladolid, Spain
(San Roman, Amat-Santos) Centro de Investigacion Biomedica en Red de
Enfermedades Cardiovasculares (CIBERCV), Spain
Publisher
Ediciones Doyma, S.L.
Abstract
Introduction and objectives: Myval technology represents the first
balloon-expandable alternative since the Edwards system became
commercially available. Despite certain controversies, its use has rapidly
expanded. We aimed to gather all the available literature regarding its
indications and outcomes. <br/>Method(s): A comprehensive search of
articles published between December 2016 and May 2024 was conducted using
BioMedCentral, Google Scholar, and PubMed to evaluate the main outcomes of
Myval for native aortic stenosis (AS) (meta-analysis) and off-label uses
(systematic review). <br/>Result(s): A total of 151 studies were
identified, and 74 were included in the analysis, covering aortic (n =
51), mitral (n = 9), tricuspid (n = 6), and pulmonary (n = 8) valve
positions. A meta-analysis of studies on native AS demonstrated that Myval
is safe and effective, with a 30-day mortality rate of 1.3%, good
hemodynamic performance, low rates of pacemaker implantation (8.8%), and
>= moderate paravalvular regurgitation (1.3%). Compared with other
contemporary devices, Myval was competitive and associated with lower
rates of pacemaker implantation. In a systematic review of off-label
indications, Myval was also found to be safe and effective. In bicuspid
AS, pure regurgitation, and aortic valve-in-valve procedures, success
rates were 100%, 92%, and 100%, respectively, with pacemaker rates of
9.9%, 22.2%, and 3%, respectively. For mitral valve-in-valve/in-ring
procedures, the success rate was 96.9%, while in tricuspid and pulmonary
positions, small case series reported 100% success rates for both, with
minimal procedural complications. <br/>Conclusion(s): Myval technology is
safe and effective for the treatment of native valvular disease and
dysfunctional prostheses or rings in all heart valve positions, although
larger scale studies are warranted.<br/>Copyright &#xa9; 2024 Sociedad
Espanola de Cardiologia

<6>
Accession Number
2024855915
Title
Targeted ablation of epicardial ganglionated plexi during cardiac surgery
with pulsed field electroporation (NEURAL AF).
Source
Journal of Interventional Cardiac Electrophysiology. 68(2) (pp 467-474),
2025. Date of Publication: 01 Mar 2025.
Author
Musikantow D.R.; Reddy V.Y.; Skalsky I.; Shaburishvili T.; van Zyl M.;
O'Brien B.; Coffey K.; Reilly J.; Neuzil P.; Asirvatham S.; de Groot J.R.
Institution
(Musikantow, Reddy) Helmsley Electrophysiology Center, Icahn School of
Medicine at Mount Sinai, Box 1030, One Gustave L. Levy Place, New York,
NY, United States
(Reddy, Skalsky, Neuzil) Homolka Hospital, Prague, Czechia
(Shaburishvili) Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia
(van Zyl) Royal Jubilee Hospital, Victoria, BC, Canada
(O'Brien, Coffey, Reilly) AtriAN Medical, Galway, Ireland
(Asirvatham) Mayo Clinic, Rochester, MN, United States
(de Groot) University Medical Center, Amsterdam, Netherlands
Publisher
Springer
Abstract
Background: Modulation of the cardiac autonomic nervous system (ANS) is a
promising adjuvant therapy in the treatment of atrial fibrillation (AF).
In pre-clinical models, pulsed field (PF) energy has the advantage of
selectively ablating the epicardial ganglionated plexi (GP) that govern
the ANS. This study aims to demonstrate the feasibility and safety of
epicardial ablation of the GPs with PF during cardiac surgery with a
primary efficacy outcome of prolongation of the atrial effective
refractory period (AERP). <br/>Method(s): In a single-arm, prospective
analysis, patients with or without a history of AF underwent epicardial GP
ablation with PF during coronary artery bypass grafting (CABG). AERP was
determined immediately pre- and post- GP ablation to assess cardiac ANS
function. Holter monitors were performed to determine rhythm status and
heart rate variability (HRV) at baseline and at 1-month post-procedure.
<br/>Result(s): Of 24 patients, 23 (96%) received the full ablation
protocol. No device-related adverse effects were noted. GP ablation
resulted in a 20.7 +/- 19.9% extension in AERP (P < 0.001). Post-operative
AF was observed in 7 (29%) patients. Holter monitoring demonstrated an
increase in mean heart rate (74.0 +/- 8.7 vs. 80.6 +/- 12.3, P = 0.01).
There were no significant changes in HRV. There were no study-related
complications. <br/>Conclusion(s): This study demonstrates the safety and
feasibility of epicardial ablation of the GP using PF to modulate the ANS
during cardiac surgery. Large, randomized analyses are necessary to
determine whether epicardial PF ablation can offer a meaningful impact on
the cardiac ANS and reduce AF. Trial registration: Clinical trial
registration: NCT04775264.<br/>Copyright &#xa9; The Author(s) 2023.

<7>
Accession Number
2038353992
Title
A Prospective double-blind, randomised controlled trial comparing
angiotensin II to norepinephrine to reduce length of hospital stay in
cardiac surgery patients (the PORTHOS study protocol).
Source
BMJ Open. 15(4) (no pagination), 2025. Article Number: e095099. Date of
Publication: 15 Apr 2025.
Author
Coulson T.G.; Paul E.; Miles L.F.; Pilcher D.; Marasco S.F.; Frei D.;
Bellomo R.
Institution
(Coulson) Department of Anaesthesiology and Perioperative Medicine, Alfred
Health, Melbourne, VIC, Australia
(Coulson) Department of Anaesthesiology and Perioperative Medicine, Monash
University, Melbourne, VIC, Australia
(Coulson, Miles) Centre for Integrated Critical Care, The University of
Melbourne Faculty of Medicine Dentistry and Health Sciences, Melbourne,
VIC, Australia
(Paul, Pilcher) Australian and New Zealand Intensive Care Research Centre,
Monash University, Melbourne, VIC, Australia
(Miles) Department of Anaesthesia and Pain Medicine, Austin Health,
Heidelberg, VIC, Australia
(Pilcher) Alfred Health, Melbourne, VIC, Australia
(Marasco) Department of Cardiothoracic Surgery, Alfred Health, Melbourne,
VIC, Australia
(Frei) Wellington Regional Hospital, Wellington, Newtown, New Zealand
(Frei) Medical Research Institute of New Zealand, Wellington, New Zealand
(Frei) University of Otago, Dunedin, New Zealand
(Bellomo) Department of Critical Care, University of Melbourne, Melbourne,
VIC, Australia
(Bellomo) Department of Intensive Care, Royal Melbourne Hospital,
Melbourne, VIC, Australia
(Bellomo) Department of Intensive Care, Austin Hospital, Heidelberg, VIC,
Australia
Publisher
BMJ Publishing Group
Abstract
Introduction Cardiac surgery is frequently associated with vasoplegia and
vasopressor treatment. Both may be associated with postoperative
complications and prolonged length of stay. The most frequently used
vasopressor is norepinephrine. However, in a pilot, double-blind,
randomised controlled trial (RCT) in cardiac surgery patients, angiotensin
II was effective in maintaining blood pressure and was associated with a
shorter duration of hospital stay than norepinephrine. Furthermore,
hyperreninaemic patients were more sensitive to angiotensin II. These
findings support the need for a larger RCT to determine whether
angiotensin II is superior to norepinephrine as a first-line treatment for
low blood pressure after cardiac surgery. Methods and analysis We will
conduct a double-blind RCT comparing an infusion of either angiotensin II
or norepinephrine intraoperatively and for up to 48 hours after the start
of surgery. We will randomly allocate 400 cardiac surgery patients at
multiple centres in two countries to either an equipotent angiotensin II
or norepinephrine infusion, titrated to a mean arterial pressure of 70-80
mm Hg. The primary outcome will be length of hospital stay. Secondary
outcomes will include a composite of renal, cardiovascular and
neurological events. A subgroup analysis of patients with elevated
baseline renin levels will be undertaken. Ethics and dissemination Ethical
approval has been granted by the Alfred Human Research Ethics Committee on
14 July 2023 (HREC/97814/Alfred-2023). Results will be published on
completion of the trial.<br/>Copyright &#xa9; Author(s) (or their
employer(s)) 2025.

<8>
Accession Number
2034313080
Title
Pericardiectomy with routine cardiopulmonary bypass: a multicenter,
randomized controlled trial.
Source
Trials. 26(1) (no pagination), 2025. Article Number: 138. Date of
Publication: 01 Dec 2025.
Author
Huang J.-B.; Lu C.-C.; Wen Z.-K.
Institution
(Huang, Lu, Wen) Department of Cardiothoracic Surgery, Guangxi Academy of
Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous
Region, 6 Taoyuan Road, Guangxi, Nanning, China
Publisher
BioMed Central Ltd
Abstract
Constrictive pericarditis is a result of chronic inflammation
characterized by thickening and calcification of pericardial fibers,
impaired diastolic filling, reduced cardiac output, and ultimately heart
failure. The main objective of this multicenter trial is to evaluate
whether conventional extracorporeal circulation pericardial resection has
a better prognosis than pericardial resection without extracorporeal
circulation. This study is a multicenter, randomized controlled, evaluator
blinded, parallel group study with an advantageous framework. A total of
436 participants with constrictive pericarditis will be randomly assigned
to either the extracorporeal circulation pericardial resection group or
the non-extracorporeal circulation pericardial clearance group in a 1:1
ratio using a computer. Incomplete pericardial detachment is associated
with low cardiac output syndrome after pericardial resection. The causes
of low cardiac output syndrome are related to incomplete resection of
thickened pericardium, unsatisfactory relief of left ventricular
compression, excessive ventricular dilation after pericardial dissection,
myocardial weakness, and heart failure. The relief of left ventricular
compression is crucial for the postoperative recovery of cardiac
function.<br/>Copyright &#xa9; The Author(s) 2025.

<9>
Accession Number
2038472487
Title
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of
Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in
Patients With CVD and Elevated Lp(a).
Source
American Heart Journal. 287 (pp 1-9), 2025. Date of Publication: 01 Sep
2025.
Author
Cho L.; Nicholls S.J.; Nordestgaard B.G.; Landmesser U.; Tsimikas S.;
Blaha M.J.; Leitersdorf E.; Lincoff A.M.; Lesogor A.; Manning B.;
Kozlovski P.; Cao H.; Wang J.; Nissen S.E.
Institution
(Cho, Lincoff, Nissen) Cleveland Clinic Heart Vascular Thoracic Institute,
Cleveland, OH, United States
(Nicholls) Monash University Victoria Heart Institute, Melbourne,
Australia
(Nordestgaard) University of Copenhagen, Copenhagen, Denmark
(Landmesser) Deutsches Herzzentrum Charite, Berlin, Germany
(Tsimikas) University of California San Diego, La Jolla, CA, United States
(Blaha) Johns Hopkins University, Baltimore, MD, United States
(Leitersdorf) Haddassah Hebrew University, Jerusalem, Israel
(Lesogor, Kozlovski) Novartis Pharmaceutical Corp, Basel, Switzerland
(Manning, Cao, Wang) Novartis Pharmaceutical Corp, East Hanover, NJ,
United States
Publisher
Elsevier Inc.
Abstract
Background: Lipoprotein(a), abbreviated Lp(a), consists of apolipoprotein
B-100 covalently bound to apolipoprotein(a), and represents an
independent, genetically-determined, causal risk factor for
atherosclerotic cardiovascular disease (CVD) and calcific aortic stenosis.
More than 20% of the world CVD population has elevated Lp(a). Currently
there are no approved pharmacologic treatments to lower Lp(a) levels, and
no randomized trials have demonstrated that lowering Lp(a) reduces CVD
risk. <br/>Study Design: Lp(a) HORIZON is a phase 3, randomized,
placebo-controlled, double-blind, parallel-group, multinational trial in
8,323 patients with established CVD and elevated Lp(a) levels of >=70
mg/dL (approximately 149 nmol/L), testing the effect of pelacarsen, an
antisense oligonucleotide (ASO) on the incidence of major adverse
cardiovascular events (MACE). Established CVD is defined as history of
myocardial infarction (MI), ischemic stroke or symptomatic peripheral
artery disease. The minimum follow-up is required to be 2.5 years. The
study will end when 993 CEC confirmed primary CV events have accumulated.
Based on the current event accrual trend, the overal study duration is
anticipated to be approximately 6 years. Patients were randomized in a 1:1
ratio to receive either monthly subcutaneous (SQ) injections of pelacarsen
80 mg or matching placebo on a background of optimized standard of care
therapy for CVD. The primary endpoint is a composite of cardiovascular
death, nonfatal MI, nonfatal stroke, or urgent coronary revascularization
requiring hospitalization. This endpoint will be evaluated in the overall
population and in a subpopulation of Lp(a) >=90 mg/dL (approximately 192
nmol/L) at screening, with multiplicity control designed to test the
primary endpoint in both the overall population and the subpopulation.
<br/>Conclusion(s): Lp(a) HORIZON will determine the effect of pelacarsen
on cardiovascular morbidity and mortality in patients with elevated Lp(a)
and established CVD. Trial Registration: NCT 04023552.<br/>Copyright
&#xa9; 2025 The Author(s)

<10>
Accession Number
2032206244
Title
Chlorthalidone vs Hydrochlorothiazide for Hypertension Treatment After
Myocardial Infarction or Stroke A Secondary Analysis of a Randomized
Clinical Trial.
Source
JAMA Network Open. 7(5) (no pagination), 2024. Article Number: e2411081.
Date of Publication: 14 May 2024.
Author
Ishani A.; Hau C.; Cushman W.C.; Leatherman S.M.; Lew R.A.; Glassman P.A.;
Taylor A.A.; Ferguson R.E.
Institution
(Ishani) Minneapolis VA Healthcare System, Minneapolis, MN, United States
(Ishani) Department of Medicine, University of Minnesota, Minneapolis,
United States
(Hau, Leatherman, Lew, Ferguson) Cooperative Studies Program Coordinating
Center, VA Boston Healthcare System, Boston, MA, United States
(Cushman) Medical Service, Memphis VA Medical Center, Memphis, TN, United
States
(Cushman) Department of Preventive Medicine, University of Tennessee
Health Science Center, Memphis, United States
(Leatherman, Lew) Department of Biostatistics, Boston University School of
Public Health, Boston, MA, United States
(Glassman) Pharmacy Benefits Management Services, Department of Veterans
Affairs, Washington, DC, United States
(Glassman) VA Greater Los Angeles Healthcare System, Los Angeles, CA,
United States
(Glassman) David Geffen School of Medicine, UCLA, Los Angeles, CA, United
States
(Taylor) Michael E. DeBakey VA Medical Center, Houston, TX, United States
(Taylor) Department of Medicine, Baylor College of Medicine, Houston, TX,
United States
(Ferguson) Department of Medicine, Boston University Chobanian & Avedisian
School of Medicine, Boston, MA, United States
Publisher
American Medical Association
Abstract
IMPORTANCE Patients with prior myocardial infarction (MI) or stroke have a
greater risk of recurrent cardiovascular (CV) events. OBJECTIVE To
evaluate the association of chlorthalidone (CTD) vs hydrochlorothiazide
(HCTZ) with CV outcomes and noncancer deaths in participants with and
without prior MI or stroke. DESIGN, SETTING, AND PARTICIPANTS This was a
prespecified secondary analysis of the Diuretic Comparison Project (DCP),
a pragmatic randomized clinical trial conducted within 72 participating
Veterans Affairs health care systems from June 2016 to June 2021, in which
patients aged 65 years or older with hypertension taking HCTZ at baseline
were randomized to continue HCTZ or switch to CTD at pharmacologically
comparable doses. This secondary analysis was performed from January 3,
2023, to February 29, 2024. EXPOSURES Pharmacologically comparable daily
dose of HCTZ or CTD and history of MI or stroke. MAIN OUTCOMES AND
MEASURES Outcome ascertainment was performed from randomization to the end
of the study. The primary outcome consisted of a composite of stroke, MI,
urgent coronary revascularization because of unstable angina, acute heart
failure hospitalization, or noncancer death. Additional outcomes included
achieved blood pressure and hypokalemia (potassium level <3.1 mEq/L; to
convert to mmol/L, multiply by 1.0). RESULTS The DCP randomized 13 523
participants to CTD or HCTZ, with a mean (SD) study duration of 2.4 (1.4)
years. At baseline, median age was 72 years (IQR, 69-75 years), and 96.8%
were male. Treatment effect was evaluated in subgroups of participants
with (n = 1455) and without (n = 12 068) prior MI or stroke at baseline.
There was a significant adjusted interaction between treatment group and
history of MI or stroke. Participants with prior MI or stroke randomized
to CTD had a lower risk of the primary outcome than those receiving HCTZ
(105 of 733 [14.3%] vs 140 of 722 [19.4%]; hazard ratio [HR], 0.73; 95%
CI, 0.57-0.94; P =.01) compared with participants without prior MI or
stroke, among whom incidence of the primary outcome was slightly higher in
the CTD arm compared with the HCTZ arm (597 of 6023 [9.9%] vs 535 of 6045
[8.9%]; HR, 1.12; 95% CI, 1.00-1.26; P =.054) (P =.01 for interaction).
The incidence of a nadir potassium level less than 3.1 mEq/L and
hospitalization for hypokalemia differed among those with and without
prior MI or stroke when comparing those randomized to CTD vs HCTZ, with a
difference only among those without prior MI or stroke (potassium level
<3.1 mEq/L: prior MI or stroke, 43 of 733 [5.9%] vs 37 of 722 [5.1%] [P
=.57]; no prior MI or stroke, 292 of 6023 [4.9%] vs 206 of 6045 [3.4%] [P
<.001]; hospitalization for hypokalemia: prior MI or stroke, 14 of 733
[1.9%] vs 16 of 722 [2.2%] [P =.72]; no prior MI or stroke: 84 of 6023
[1.4%] vs 57 of 6045 [0.9%] [P =.02]). CONCLUSIONS AND RELEVANCE Results
of this secondary analysis of the DCP trial suggest that CTD may be
associated with reduced major adverse CV events and noncancer deaths in
patients with prior MI or stroke compared with HCTZ.<br/>Copyright &#xa9;
2024 American Medical Association. All rights reserved.

<11>
Accession Number
2005551875
Title
Outcomes of mechanical circulatory support for giant cell myocarditis: A
systematic review.
Source
Journal of Clinical Medicine. 9(12) (no pagination), 2020. Article Number:
3905. Date of Publication: 01 Dec 2020.
Author
Patel P.M.; Saxena A.; Wood C.T.; O'malley T.J.; Maynes E.J.; Entwistle
J.W.C.; Massey H.T.; Pirlamarla P.R.; Alvarez R.J.; Cooper L.T.; Eduardo
Rame J.; Tchantchaleishvili V.
Institution
(Patel, Saxena, Wood) Sidney Kimmel Medical College, Thomas Jefferson
University, Philadelphia, PA, United States
(O'malley, Maynes, Entwistle, Massey, Eduardo Rame, Tchantchaleishvili)
Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson
University, Philadelphia, PA, United States
(Pirlamarla, Alvarez) Division of Cardiology, Department of Medicine,
Thomas Jefferson University, Philadelphia, PA, United States
(Cooper) Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville,
FL, United States
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Treatment of giant cell myocarditis (GCM) can require bridging to
orthotopic heart transplantation (OHT) or recovery with mechanical
circulatory support (MCS). Since the roles of MCS and immunotherapy are
not well-defined in GCM, we sought to analyze outcomes of patients with
GCM who required MCS. A systematic search was performed in June 2019 to
identify all studies of biopsy-proven GCM requiring MCS after 2009. We
identified 27 studies with 43 patients. Patient-level data were extracted
for analysis. Median patient age was 45 (interquartile range (IQR): 32-57)
years. 42.1% (16/38) were female. 34.9% (15/43) presented in acute heart
failure. 20.9% (9/43) presented in cardiogenic shock. Biventricular
(BiVAD) MCS was required in 76.7% (33/43) of cases. Of the 62.8% (27/43)
of patients who received immunotherapy, 81.5% (22/27) used steroids
combined with at least one other immunosuppressant. Cyclosporine was the
most common non-steroidal agent, used in 40.7% (11/27) of regimens.
Immunosuppression was initiated before MCS in 59.3% (16/27) of cases,
after MCS in 29.6% (8/27), and not specified in 11.1% (3/27).
Immunosuppression started prior to MCS was associated with significantly
better survival than MCS alone (p = 0.006); 60.5% (26/43) of patients
received bridge-to-transplant MCS; 39.5% (17/43) received
bridge-to-recovery MCS; 58.5% (24/41) underwent OHT a median of 104
(58-255) days from diagnosis. GCM recurrence after OHT was reported in
8.3% (2/24) of transplanted cases. BiVAD predominates in mechanically
supported patients with GCM. Survival and bridge to recovery appear better
in patients on immunosuppression, especially if initiated before
MCS.<br/>Copyright &#xa9; 2020 by the authors. Licensee MDPI, Basel,
Switzerland.

<12>
Accession Number
2005551743
Title
The pharmacological approach to oncologic patients with acute coronary
syndrome.
Source
Journal of Clinical Medicine. 9(12) (no pagination), 2020. Article Number:
3926. Date of Publication: 01 Dec 2020.
Author
Radmilovic J.; Di Vilio A.; D'andrea A.; Pastore F.; Forni A.; Desiderio
A.; Ragni M.; Quaranta G.; Cimmino G.; Russo V.; Scherillo M.; Golino P.
Institution
(Radmilovic, Di Vilio, D'andrea, Pastore, Forni, Desiderio, Ragni,
Quaranta) Unit of Cardiology and Intensive Coronary Care, "Umberto I"
Hospital, Nocera Inferiore, Italy
(Di Vilio, D'andrea, Cimmino, Russo, Golino) Unit of Cardiology,
Department of Translational Medical Sciences, University of Campania
"Luigi Vanvitelli", Monaldi Hospital, Naples, Italy
(Scherillo) Unit of Cardiology and Intensive Coronary Care, "San Pio"
Hospital, Benevento, Italy
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Among acute coronary syndrome (ACS) patients, 15% have concomitant cancer,
especially in the first 6 months after their diagnosis, as well as in
advanced metastatic stages. Lung, gastric, and pancreatic cancers are the
most frequent malignancies associated with ACS. Chemotherapy and
radiotherapy exert prothrombotic, vasospastic, and proinflammatory
actions. The management of cancer patients with ACS is quite challenging:
percutaneous revascularization is often underused, and antiplatelet and
anticoagulant pharmacological therapy should be individually tailored to
the thrombotic risk and to the bleeding complications. Sometimes
oncological patients also show different degrees of thrombocytopenia,
which further complicates the pharmacological strategies. The aim of this
review is to summarize the current evidence regarding the treatment of ACS
in cancer patients and to suggest the optimal management and therapy to
reduce the risk of adverse coronary events after ACS in this high-risk
population.<br/>Copyright &#xa9; 2020 by the authors. Licensee MDPI,
Basel, Switzerland.

<13>
Accession Number
2005631348
Title
Effect of obstructive sleep apnea and CPAP treatment on cardiovascular
outcomes in acute coronary syndrome in the RICCADSA trial.
Source
Journal of Clinical Medicine. 9(12) (no pagination), 2020. Article Number:
4051. Date of Publication: 01 Dec 2020.
Author
Peker Y.; Thunstrom E.; Glantz H.; Eulenburg C.
Institution
(Peker) Department of Pulmonary Medicine, Koc University School of
Medicine, Istanbul, Turkey
(Peker, Thunstrom) Department of Molecular and Clinical Medicine,
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
(Peker) Department of Clinical Sciences, Respiratory Medicine and
Allergology, Faculty of Medicine, Lund University, Lund, Sweden
(Peker) Division of Pulmonary, Allergy, and Critical Care Medicine,
University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
(Thunstrom) Department of Cardiology, Sahlgrenska University
Hospital/Ostra, Gothenburg, Sweden
(Glantz) Department of Internal Medicine, Skaraborg Hospital, Lidkoping,
Sweden
(Eulenburg) Department for Epidemiology, University of Groningen,
Groningen, Netherlands
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
We aimed to address the impact of OSA and its treatment with continuous
positive airway pressure (CPAP) on major adverse cardiovascular and
cerebrovascular events (MACCE) in patients with acute coronary syndrome
(ACS). In this current analysis of the revascularized ACS subgroup (n =
353) of the Randomized Intervention with CPAP in Coronary Artery Disease
and Obstructive Sleep Apnea (RICCADSA) trial (Trial Registry:
ClinicalTrials.gov; No: NCT 00519597), participants with non-sleepy OSA
(apnea-hypopnea-index [AHI] >= 15 events/h on a home sleep apnea testing,
and Epworth Sleepiness Scale [ESS] score < 10; n = 171) were randomized to
CPAP (n = 86) or no-CPAP (n = 85). The sleepy OSA patients (AHI >= 15
events/h and ESS >= 10) who were offered CPAP, and the ones with no-OSA
(AHI < 5 events/h) were included in the observational arm. A post-hoc
analysis was done to compare untreated OSA (no-CPAP; n = 78) and
nonadherent sleepy/non-sleepy OSA (n = 96) with the reference group
without OSA (n = 81). The primary endpoint (the first event of repeat
revascularization, myocardial infarction, stroke or cardiovascular
mortality) during a median 4.7-year follow-up was evaluated in
time-dependent Cox proportional hazards models adjusted for confounding
factors. The incidence of MACCE did not differ significantly in
intention-to-treat population. On-treatment analysis showed a significant
risk reduction in those who used CPAP for >=4 vs. <4 h/day or did not
receive treatment (adjusted hazard ratio [HR] 0.17; 95% confidence
interval [CI] 0.03-0.81; p = 0.03). Compared with the reference group,
nonadherent/untreated OSA was associated with an increased cardiovascular
risk (adjusted HR 1.97, 95% CI 1.03-3.77; p = 0.04). We conclude that OSA
is an independent risk factor for adverse cardiovascular outcomes in
patients with ACS. CPAP treatment may reduce this risk, if the device is
used at least 4 h/day.<br/>Copyright &#xa9; 2020 by the authors. Licensee
MDPI, Basel, Switzerland.

<14>
Accession Number
2035529187
Title
Diagnostic performance of CCTA and CTP imaging for clinically suspected
in-stent restenosis: A meta-analysis.
Source
Journal of Cardiovascular Computed Tomography. 19(2) (pp 183-190), 2025.
Date of Publication: 01 Mar 2025.
Author
Dahdal J.; Jukema R.A.; Remmelzwaal S.; Raijmakers P.G.; van der Harst P.;
Guglielmo M.; Cramer M.J.; Chamuleau S.A.J.; van Diemen P.A.; Knaapen P.;
Danad I.
Institution
(Dahdal, Jukema, Chamuleau, van Diemen, Knaapen, Danad) Department of
Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije
Universiteit Amsterdam, Amsterdam, Netherlands
(Remmelzwaal) Department of Epidemiology and Biostatistics, Amsterdam UMC,
Amsterdam, Netherlands
(Raijmakers) Department of Radiology, Nuclear Medicine & PET Research,
Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
(Dahdal) Departamento de Enfermedades Cardiovasculares, Clinica Alemana de
Santiago, Facultad de Medicina, Clinica Alemana Universidad Del
Desarrollo, Santiago, Chile
(van der Harst, Guglielmo, Cramer) Department of Cardiology, University
Medical Center Utrecht, Utrecht, Netherlands
(Guglielmo) Department of Cardiology, Haga Teaching Hospital, The Hague,
Netherlands
(Danad) Department of Cardiology, Radboud University Medical Center,
Nijmegen, Netherlands
Publisher
Elsevier Inc.
Abstract
Aims: The objective of this study is to conduct a meta-analysis to assess
the diagnostic performance of Coronary Computed Tomography Angiography
(CCTA) and a hybrid approach that incorporates Computed Tomography
Perfusion (CTP) in addition to CCTA (CCTA + CTP) for the detection of
in-stent restenosis (ISR), as defined by angiography. <br/>Method(s): A
comprehensive search of articles identified 18,513 studies. After removing
duplicates, title/abstract screening, and full-text review, 17 CCTA and 3
CCTA + CTP studies were included. Only studies using >=64-slices
multidetector computed tomography (CT) were considered eligible.
<br/>Result(s): The per-patient ISR prevalence was 43 %, with 92 % of
stents fully interpretable with CCTA. Meta-analysis exhibited a per-stent
CCTA (n = 2674) sensitivity of 90 % (95 % CI; 84-94 %), specificity of 89
% (95 % CI; 86-92 %), positive likelihood ratio of 7.17 (95 % CI;
5.24-9.61), negative likelihood ratio of 0.17 (95 % CI; 0.10-0.25), and
diagnostic odds ratio of 45.7 (95 % CI; 22.71-82.43). Additional
sensitivity analyses revealed no influence of stent diameter or strut
thickness on the diagnostic yield of CCTA. The per-stent diagnostic
performance of CCTA + CTP (n = 752) did not show differences compared to
CCTA. <br/>Conclusion(s): With currently utilized scanners, CCTA and CCTA
+ CTP demonstrated high diagnostic performance for in-stent restenosis
evaluation. Consequently, a history of previous stent implantation should
not be an argument to preclude using these methods in clinically suspected
patients.<br/>Copyright &#xa9; 2024 The Authors

<15>
[Use Link to view the full text]
Accession Number
2038177971
Title
Reconsidering Pre-Procedural Fasting for Elective Percutaneous Cardiac
Procedures.
Source
Circulation: Cardiovascular Interventions. 18(4) (pp e015089), 2025. Date
of Publication: 01 Apr 2025.
Author
Ibrahim S.; Singireddy S.; Ezenna C.; Romero Acero L.M.; Nouri A.; Akman
Z.; Babapour G.; Frampton J.; Goldsweig A.M.; Damluji A.A.; Nanna M.G.
Institution
(Ibrahim) Department of Internal Medicine, Piedmont Athens Regional
Medical Center, Athens, GA, United States
(Singireddy) Department of Cardiovascular Medicine, University of
Illinois, College of Medicine, Peoria, United States
(Ezenna) Department of Medicine, University of Massachusetts, Baystate
Medical Center, Springfield, United States
(Romero Acero) Cardiology Division, Cardiac Care and Vascular Medicine,
Albert Einstein College of Medicine, Bronx, NY, United States
(Nouri, Babapour, Frampton, Nanna) Section of Cardiovascular Medicine,
Yale School of Medicine, New Haven, CT, United States
(Akman) Department of Medicine, Yale School of Medicine, New Haven, CT,
United States
(Goldsweig) Department of Cardiovascular Medicine, Baystate Medical
Center, Division of Cardiovascular Medicine, University of
Massachusetts-Baystate, Springfield, United States
(Damluji) Inova Center of Outcomes Research, Inova Heart and Vascular
Institute, Falls Church, VA, United States
(Damluji) Johns Hopkins University, School of Medicine, Baltimore, MD,
United States
Publisher
Lippincott Williams and Wilkins

<16>
[Use Link to view the full text]
Accession Number
2038177837
Title
Effects of Nicorandil, Isosorbide Mononitrate, or Diltiazem on Radial
Artery Grafts After CABG: The Randomized ASRAB-Pilot Trial.
Source
Circulation: Cardiovascular Interventions. 18(4) (pp e014542), 2025. Date
of Publication: 01 Apr 2025.
Author
Zhu Y.; Zhang W.; Qin K.; Liu Y.; Yao H.; Wang Z.; Ye X.; Zhou M.; Li H.;
Qiu J.; Xu H.; Sun Y.; Gaudino M.; Zhao Q.
Institution
(Zhu, Qin, Liu, Yao, Wang, Ye, Zhou, Li, Qiu, Xu, Sun, Zhao) Department of
Cardiovascular Surgery, Ruijin Hospital, Shanghai Jiao Tong University,
School of Medicine, China
(Zhang) School of Public Health, Fudan University, Shanghai, China
(Gaudino) Department of Cardiothoracic Surgery, Weill Cornell Medicine,
New York, NY, United States
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: The optimal antispastic treatment after coronary artery bypass
grafting using radial artery (RA) grafts is controversial. This clinical
trial aimed to generate pilot comparative data on the effects of
nicorandil, isosorbide mononitrate, or diltiazem on RA grafts.
<br/>METHOD(S): This was a single-center, randomized, open-label,
parallel-group pilot trial. Eligible patients who underwent coronary
artery bypass grafting using RA grafts were randomized in a 1:1:1 ratio to
receive oral nicorandil (15 mg daily), isosorbide mononitrate (50 mg
daily), or diltiazem (180 mg daily) for 24 weeks post-coronary artery
bypass grafting. The primary outcome was RA graft failure (modified
Fitzgibbon grade B, S, or O) at 1 and 24 weeks, assessed by coronary
computed tomography angiography. <br/>RESULT(S): Among 150 randomized
participants, 149 (mean age, 56.8 years; 13.4% women) with 177 RA grafts
were assessed at least once by coronary computed tomography angiography,
including 50 participants with 64 RA grafts in the nicorandil group, 50
participants with 57 RA grafts in the isosorbide mononitrate group, and 49
participants with 56 RA grafts in the diltiazem group, respectively. At 1
week post-coronary artery bypass grafting, the RA graft failure rates were
lower with nicorandil versus diltiazem (19.4% versus 25.0%; difference,
-5.6% [95% CI, -20.6% to 9.3%]) and isosorbide mononitrate versus
diltiazem (18.2% versus 25.0%; difference, -6.8% [95% CI, -21.8% to
8.6%]). The RA graft failure rates were slightly higher with nicorandil
versus isosorbide mononitrate (19.4% versus 18.2%; difference, 1.2% [95%
CI, -13.3% to 15.2%]). At 24 weeks, RA graft failure rates were lower with
nicorandil versus diltiazem (16.1% versus 27.8%; difference, -11.7% [95%
CI, -26.6% to 3.4%]), and isosorbide mononitrate versus diltiazem (12.5%
versus 27.8%; difference, -15.3% [95% CI, -29.8% to -0.2%]), and slightly
higher with nicorandil versus isosorbide mononitrate (16.1% versus 12.5%;
difference, 3.6% [95% CI, -9.6% to 16.4%]). <br/>CONCLUSION(S): In this
pilot trial, treatment with nicorandil or isosorbide mononitrate was
associated with a lower RA graft failure rate compared with diltiazem.
Larger hypothesis-testing trials are warranted. REGISTRATION: URL:
https://www.clinicaltrials.gov; Unique identifier:
NCT04310995.<br/>Copyright &#xa9; 2025 Lippincott Williams and Wilkins.
All rights reserved.

<17>
Accession Number
2036186803
Title
Invasive Strategy With Intended Percutaneous Coronary Intervention Versus
Conservative Treatment in Older People With ST-Segment-Elevation
Myocardial Infarction: A Meta-Analysis.
Source
Journal of the American Heart Association. 14(8) (no pagination), 2025.
Article Number: e040435. Date of Publication: 15 Apr 2025.
Author
Macherey-Meyer S.; Dilley D.; Heyne S.; Meertens M.M.; Nies R.J.; Lee S.;
Adler C.; Baldus S.; Eitel I.; Stiermaier T.; Frerker C.; Schmidt T.
Institution
(Macherey-Meyer, Heyne, Meertens, Nies, Lee, Adler, Baldus) Faculty of
Medicine and University Hospital Cologne, Clinic III for Internal
Medicine, University of Cologne, Cologne, Germany
(Dilley) Faculty of Medicine, University Schleswig-Holstein, University
Hospital Lubeck, Lubeck, Germany
(Meertens) Center of Cardiology, Cardiology III-Angiology, University
Medical Center of the Johannes Gutenberg-University, Mainz, Germany
(Adler) Department of Emergency Medicine, Leverkusen Hospital, Leverkusen,
Germany
(Eitel, Stiermaier, Frerker, Schmidt) Medical Clinic II, University Heart
Center Lubeck, University Schleswig-Holstein, Lubeck, Germany
(Stiermaier) Asklepios Westklinikum Hamburg, Clinic for Cardiology,
Hamburg, Germany
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: Patients >=80 years old were underrepresented or excluded from
landmark trials demonstrating the superiority of primary percutaneous
coronary intervention (PCI) in ST-segment-elevation myocardial infarction.
The current meta-analysis assessed the effects of an invasive strategy
with intended PCI compared with conservative treatment in older people
(>=80 years) with ST-segment-elevation myocardial infarction.
<br/>METHOD(S): A structured literature search was performed. The primary
outcome was overall survival. Secondary outcome analyses included but were
not limited to 30-day and 1-year mortality. <br/>RESULT(S): Thirteen
studies reporting on 102 158 older adults were included. Of these, 31 629
(31%) were assigned to PCI and 70 529 (69%) were treated conservatively.
The overall survival was 76.5% in PCI and 67.2% in conservative treatment
at the time of longest available follow-up (odds ratio [OR], 2.18 [95% CI,
1.79-2.66], P<0.001, I²=88%, favoring PCI). The follow-up
period ranged from 30 days to 26.5 months. The 30-day. (OR, 0.39 [95% CI,
0.31-0.50], P<0.001, I²=0%) and 1-year mortality (OR, 0.34 [95%
CI, 0.25-0.46], P<0.001, I²=0%), were lower in the PCI group.
<br/>CONCLUSION(S): This meta-analysis indicates a potential underuse of
PCI in older adults with ST-segment-elevation myocardial infarction. PCI
was advantageous in short-and long-term survival, but these results were
affected by confounding. Nonetheless, every second patient not referred
for invasive treatment survived at least 1 year. These findings have
hypothesis generating implications, but they indicate ageism and emphasize
that PCI should not be automatically withheld in older
patients.<br/>Copyright &#xa9; 2025 The Author(s).

<18>
Accession Number
647102172
Title
Prevention of infection in aortic or aortoiliac peripheral arterial
reconstruction.
Source
Cochrane Database of Systematic Reviews. 2025(4) (no pagination), 2025.
Article Number: CD015192. Date of Publication: 22 Apr 2025.
Author
Cristino M.A.B.; Nakano L.C.U.; Vasconcelos V.; Correia R.M.; Flumignan
R.L.G.
Institution
(Cristino, Nakano, Vasconcelos, Correia, Flumignan) Department of Surgery,
Division of Vascular and Endovascular Surgery, Universidade Federal de Sao
Paulo, Sao Paulo, Brazil
(Nakano, Vasconcelos, Flumignan) Cochrane Brazil, Universidade Federal de
Sao Paulo, Sao Paulo, Brazil
Publisher
John Wiley and Sons Ltd
Abstract
Background: Peripheral arterial disease (PAD) results from the narrowing
of arteries. Aortic aneurysms - abnormal dilatations in artery walls - are
a related concern. For severe cases, arterial reconstruction surgery is
the treatment option. Surgical site infections (SSIs) are a feared and
common complication of vascular surgery. These infections have a
significant global healthcare impact. Evaluating the effectiveness of
preventive measures is essential. <br/>Objective(s): To assess the effects
of pharmacological and non-pharmacological interventions, including
antimicrobial therapy, antisepsis, and wound management, for the
prevention of infection in people undergoing any open or hybrid aortic or
aortoiliac peripheral arterial reconstruction. <br/>Search Method(s): The
Cochrane Vascular Information Specialist searched the Cochrane Vascular
Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases, and
the World Health Organization International Clinical Trials Registry
Platform, LILACS, and ClinicalTrials.gov up to 11 November 2024.
<br/>Selection Criteria: We included all randomised controlled trials
(RCTs) with a parallel (e.g. cluster or individual) or split-body design,
and quasi-RCTs, which assessed any intervention to reduce or prevent
infection following aortic or aortoiliac procedures for the treatment of
aneurysm or PAD. There were no limitations regarding age and sex.
<br/>Data Collection and Analysis: We used standard Cochrane
methodological procedures. Two review authors independently extracted the
data and assessed the risk of bias of the trials. A third review author
resolved disagreements when necessary. We assessed the evidence certainty
for key outcomes using GRADE. <br/>Main Result(s): We included 21 RCTs
with 4952 participants. Fifteen studies were assessed as having a high
risk of bias in at least one domain, and 19 studies had an unclear risk of
bias in at least one domain. We analysed 10 different comparisons for
eight different outcomes. The comparisons were antibiotic versus placebo
or no treatment; short-duration antibiotics (<= 24 hours) versus
long-duration antibiotics (> 24 hours); different types of systemic
antibiotics (one versus another); antibiotic-bonded implant versus
standard implant; Dacron graft versus stretch polytetrafluoroethylene
graft; prophylactic closed suction drainage versus undrained wound;
individualised goal-directed therapy (IGDT) versus fluid therapy based on
losses, standard haemodynamic parameters and arterial blood gas values
(standard care); comprehensive geriatric assessment versus standard
preoperative care; percutaneous versus open-access technique; and negative
pressure wound therapy (NPWT) versus standard dressing. The primary
outcomes were graft infection rate and SSI rate. The secondary outcomes
included all-cause mortality, arterial reconstruction failure rate,
re-intervention rate, amputation rate, pain resulting from the
intervention, and adverse events resulting from the interventions to
prevent infection. We did not assess all the outcomes across the different
comparisons. The main findings are presented below. Antibiotic versus
placebo or no treatment (five studies). Very low-certainty evidence from
five included studies suggests that antibiotic prophylaxis reduces SSI
(risk ratio (RR) 0.33, 95% confidence interval (CI) 0.15 to 0.71; 5
studies, 583 participants; number needed to treat for an additional
beneficial outcome (NNT) 9). With very low- to low-certainty evidence,
there was little or no difference between the groups in the other assessed
outcomes (graft infection rate, all-cause mortality, re-intervention rate,
and amputation rate). We did not quantitatively assess other outcomes in
this comparison. Short duration antibiotics (<= 24 hours) versus long
duration antibiotics (> 24 hours) (three studies). Very low-certainty
evidence from three included studies suggests that there is little or no
difference in graft infection rate (RR 2.74, 95% CI 0.11 to 65.59; 1
study, 88 participants) or SSI rate (RR 3.65, 95% CI 0.59 to 7.71; 1
study, 88 participants) between short- and long-duration antibiotic
prophylaxis. We did not quantitatively assess other outcomes in this
comparison. Different types of systemic antibiotics (one versus another)
(seven studies). We grouped seven studies comparing one antibiotic to
another into three subgroups that compared different classes of
antibiotics amongst themselves. We found little or no difference between
the groups analysed. Graft infection rate: beta-lactams versus
cephalosporins (RR 0.36, 95% CI 0.02 to 8.71; 1 study, 88 participants;
very low-certainty evidence); glycopeptides versus cephalosporins (RR
5.00, 95% CI 0.24 to 103.05; 1 study, 238 participants; low-certainty
evidence); one cephalosporin versus another (RR not estimable, CI not
estimable; 1 study; 69 participants; very low-certainty evidence); SSI
rate: beta-lactams and cephalosporins (RR 0.27, 95% CI 0.03 to 2.53; 2
studies, 229 participants; very low-certainty evidence); glycopeptides
versus cephalosporins (RR 2.17, 95% CI 0.65 to 7.23; 2 studies, 312
participants; very low-certainty evidence); and one cephalosporin versus
another (RR 1.26, 95% CI 0.21 to 7.45; 3 studies, 625 participants; very
low-certainty evidence). We could extract all-cause mortality data for the
glycopeptide versus cephalosporin comparison; there was little or no
difference between groups (RR 1.33, 95% CI 0.30 to 5.83; 1 study, 238
participants; low-certainty evidence). We did not quantitatively assess
other outcomes in this comparison. Authors' conclusions: Very
low-certainty evidence suggests that the use of prophylactic antibiotics
may prevent SSIs in aortic or aortoiliac peripheral arterial
reconstruction. We found no superiority amongst specific antibiotics or
differences in extended antibiotic use (over 24 hours) compared with
shorter use (up to 24 hours), with low-certainty evidence. For other
interventions, very low- to moderate-certainty evidence showed little or
no difference across various outcomes. We advise interpreting these
conclusions with caution due to the limited number of events in all groups
and comparisons.<br/>Copyright &#xa9; 2025 The Cochrane Collaboration.
Published by John Wiley & Sons, Ltd.

<19>
Accession Number
2037738077
Title
Clinical impact of CCT-FFR as first-strategy in patients with symptomatic
stable coronary artery disease: A systematic review and meta-analysis.
Source
Journal of Cardiovascular Computed Tomography. 19(2) (pp 174-182), 2025.
Date of Publication: 01 Mar 2025.
Author
Di Pietro G.; Improta R.; De Filippo O.; Bruno F.; Birtolo L.I.; Bruno E.;
Galea N.; Francone M.; Dewey M.; D'Ascenzo F.; Mancone M.
Institution
(Di Pietro, Improta, Birtolo, Bruno, Mancone) Department of Clinical,
Internal, Anesthesiological and Cardiovascular Sciences, Umberto I
Hospital, La Sapienza University of Rome, Italy
(De Filippo, Bruno, D'Ascenzo) Division of Cardiology, Cardiovascular and
Thoracic Department, AOU Citta della Salute e della Scienza di Torino and
Department of Medical Sciences, University of Turin, Italy
(Galea) Department of Radiological, Oncological and Pathological Sciences,
Sapienza University of Rome, Viale Regina Elena 324, Rome, Italy
(Francone) IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano,
Milan, Italy
(Francone) Department of Biomedical Sciences, Humanitas University, Pieve
Emanuele, Milan, Italy
(Dewey) Department of Radiology, Charite - Universitatsmedizin Berlin,
corporate member of Freie Universitat Berlin and Humboldt-Universitat zu
Berlin, Berlin, Germany
Publisher
Elsevier Inc.
Abstract
Aims: Despite the promising results, the clinical implications of the
CCT-FFR is already debated. This metanalysis aimed to determine the
potential benefits of incorporating FFRCT into stable CAD management.
<br/>Method(s): After searching for studies comparing outcomes of patients
with suspected stable CAD who underwent CCT-FFR as a first strategy versus
non-urgent cardiovascular testing after a clinical judgment, we calculated
odds ratios (ORs) and 95 % confidence intervals (CIs) using a
random-effects or fixed-effects meta-analysis model depending on
heterogeneity significance. <br/>Result(s): 5 studies (3 RCTs and 2
observational studies) globally encompassing 5282 patients (CCT-FFR = 2604
patients, Control Group = 2678 patients) were included in the quantitative
analysis. The rates of ICA overall (OR 1.57, 95%CI 1.36-1.81, p value <
0.001) and those without obstructive CAD (OR 6.63, 95%CI 4.79-9.16, p
value < 0.001) were reduced in the CCTAFFR group, as compared to the
control group. Moreover, CCT-FFR patients underwent coronary
revascularization more frequently than patients in the control arm (OR
0.48,CI 0.38-0.62, p value < 0.001). There was no significance difference
between the two strategies in terms of 1 year MACE (OR 1.11,CI 0.86-1.44,
p value 0.42), nonfatal MI (OR 0.73, CI 0.41-1.33, p value 0.31),
all-cause mortality (OR 1.29,CI 0.47-3.54, p value 0.63) and unplanned
revascularization for angina (OR 0.99, 95%CI 0.65-1.49, p value 0.95).
<br/>Conclusion(s): In conclusion, in the management of stable CAD, the
use of CCT-FFR was associated with lower overall rates of ICA but higher
rates of coronary revascularization with comparable 1-year clinical
impact.<br/>Copyright &#xa9; 2025 The Authors

<20>
Accession Number
2038026250
Title
Analgesic Efficacy of Bilateral Ultrasound-Guided Transversus Thoracic
Muscle Plane Block Versus Erector Spinae Plane Block in Pediatric Patients
Undergoing Corrective Cardiac Surgeries: A Randomized Controlled Study.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 39(6) (pp 1495-1505),
2025. Date of Publication: 01 Jun 2025.
Author
Madkour M.A.F.A.; Abueldahab E.I.B.; Elela A.H.A.; Youssef M.F.; Gado A.A.
Institution
(Madkour, Abueldahab, Elela, Youssef, Gado) Department of Anesthesiology
and Intensive Care Medicine, Cairo University, Cairo, Egypt, Egypt
Publisher
W.B. Saunders
Abstract
Objectives: Transversus thoracic plane block (TTPB) and erector spinae
plane block (ESPB) are gaining popularity in cardiac surgeries to avoid
excessive narcotic use and achieve fast-track extubation This study was
performed to compare the analgesic efficacy of TTPB to that of ESPB in
pediatric patients undergoing cardiac surgeries. The study was conducted
in a university pediatric hospital (ClinicalTrials.gov NCT05559684).
<br/>Design(s): Single-center prospective randomized controlled study.
<br/>Setting(s): Tertiary referring pediatric university hospital.
<br/>Participant(s): Sixty pediatric patients undergoing corrective
cardiac surgeries during the period from November 2022 to August 2023.
<br/>Intervention(s): Randomization was done using a sealed envelope
technique that contained 20 labels of (control), 20 labels of (ESPB), and
another 20 labels of (TTPB). Patients in the control group (n = 20) were
given fentanyl infusion at a dosage of 0.5 microg/kg/h throughout the
whole operation, in addition to 1 microg/kg during skin incision,
sternotomy, and aortic cannulation. Patients in the ESPB group (n = 20)
were given fentanyl infusion at a dose of 0.5 microg/kg/h all through the
whole operation plus ultrasound-guided ESPB done bilaterally by injecting
0.4 mL/kg (1:1 solution of Bupivacaine25 % and lidocaine 1%) on each side.
Patients in the TTPB group were given fentanyl infusion at a dose of 0.5
microg/kg/h throughout the operation plus ultrasound-guided TTPB done
bilaterally by injecting 0.4 mL/kg on each side (1:1 solution of
bupivacaine 0.25 % and lidocaine 1%). <br/>Measurements and Main Results:
Primary outcome was the total intraoperative fentanyl consumption;
secondary outcomes included hemodynamics and time to first analgesic
request (which is the elapsed time between giving the block and the
patient's FLACC score >=4), postoperative fentanyl consumption, extubation
time, and adverse events. Intraoperative fentanyl consumption was
significantly decreased in the TTPB group (3.4 +/- 2.9) compared with the
control group (6.7 +/- 4.2), mean difference = 3.35, 95% CI (0.84, 5.86),
p = 0.006. It was comparable between the ESPB group and the control group.
Also, the TTPB and ESPB groups were comparable regarding the primary
outcome, mean difference 1.2, 95% CI (-1.31, 3.71), p = 0.486. Total
fentanyl consumption in the intensive care unit was significantly
decreased in the TTPB group (1.1 +/- 1.54) than in the control group (4.6
+/- 4.25), mean difference 3.55, 95% CI (1.5, 5.6) with p = 0.001. Other
pairwise comparisons were comparable between the groups. The time to first
rescue analgesia was significantly longer in TTPB group (5.15 +/- 4.21)
compared to the control group (1.95 +/- 3.5), mean difference -3.2, 95% CI
(-5.68, -0.72), p = 0.04. Patients in ESPB needed first rescue analgesia
slightly earlier (4.9 +/- 4.4) than patients in TTPB group, mean
difference -0.25, 95% CI (-3.01, 2.51), p = 0.979 and non-significantly
longer than control group, mean difference -2.95, 95% CI (-5.5, -0.4), p =
0.064. Fast-track extubation was significantly increased in patients who
received TTPB (85%) than in those who received ESPB (50%), relative risk =
0.58, 95% CI (0.36, 0.94), p = 0.018 and those in the control group (30%),
relative risk = 0.35, 95% CI (0.17, 0.706), p < 0.001). Also,
ultrafast-track extubation was significantly increased in patients who
received TTPB (60%) than those in the control group 15%), relative risk =
0.25, 95% CI (0.08, 0.75), p = 0.007. <br/>Conclusion(s): Both TTPB and
ESPB reduced nociception and appeared comparable in providing
perioperative analgesia as they reduced pain scores and intraoperative and
postoperative narcotic dosage, which facilitated early extubation. TTPB
was superior to ESPB regarding fast-track extubation and provided a double
incidence for the ultrafast-track extubation, but this was related to the
hyper incidence of adverse events not thought related to
analgesia.<br/>Copyright &#xa9; 2025 Elsevier Inc.

<21>
Accession Number
2038417261
Title
Letter to the Editor, "The effects of sodium-glucose transporter 2
inhibition on cardiac surgery-associated acute kidney injury: An
open-label randomized pilot study".
Source
Journal of Clinical Anesthesia. 104 (no pagination), 2025. Article Number:
111838. Date of Publication: 01 Jun 2025.
Author
Jiang L.; Peng Z.
Institution
(Peng) Foshan Women and Children Hospital, China
(Jiang) The Seventh Affiliated Hospital of Southern Medical University,
China
Publisher
Elsevier Inc.

<22>
Accession Number
2032783208
Title
The efficacy and safety of Empagliflozin on outcomes of patients with
myocardial infarction undergoing primary PCI: a systematic review and
meta-analysis.
Source
Naunyn-Schmiedeberg's Archives of Pharmacology. 398(5) (pp 4969-4977),
2025. Date of Publication: 01 May 2025.
Author
Alizadehasl A.; Hakimian H.; Abdolkarimi L.; Afsari Zonooz Y.;
Amini-Salehi E.; Hosseini Jebelli S.F.; Yalameh Aliabadi A.
Institution
(Alizadehasl, Hakimian, Afsari Zonooz, Hosseini Jebelli, Yalameh Aliabadi)
Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and
Research Center, Iran University of Medical Science, Tehran, Iran, Islamic
Republic of
(Abdolkarimi) Rajaie Cardiovascular Medical and Research Center, Iran
University of Medical Science, Tehran, Iran, Islamic Republic of
(Amini-Salehi) Guilan University of Medical Science, Rasht, Iran, Islamic
Republic of
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has
garnered significant interest due to its potential cardiovascular
benefits, particularly in patients experiencing acute myocardial
infarction (AMI) who are undergoing primary percutaneous coronary
intervention (PCI). This systematic review aims to evaluate the
effectiveness of Empagliflozin in improving clinical outcomes in this
patient population. A systematic review of randomized controlled trials
(RCTs) was conducted to assess the effects of Empagliflozin on clinical
outcomes in patients with AMI undergoing primary PCI. Electronic
databases, including PubMed, Scopus, Web of Science, Cochrane, and the
Scientific Information Database, were searched up to July 31, 2024. The
risk of bias in the included studies was evaluated using the Cochrane
Collaboration criteria. Data analysis was performed using Comprehensive
Meta-Analysis software version 3, with outcomes expressed as risk ratios
(RR) and 95% confidence intervals (CI). Seven studies were included in the
meta-analysis. The results demonstrated that Empagliflozin significantly
reduced the risk of heart failure hospitalization compared to placebo,
with a risk ratio of 0.48 (95% CI: 0.23-0.99; P = 0.049), indicating a 52%
reduction in hospitalization risk. However, secondary outcomes showed that
Empagliflozin was associated with a reduction in cardiovascular mortality
(RR = 0.45; 95% CI: 0.06-3.02; P = 0.415) and the need for coronary
revascularization (RR = 0.75; 95% CI: 0.15-3.59; P = 0.717), although
these results did not achieve statistical significance. Empagliflozin is
associated with a significant reduction in heart failure hospitalizations
among patients with AMI undergoing primary PCI, while its effects on
cardiovascular mortality and the necessity for coronary revascularization
were not statistically significant. Despite these secondary outcomes, the
favorable safety profile of Empagliflozin supports its use as a treatment
option for high-risk patients following acute coronary events. Further
research is warranted to investigate the long-term impact of Empagliflozin
on cardiovascular outcomes in this population.<br/>Copyright &#xa9; The
Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part
of Springer Nature 2024.

<23>
Accession Number
2038407791
Title
Comparison of PCI vs. CABG in Multi-Vessel Disease.
Source
European Journal of Cardiovascular Medicine. 15(4) (pp 587-592), 2025.
Date of Publication: 01 Apr 2025.
Author
Haridas P.V.; Das A.
Institution
(Haridas) Dept of Cardiology, Malabar Medical College Hospital & Research
Centre, Ulliyeri, Kerala, Calicut, India
(Das) Dept of Community Medicine, PSP Medical College, Tamil Nadu,
Chennai, India
Publisher
Healthcare Bulletin
Abstract
Background: Coronary artery bypass grafting (CABG) and percutaneous
coronary intervention (PCI) are the two primary revascularization
strategies for multivessel coronary artery disease (MVD) and left main
coronary artery disease (LMCAD). While PCI offers a minimally invasive
alternative, concerns remain regarding its long-term efficacy compared to
CABG. This study aims to compare the long-term outcomes of CABG and PCI in
patients with MVD and LMCAD. <br/>Method(s): A retrospective cohort study
was conducted on patients undergoing revascularization for MVD and LMCAD.
Clinical outcomes, including major adverse cardiac events (MACE),
all-cause mortality, myocardial infarction, and repeat revascularization,
were assessed over a long-term follow-up period. Kaplan-Meier survival
curves were used to evaluate event-free survival rates. Statistical
analysis was performed using a Cox proportional hazards model to adjust
for confounding variables. <br/>Result(s): The results supported that
although CABG was associated with reduced occurrence of major adverse
cardiovascular events (MACE) and repeat revascularization rates compared
to PCI, survival at the end-results was similar among the two. Event-free
survival was superior within the CABG group at each follow-up duration, in
harmony with prior meta-analyses. Nonetheless, PCI still held acceptable
long-term results, particularly in selected subjects with less elaborate
coronary anatomy, affirming the validity of alternative use of surgery for
revascularization. <br/>Conclusion(s): CABG and PCI are both effective
forms of revascularization in patients with multivessel coronary artery
disease (MVD) and left main coronary artery disease (LMCAD). Although CABG
might be superior in event prevention in the long term, PCI is not
necessarily inferior in general and especially not in properly selected
cases. Personalized treatment planning on the basis of patient risk
profile and anatomical complexity is paramount. More research is needed to
improve selection criteria and long-term cardiovascular results for both
modalities.<br/>Copyright &#xa9; 2025 Healthcare Bulletin. All rights
reserved.

<24>
Accession Number
2034315830
Title
CT-derived adipose tissue characteristics and TAVI all-cause mortality and
complications: a systematic review.
Source
European Journal of Medical Research. 30(1) (no pagination), 2025. Article
Number: 325. Date of Publication: 01 Dec 2025.
Author
Pekar M.; Branny P.; Jiravsky O.; Spacek R.; Mohr J.A.; Ranic I.; Godula
B.J.; Konecna A.C.; Kantor M.; Hecko J.; Neuwirth R.; Sknouril L.; Novak
J.
Institution
(Pekar, Branny, Jiravsky, Spacek, Mohr, Ranic, Godula, Konecna, Kantor,
Hecko, Neuwirth, Sknouril) Hospital AGEL Trinec-Podlesi, Konska 453,
Trinec, Czechia
(Pekar, Mohr, Novak) Department of Physiology Faculty of Medicine Masaryk
University Kamenice, Brno, Czechia
(Branny, Godula) Faculty of Medicine, Palacky University, Krizkovskeho
511/8, Olomouc, Czechia
(Jiravsky, Ranic, Konecna, Sknouril) Medicine, Faculty of Medicine,
University of Ostrava, Syllabova 19, Ostrava, Czechia
(Spacek) Third Faculty of Medicine, Charles University, Ruska 87, Prague
10, Czechia
(Hecko) Faculty of Electrical Engineering and Computer Science, VSB -
Technical University of Ostrava, 17. Listopadu Street 2172/15, Ostrava,
Czechia
(Neuwirth) Faculty of Medicine Masaryk University Kamenice, Brno, Czechia
(Novak) Second Department of Internal Medicine St. Anne's University
Hospital in Brno, Pekarska 53, Brno, Czechia
Publisher
BioMed Central Ltd
Abstract
Transcatheter Aortic Valve Implantation (TAVI) has revolutionized severe
aortic stenosis treatment, but risk stratification remains challenging.
This systematic review examined the association between computed
tomography (CT)-derived adipose tissue parameters and TAVI outcomes. We
searched major databases for studies on visceral (VAT), subcutaneous
(SAT), and intramuscular (IMAT) adipose tissue parameters and post-TAVI
outcomes. Fourteen studies (9692 patients) were included. Higher SAT
area/volume was consistently associated with better survival (5 studies,
HR range: 0.83-2.77, p < 0.05). Lower SAT and VAT density also correlated
with better survival (5 and 4 studies, respectively, HR range: 1.31-1.46,
p < 0.05). VAT area showed mixed results. A VAT:SAT ratio < 1 was
associated with better cardiovascular outcomes in one study. Lower IMAT
index correlated with shorter hospital stays in a single study. This
review reveals complex relationships between adipose tissue parameters and
TAVI outcomes. Lower adipose tissue density and higher subcutaneous
adiposity were most consistently associated with better outcomes. These
findings suggest that detailed analysis of adipose tissue characteristics
may enhance risk stratification in TAVI candidates.<br/>Copyright &#xa9;
The Author(s) 2025.

<25>
Accession Number
2034317072
Title
The Impact of Concomitant Mitral Regurgitation on Echocardiography
Parameters After TransCatheter Aortic Valve Replacement: A Systematic
Review and Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. (no pagination), 2025.
Date of Publication: 2025.
Author
Darouei B.; Amani-Beni R.; Rabiee Rad M.; Ghasempour Dabaghi G.; Eshraghi
R.; Bahrami A.; Amini-Salehi E.; Hashemi S.M.; Mazaheri-Tehrani S.;
Movahed M.R.
Institution
(Darouei, Amani-Beni, Rabiee Rad, Ghasempour Dabaghi) Isfahan
Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan
University of Medical Sciences, Isfahan, Iran, Islamic Republic of
(Eshraghi) Social Determinants of Health Research Center, Isfahan
University of Medical Sciences, Isfahan, Iran, Islamic Republic of
(Bahrami) Student Research Committee, Kashan University of Medical
Sciences, Kashan, Iran, Islamic Republic of
(Amini-Salehi) Guilan University of Medical Sciences, Rasht, Iran, Islamic
Republic of
(Hashemi) Cardiovascular Research Center, Hormozgan University of Medical
Sciences, Bandar Abbas, Iran, Islamic Republic of
(Mazaheri-Tehrani) Child Growth and Development Research Center, Research
Institute for Primordial Prevention of Non-Communicable Disease, Isfahan
University of Medical Sciences, Isfahan, Iran, Islamic Republic of
(Movahed) Department of Medicine, University of Arizona College of
Medicine, Phoenix, United States
(Movahed) Department of Medicine, University of Arizona Sarver Heart
Center, Tucson, AZ, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Mitral regurgitation (MR) commonly coexists with aortic
stenosis (AS) and is a potential risk factor influencing outcomes
following transcatheter aortic valve replacement (TAVR). This
meta-analysis aimed to evaluate the mean changes in key echocardiographic
parameters before and after TAVR and to compare these changes between
patients with moderate-to-severe MR (MR >= 2) and those with none-to-mild
MR (MR < 2). <br/>Method(s): A comprehensive literature search was
conducted using six electronic databases. We included studies that
evaluated patients undergoing TAVR, classified them based on baseline MR
grade >= 2 (moderate/severe MR) or MR grade < 2 (none/mild MR), and
reported the mean difference (MD) in echocardiographic parameters before
and after TAVR in both groups. The primary outcomes included changes in
ejection fraction (EF), LV end-diastolic volume (LVEDV) index, LV
end-systolic volume (LVESV) index, LV end-diastolic diameter (LVEDD), LV
end-systolic diameter (LVESD), aortic valve area (AVA), and the mean
aortic gradient. Pooled MDs were analyzed using a random-effects model.
<br/>Result(s): Thirteen studies with 7163 patients were included, of
which 2376 had an MR >= 2. The MR < 2 and MR >= 2 groups experienced
significant improvements in AVA and reductions in mean aortic gradient,
LVEDV index, LVESV index, LVEDD, and LVESD. Compared to MR < 2 patients,
those with MR >= 2 exhibited significantly greater improvements in EF (MD
= 2.03; 95% CI: 0.81, 3.24), LVEDV index (MD = -5.55; 95% CI: -7.85,
-3.26), LVESV index (MD = -5.43; 95% CI: -7.28, -3.58), LVESD (MD = -2.23;
95% CI: -3.71, -0.26), and mean aortic gradient (MD = 1.43; 95% CI: 0.79,
2.07). However, the changes in LVEDD and AVA were not significantly
different between the groups. <br/>Conclusion(s): These findings suggest
that patients with moderate-to-severe baseline MR before TAVR showed
greater pronounced improvements in specific echocardiographic parameters
related to LV function and geometry, particularly in LVEF, LVEDV index,
LVESV index, and LVESD, compared to those with none-to-mild MR. Future
studies should focus on stratifying outcomes according to MR etiology and
using advanced imaging techniques to delineate better the mechanisms
underlying these improvements.<br/>Copyright &#xa9; 2025 Wiley Periodicals
LLC.

<26>
Accession Number
2032061294
Title
Gabapentin as a novel adjunct for postoperative irritability after
superior cavopulmonary connection operation in children.
Source
Cardiology in the Young. 34(9) (pp 1893-1899), 2024. Date of Publication:
01 Sep 2024.
Author
Thibault C.; Ramsey E.Z.; Collier H.; Shu D.; Faerber J.; Schwartz E.;
Chen J.; Goldberg D.J.; Yehya N.; Gardner M.M.
Institution
(Thibault, Yehya, Gardner) Department of Anesthesiology and Critical Care,
Children's Hospital of Philadelphia, Philadelphia, PA, United States
(Thibault) Department of Pediatrics, Universite de Montreal, Montreal, QC,
Canada
(Thibault) Division of Critical Care Medicine, Department of Pediatrics,
CHU Sainte-Justine, Montreal, QC, Canada
(Ramsey, Collier) Department of Pharmacy Services, The Children's Hospital
of Philadelphia, Philadelphia, PA, United States
(Shu) Department of Biostatistics, Epidemiology and Informatics,
University of Pennsylvania, Philadelphia, PA, United States
(Shu) The Clinical Futures, Research Institute, The Children's Hospital of
Philadelphia, Philadelphia, PA, United States
(Faerber) Department of Biomedical and Health Informatics, Data Science
and Biostatistics Unit, The Children's Hospital of Philadelphia,
Philadelphia, PA, United States
(Schwartz, Goldberg) Division of Cardiology, The Children's Hospital of
Philadelphia, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, United States
(Chen) Division of Cardiothoracic Surgery, The Children's Hospital of
Philadelphia, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, United States
Publisher
Cambridge University Press
Abstract
Objectives: Describing our institution's off-label use of gabapentin to
treat irritability after superior cavopulmonary connection surgery and its
impact on subsequent opiate and benzodiazepine requirements.
<br/>Method(s): This is a single-center retrospective cohort study
including infants who underwent superior cavopulmonary connection
operation between 2011 and 2019. <br/>Result(s): Gabapentin was
administered in 74 subjects (74/323, 22.9%) during the observation period,
with a median (IQR) starting dose of 5.7 (3.3, 15.0) mg/kg/day and a
maximum dose of 10.7 (5.5, 23.4) mg/kg/day. Infants who underwent surgery
in 2015-19 were more likely to receive gabapentin compared with those who
underwent surgery in 2011-14 (p < 0.0001). Infants prescribed gabapentin
were younger at surgery (137 versus 146 days, p = 0.007) and had longer
chest tube durations (1.8 versus 0.9 days, p < 0.001), as well as longer
postoperative intensive care (5.8 versus 3.1 days, p < 0.0001) and
hospital (11.5 versus 7.0 days, p < 0.0001) lengths of stays. The year of
surgery was the only predisposing factor associated with gabapentin
administration in multivariate analysis. In adjusted linear regression,
infants prescribed gabapentin on postoperative day 0-4 (n = 64) had
reduced benzodiazepine exposure in the following 3 days (-0.29 mg/kg, 95%
CI-0.52- 0.06, p = 0.01) compared with those not prescribed gabapentin,
while no difference was seen in opioid exposure (p = 0.59).
<br/>Conclusion(s): Gabapentin was used with increasing frequency during
the study period. There was a modest reduction in benzodiazepine
requirements associated with gabapentin administration and no reduction in
opioid requirements. A randomised controlled trial could better assess
gabapentin's benefits postoperatively in children with congenital heart
disease.<br/>Copyright &#xa9; The Author(s), 2024.

<27>
Accession Number
2037511583
Title
Outcomes of aortic stenosis in patients with cardiac amyloidosis: A
systematic review and meta-analysis.
Source
Cardiovascular Revascularization Medicine. 73 (pp 98-106), 2025. Date of
Publication: 01 Apr 2025.
Author
Ahmad S.; Ahsan M.J.; Newlun M.; Sand M.; Rmilah A.A.; Yousaf A.; Shabbir
M.A.; Malik S.A.; Goldsweig A.M.
Institution
(Ahmad, Shabbir, Malik, Goldsweig) Division of Cardiovascular Medicine,
University of Nebraska Medical Center, Omaha, NE, United States
(Ahsan) Department of Cardiovascular Medicine, Baylor University Medical
Center, Dallas, TX, United States
(Newlun, Sand) Department of Medicine, University of Nebraska Medical
Center, Omaha, NE, United States
(Rmilah) Department of Medicine, Magnolia Regional Health Center, Corinth,
MS, United States
(Yousaf) Department of Medicine, McLaren Flint-Michigan State University,
Flint, MI, United States
(Goldsweig) Department of Cardiovascular Medicine, Baystate Medical Center
and University of Massachusetts-Baystate, Springfield, MA, United States
Publisher
Elsevier Inc.
Abstract
Background: Cardiac amyloidosis (CA) results from the deposition of
abnormally folded protein fibrils, leading to restrictive cardiomyopathy,
valvular heart disease, and arrhythmias. Up to 15 % of patients with
severe aortic stenosis (AS) have concomitant CA (AS-CA). We conducted this
systematic review and meta-analysis to compare medical management,
transcatheter aortic valve replacement (TAVR), and surgical AVR (SAVR) in
AS-CA. <br/>Method(s): A comprehensive literature search was conducted for
relevant studies from inception through January 20, 2024. Studies
exploring outcomes in adult AS patients with and without CA receiving
medical therapy, TAVR, or SAVR were included in this analysis.
<br/>Result(s): Fifteen studies including 253,334 patients (AS-CA 6704; AS
alone 246,630) were identified. AS-CA patients had significantly higher
all-cause mortality (RR = 2.60, 95 % CI 1.48-4.57, P = 0.0009) compared to
AS alone. Among patients with AS-CA, TAVR was associated with lower
all-cause mortality compared to both medical therapy (RR = 0.50, 95 % CI
0.29-0.89, P = 0.02) and SAVR (RR = 0.41, 95 % CI 0.22-0.78, P = 0.007).
AS-CA patients undergoing TAVR were more likely to have paradoxical
low-flow, low-gradient AS (RR = 1.56, 95 % CI 1.15-2.12, P = 0.04) at
baseline and had a higher risk of post-TAVR acute kidney injury (RR =
1.95, 95 % CI 1.35-2.80, P = 0.0003) compared to patients undergoing TAVR
for AS alone. There were similar risks of other post-TAVR complications,
including major bleeding, vascular complications, stroke, and new
pacemaker implantation between AS-CA and AS alone. <br/>Conclusion(s): CA
is associated with a higher mortality in patients with severe AS. In
patients with concomitant AS and CA, TAVR is safe and associated with
better survival than medical therapy or SAVR. Social media abstract:
#Meta-Analysis: Cardiac amyloidosis is associated with increased mortality
in severe AS. #TAVR is safe in amyloidosis & improves survival more than
medical therapy or SAVR.<br/>Copyright &#xa9; 2025 Elsevier Inc.

<28>
Accession Number
2038411834
Title
Even aortic insufficiency can be treated percutaneously: Right?.
Source
European Heart Journal, Supplement. 27(Supplement_3) (pp iii105-iii110),
2025. Date of Publication: 01 Mar 2025.
Author
Guicciardi N.A.; Beneduce A.; Maisano F.
Institution
(Guicciardi, Beneduce, Maisano) Department of Cardiac Surgery, Valve
Center - Irccs San Raffaele Hospital, Milan, Italy
Publisher
Oxford University Press
Abstract
Moderate or severe aortic insufficiency (AI) is a relatively rare
condition but with significant clinical implications, especially in
elderly patients at high surgical risk. Although surgical aortic valve
replacement remains the gold standard for treatment, a significant
proportion of patients are not eligible due to the high surgical risk. In
recent years, transcatheter aortic valve implantation (TAVI) has
revolutionized the treatment of aortic stenosis, but its application to AI
has encountered significant challenges, mainly related to specific
anatomical characteristics of this population. This review provides an
overview of the evolution of the transcatheter treatment of AI,
highlighting the critical issues of first-generation TAVI devices and the
improvements achieved with new-generation and dedicated devices, such as
JenaValve and J-Valve. Preliminary data demonstrate encouraging procedural
results, including a reduction in residual insufficiency and improved
safety in patients at high surgical risk. However, limitations remain,
including the high incidence of pacemaker implantation and the lack of
long-term randomized clinical trials. In light of technological advances,
TAVI represents a promising therapeutic option for selected patients with
AI, if performed in high-volume centres with extensive experience in the
treatment of aortic disease.<br/>Copyright &#xa9; 2025 The Author(s).
Published by Oxford University Press on behalf of the European Society of
Cardiology.

<29>
[Use Link to view the full text]
Accession Number
2038463849
Title
Meta-Analysis on Comparison of Fasting Versus No Fasting Before Cardiac
Catheterization.
Source
Cardiology in Review. (no pagination), 2025. Article Number:
10.1097/CRD.0000000000000930. Date of Publication: 2025.
Author
Basit J.; Ahmed M.; Burhan M.; Shahzad M.; Ahsan A.; Ullah W.; Alonso A.
Institution
(Basit, Ahmed, Burhan) Department of Medicine, Rawalpindi Medical
University, Rawalpindi, Pakistan
(Shahzad) Department of Medicine, Dow University of Health Sciences,
Karachi, Pakistan
(Ahsan) Department of Medicine, Foundation University Medical College,
Islamabad, Pakistan
(Ullah, Alonso) Department of Interventional Cardiology, University of
Massachusetts, Worcester, MA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Patients undergoing cardiac catheterization are advised not to take
anything by mouth after midnight. However, limited scientific data exist
on whether fasting before catheterization procedures improves clinical
outcomes compared with nonfasting. A comprehensive literature search was
performed by investigators using major bibliographic databases to identify
studies that compared clinical outcomes for fasting versus nonfasting
patient groups following cardiac catheterization procedures. The risk
ratios (RR) and mean difference (MD) were pooled along with 95% confidence
intervals (CIs) for dichotomous and continuous outcomes using R studios. A
total of 9 trials were included in the review reporting data for 3432
patients (fasting: 1710 and nonfasting: 1702). There was no statistically
significant difference between the 2 groups for incidence of procedural
complications (RR: 1.05, 95% CI: 0.78-1.40; P = 0.757), 30-day mortality
(RR: 0.83, 95% CI: 0.32-2.18; P = 0.71), 30-day readmissions (RR: 1.05,
95% CI: 0.74-1.49; P = 0.77), aspiration (RR: 0.45, 95% CI: 0.06-3.50; P =
0.45), contrast-associated acute kidney injury (RR: 0.90, 95% CI:
0.52-1.58; p 0.72), hypoglycemia (RR: 1.27, 95% CI: 0.74-2.17; P = 0.39),
and nausea/vomiting (RR: 0.83, 95% CI: 0.46-1.51; P = 0.55). The
nonfasting group was associated with significantly better satisfaction
scores compared to the fasting group (standardized MD: 0.70, 95% CI:
0.13-1.27; P = 0.02). Before cardiac catheterization, a nonfasting
approach is associated with higher satisfaction and similar procedural
outcomes and adverse events compared to a fasting approach. The practice
of routine fasting before cardiac catheterization should be
reconsidered.<br/>Copyright &#xa9; 2025 Wolters Kluwer Health, Inc.

<30>
Accession Number
2034346591
Title
Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About
Icosapent Ethyl? A Systematic Review and Meta-Analysis.
Source
Pharmaceuticals. 18(4) (no pagination), 2025. Article Number: 601. Date of
Publication: 01 Apr 2025.
Author
Machado N.M.; Oliveira M.V.B.; Quesada K.; Haber J.F.D.S.; Jose Tofano R.;
Rubira C.J.; Zutin T.L.M.; Direito R.; Pereira E.D.S.B.M.; de Oliveira
C.M.; Goulart R.D.A.; Valenti V.E.; Sloan K.P.; Sloan L.A.; Laurindo L.F.;
Barbalho S.M.
Institution
(Machado, Oliveira, Quesada, Haber, Jose Tofano, Rubira, Zutin, de
Oliveira, Goulart, Laurindo, Barbalho) Department of Biochemistry and
Pharmacology, School of Medicine, University of Marilia (UNIMAR), Sao
Paulo, Marilia, Brazil
(Quesada, Jose Tofano, Zutin, Pereira, Goulart, Laurindo, Barbalho)
Postgraduate Program in Structural and Functional Interactions in
Rehabilitation, University of Marilia (UNIMAR), Sao Paulo, Marilia, Brazil
(Direito) Laboratory of Systems Integration Pharmacology, Clinical and
Regulatory Science, Research Institute for Medicines, Universidade de
Lisboa (iMed.ULisboa), Av. Prof. Gama Pinto, Lisbon, Portugal
(Valenti) Faculty of Philosophy and Sciences, Universidade Estadual
Paulista (UNESP), Sao Paulo, Marilia, Brazil
(Sloan, Sloan) Department of Clinical Metabolism, Texas Institute for
Kidney and Endocrine Disorders (TIKED), Lufkin, TX, United States
(Sloan) Department of Internal Medicine, University of Texas Medical
Branch, Galveston, TX, United States
(Barbalho) Research Coordination, UNIMAR Charitable Hospital, Sao Paulo,
Marilia, Brazil
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Lipid-lowering therapies are an option for stabilizing lipid
levels. Icosapent ethyl (IPE) is a highly purified formulation of
eicosapentaenoic acid, which can reduce lipid action, improve plaque
stabilization, reduce platelet aggregation, lower TG, and prevent
cardiovascular events. IPE is frequently used with statins to manage
elevated TG levels. However, the evidence on IPE as a lipid-lowering agent
is limited, and no updated systematic review and meta-analysis have been
published considering the recent advancements in the field and newly
published studies. Therefore, we aim to fill this gap. <br/>Method(s): We
used the PRISMA guidelines and the PICO (Population, Intervention,
Comparison, and Outcome) framework to conduct this review, aiming to
answer the question, "Can IPE benefit patients at cardiovascular risk?"
GRADE was used to evaluate evidence levels to adhere to the highest
criteria. <br/>Result(s): Predominantly, the evaluated population
presented TG levels between >=135 mg/dL and 500 mg/dL and LDL-C levels
between >40 mg/dL and <=100 mg/dL. The included studies showed a reduction
in TG and LDL-C and a decrease in cardiovascular events. It means that,
according to our systematic review evidence analysis, IPE has been
effective in lowering blood lipid levels, including TG, and reducing
cardiovascular death and events, such as non-fatal stroke or
hospitalization for unstable angina. However, it is worth noting that
these results were primarily from patients undergoing statin therapy.
According to our meta-analysis, IPE may not be considered a lipid-lowering
drug, as limited action associated with its use was evident in the
quantitative results. However, caution is necessary, as only two studies
were suitable for inclusion due to the differing outcomes in the analyzed
samples. <br/>Conclusion(s): Despite the quantitative synthesis, IPE
possesses anti-inflammatory, anti-thrombotic, and anti-atherogenic
properties, highly related to cardiovascular protection. Based on our
included studies, IPE was considered a promising therapy for
atherosclerotic cardiovascular disease in conjunction with other
lipid-lowering therapies, particularly statins, for patients with
extremely high TG levels. The limitations of the reviewed studies may
include small sample sizes, varying outcomes, and a small duration of
interventions. Future clinical trials with similar outcomes, sample sizes,
and intervention durations must be designed, and updated meta-analyses
must be published in the following years to fully assess the effects of
IPE as a lipid-lowering and cardiovascular protector drug.<br/>Copyright
&#xa9; 2025 by the authors.

<31>
Accession Number
2034293830
Title
Probiotic mitigates gut hypoperfusion-associated acute gastrointestinal
injury in patients undergoing cardiopulmonary bypass: a randomized
controlled trial.
Source
BMC Medicine. 23(1) (no pagination), 2025. Article Number: 238. Date of
Publication: 01 Dec 2025.
Author
Yang X.; Liu R.; An Z.; Li B.; Lin Y.; Li Y.; Song B.; Yuan J.; Meng W.;
Waydhas C.
Institution
(Yang, Liu, Meng) The First School of Clinical Medicine, Lanzhou
University, Gansu, Lanzhou, China
(Yang, Liu, An, Li, Song) Department of Cardiovascular Surgery, The First
Hospital of Lanzhou University, Gansu, Lanzhou, China
(Lin, Meng) Department of General Surgery, The First Hospital of Lanzhou
University, Gansu, Lanzhou, China
(Meng) Gansu Province Key Laboratory of Biological Therapy and
Regenerative Medicine Transformation, Gansu, Lanzhou, China
(Li) Department of Pharmacy, The First Hospital of Lanzhou University,
Gansu, Lanzhou, China
(Yuan) Clinical Research Center, Big Data Center, The Seventh Affiliated
Hospital, Sun Yat-Sen University, Guangdong, Shenzhen, China
(Waydhas) Trauma Intensive Care, Department of Trauma Surgery, University
Hospital Essen, University Duisburg-Essen, Essen, Germany
Publisher
BioMed Central Ltd
Abstract
Background: Acute gastrointestinal injury (AGI) after cardiopulmonary
bypass (CPB) is associated with poor prognosis. This study aimed to
evaluate the effect of preoperative probiotic supplementation on the
incidence of AGI in patients undergoing CPB procedure. <br/>Method(s):
This was a double-blind, randomized controlled trial conducted in a single
center. The patients undergoing HVR with CPB between September 2022 and
February 2023 were randomly assigned to receive either probiotic (Lac
group) or placebo (Placebo group). The probiotic was administered daily
for seven days prior to surgery.Univariate and multivariate logistic
regression analysis was performed to identify independent risk factors for
AGI. A P-value < 0.05 was considered statistically significant. Gut
microbiota composition was assessed using 16 s rRNA analysis.
<br/>Result(s): A total of 52 patients were randomly assigned to two
groups (26 in the Lac group, 26 in the Placebo group). Patients were
followed for at least 30 days after surgery. During the follow-up period,
15 of the 52 patients (28.85%) developed AGI. The incidence of AGI was
significantly lower in the Lac group (15.38%) compared to the Placebo
group (42.31%), with a difference of 26.93% (P = 0.032). Moreover,
patients in the Lac group had a significantly shorter ICU stay (6 [5, 36]
vs. 5 [4, 5.5] days, P = 0.041) and a lower incidence of nosocomial
infections (11.54% vs. 34.62%, P = 0.048). Multivariate analysis
identified a higher Cardiac Surgery Score (CASUS) and CPB duration >= 132
min as independent risk factors for AGI, whereas probiotic supplementation
was the only protective factor. Furthermore, 16S rRNA sequencing revealed
significant differences in gut microbiota composition between the Lac and
Placebo groups. <br/>Conclusion(s): Preoperative probiotic supplementation
may be an effective strategy to reduce the incidence of AGI and
AGI-related complications in CPB patients. These findings suggest that
probiotics could be considered a preventive intervention for AGI in this
patient population. Trial registration: ClinicalTrials.gov:
NCT05498948.<br/>Copyright &#xa9; The Author(s) 2025.

<32>
Accession Number
2038026244
Title
Effect of Dexmedetomidine on Cerebrovascular Carbon Dioxide Reactivity
During Pediatric Cardiac Surgery With Cardiopulmonary Bypass.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 39(6) (pp 1482-1488),
2025. Date of Publication: 01 Jun 2025.
Author
Sun L.; Zhang K.; Wang H.; Ji W.; Huang Y.; Bai J.; Zheng J.
Institution
(Sun, Zhang, Ji, Huang, Bai, Zheng) Department of Anesthesiology, Shanghai
Children's Medical Center, Shanghai Jiao Tong University School of
Medicine, Shanghai, China
(Sun, Zhang, Ji, Huang, Bai, Zheng) Department of Anesthesiology, National
Children's Medical Center, Shanghai, China
(Wang) GE Healthcare, Shanghai, China
Publisher
W.B. Saunders
Abstract
Objective: To assess the effects of dexmedetomidine (DEX) on
cerebrovascular autoregulation in children with congenital heart disease
(CHD) using transcranial color-coded duplex sonography (TCCD).
<br/>Design(s): Randomized controlled trial. <br/>Setting(s): This
single-center study was conducted at a tertiary care center in Shanghai,
China. <br/>Patient(s): Fifty-nine children aged 0 to 6 years with CHD who
underwent cardiac surgery with cardiopulmonary bypass were enrolled.
<br/>Intervention(s): Children were randomly assigned to receive either
DEX (DEX group) or normal saline (control group) for 10 minutes following
anesthetic induction. Cerebrovascular carbon dioxide reactivity
(CVR-CO<inf>2</inf>) was assessed by adjustment of lung ventilation.
<br/>Measurements and Main Results: Patients underwent TCCD before and
after surgery. CVR-CO<inf>2</inf>, resistance index (RI), pulsatility
index (PI), mean blood flow velocity (V<inf>mean</inf>) of the right
middle cerebral artery, and regional cerebral oxygen saturation
(ScrO<inf>2</inf>) of the right frontal lobe were measured and analyzed at
three distinct time points, resulting in six measurements. Hemodynamic
parameters, including heart rate (HR) and mean arterial pressure (MAP),
were recorded at each time point. The parameters CVR-CO<inf>2</inf> (p =
0.402), PI (p = 0.203), RI (p = 0.290), V<inf>mean</inf> (p = 0.290),
ScrO<inf>2</inf> (p = 0.426), HR (p = 0.522), and MAP (p = 0.236) were
comparable between the two groups. In the control group, PI, RI, and HR
significantly differed before and after surgery. In the DEX group, RI,
V<inf>mean</inf>, ScrO<inf>2,</inf> and HR significantly differed before
and after surgery. <br/>Conclusion(s): A low loading dose of DEX did not
compromise CVR-CO<inf>2</inf> in children with CHD undergoing cardiac
surgery with cardiopulmonary bypass.<br/>Copyright &#xa9; 2025 Elsevier
Inc.

<33>
Accession Number
2034300753
Title
Optimal duration of anticoagulation after left atrial appendage closure: a
systematic review and meta-analysis.
Source
BMC Cardiovascular Disorders. 25(1) (no pagination), 2025. Article Number:
304. Date of Publication: 01 Dec 2025.
Author
Lu X.; Yang Z.; Fang W.; Niu X.; Wang Q.; Li Y.
Institution
(Lu, Yang, Fang, Niu, Wang, Li) Department of Cardiology, Tangdu Hospital,
The Fourth Military Medical University, Xi'an, China
Publisher
BioMed Central Ltd
Abstract
Background: Left atrial appendage closure (LAAC) has become the treatment
of choice for stroke prevention in patients with nonvalvular atrial
fibrillation who are at high risk of bleeding or with contraindications
for anticoagulation. However, the optimal duration of anticoagulation
after LAAC remains uncertain. The aim of this study was to evaluate the
optimal duration of treatment with novel oral anticoagulants (NOACs) after
LAAC. <br/>Method(s): We searched the PubMed, Embase, Cochrane Library,
and Web of Science databases for studies related to LAAC published from
inception to 20 December 2023, and performed a meta-analysis comparing the
efficacy and safety of 45-day and 3-month postoperative NOAC treatment
using R4.3.1 software. <br/>Result(s): A total of 14 studies were included
in this study, of which 4 were prospective cohort studies and 10 were
retrospective cohort studies. The incidence of stroke or transient
ischaemic attack (0.018 [95% CI: 0.007-0.033] in the 3-month group and
0.005 [95% CI: 0.001-0.011] in the 45-day group; P = 0.07) and the
incidence of device-related thrombus (0.025 [95% CI: 0.002-0.065] in the
3-month group and 0.020 [95% CI: 0.007-0.037] in the 45-day group; P =
0.81) were not significantly different. However, the incidence of major
bleeding was significantly greater in the 3-month group than in the 45-day
group (0.033 [95% CI: 0.018-0.053] in the 3-month group and 0.003 [95% CI:
0.000-0.008] in the 45-day group; P < 0.01). <br/>Conclusion(s): Compared
with the 3-month scheme, 45 days of postoperative anticoagulation
significantly reduced the risk of major bleeding in patients without
compromising the efficacy of preventing stroke or transient ischaemic
attack and device-related thrombus. Trial registration: Our meta-analysis
was registered in the PROSPERO international database
(CRD42024524661).<br/>Copyright &#xa9; The Author(s) 2025.

<34>
Accession Number
2037915051
Title
Vasoplegia in Cardiac Surgery: A Systematic Review and Meta-analysis of
Current Definitions and Their Influence on Clinical Outcomes.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 39(6) (pp 1451-1463),
2025. Date of Publication: 01 Jun 2025.
Author
Papazisi O.; van der Schoot M.M.; Berendsen R.R.; Arbous S.M.; le Cessie
S.; Dekkers O.M.; Klautz R.J.M.; Marczin N.; Palmen M.; de Waal E.E.C.
Institution
(Papazisi, Klautz, Palmen, de Waal) Department of Cardiothoracic surgery,
Leiden University Medical Center, Leiden, Netherlands
(van der Schoot, Berendsen) Department of Anesthesiology, Leiden
University Medical Center, Leiden, Netherlands
(Arbous) Department of Intensive Care, Leiden University Medical Center,
Leiden, Netherlands
(le Cessie, Dekkers) Department of Clinical Epidemiology, Leiden
University Medical Center, Leiden, Netherlands
(le Cessie) Department of Biomedical Data Sciences, Leiden University
Medical Center, Leiden, Netherlands
(Klautz) Department of Cardiothoracic surgery, Amsterdam University
Medical Center, Amsterdam, Netherlands
(Marczin) Division of Anaesthesia, Pain Medicine and Intensive Care,
Imperial College London, Royal Brompton & Harefield Hospitals, Guy's & St.
Thomas' NHS, London, United Kingdom
(Marczin) Department of Anesthesia and Intensive Care, Semmelweis
University, Budapest, Hungary
(de Waal) Department of Anesthesiology, University Medical Center Utrecht,
Netherlands
Publisher
W.B. Saunders
Abstract
Objectives: To identify differences in the reported vasoplegia incidence,
intensive care unit (ICU) length of stay (LOS), and 30-day mortality rates
as influenced by different vasoplegia definitions used in cardiac surgery
studies. <br/>Design(s): A systematic review was performed covering the
period 1977 to 2023 using PubMed/MEDLINE, Embase, Web of Science, Cochrane
Library, and Emcare and a meta-analysis (PROSPERO: CRD42021258328) was
performed. Setting and Participants: One hundred studies defining
vasoplegia in cardiac surgery patients were systematically reviewed. Sixty
studies with 20 or more patients, irrespective of design, reporting
vasoplegia incidence, ICU LOS, or 30-day mortality were included for
meta-analysis. <br/>Intervention(s): Cardiac surgery on cardiopulmonary
bypass. <br/>Measurements and Main Results: Studies were categorized
depending on the used mean arterial pressure (MAP) thresholds. Random
intercept logistic regression models were used for meta-analysis of
incidence and mortality. Random effect meta-analysis was used for ICU LOS.
One hundred studies were reviewed systematically. MAP and cardiac index
thresholds varied considerably (<50-80 mmHg and 2.0-3.5
L.min^-1m^-2, respectively). Vasopressor dosages also
differed between definitions. The reported incidence (60 studies; mean
incidence, 19.9%; 95% confidence interval [CI], 16.1-24.4) varied largely
between studies (2.5%-66.3%; I² = 97%; p < 0.0001).
Meta-regression models, including the MAP-threshold, did not explain this
heterogeneity. Similarly, the effect of vasoplegia on ICU LOS, and 30-day
mortality was very heterogeneous among studies (I² = 99% and
I² = 73%, respectively). <br/>Conclusion(s): The large
variability in vasoplegia definitions is associated with significant
heterogeneity regarding incidence and clinical outcomes, which cannot be
explained by factors included in our models. Such variations in
definitions leads to inconsistent patient diagnosis and renders published
vasoplegia research incomparable.<br/>Copyright &#xa9; 2025 The Authors

<35>
Accession Number
2038026254
Title
Acute Pain Management with Ultrasound-Guided Erector Spinae Plane Block
and Serratus Anterior Plane Block in Patients Undergoing Coronary Artery
Bypass via Mini-thoracotomy: A Randomized Controlled Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 39(6) (pp 1514-1521),
2025. Date of Publication: 01 Jun 2025.
Author
Xin L.; Wang L.; Feng Y.
Institution
(Xin, Feng) Department of Anesthesiology, Peking University People's
Hospital, Beijing, China
(Wang) Department of Anesthesiology, Fuwai Hospital, Chinese Academy of
Medical Science and Peking Union Medical College, Beijing, China
Publisher
W.B. Saunders
Abstract
Objective: This study was designed to examine the analgesic efficacy of
erector spinae plane (ESP) block or combined ESP and superficial serratus
anterior plane (SAP) block in patients undergoing elective coronary artery
bypass via mini-thoracotomy. <br/>Design(s): Randomized controlled study.
<br/>Setting(s): Operating room, intensive care unit, and ward.
<br/>Patient(s): Fifty-four patients undergoing elective coronary artery
bypass via mini-thoracotomy. <br/>Intervention(s): Eligible patients were
randomly allocated to single-ESP block (ESP group) or combined ESP and
superficial SAP block (ESP+SAP group). <br/>Measurements and Main Results:
The primary outcome was dynamic numerical rating scale (NRS) scores (on
coughing) for the surgical incision site 6 hours after skin closure.
Secondary outcomes included dynamic NRS scores for surgical incision at
12, 18, 24, and 48 hours postoperatively plus NRS scores for the chest
tube, hydromorphone consumption, quality of recovery, and adverse events
within 48 hours postoperatively. The ESP+SAP group had lower dynamic NRS
scores for surgical incision at postoperative 6 hours (mean difference:
-2.1, 95% CI -2.8 to -1.4, adjusted p < 0.001) and 12 hours (-1.3, 95% CI
-2.0 to -0.7, adjusted p < 0.001) compared to the ESP group. The ESP+SAP
group also showed lower dynamic NRS scores for the chest tube at 6 hours
(-1.4, 95% CI -2.0 to -0.9, adjusted p < 0.001) and 12 hours (-1.2, 95% CI
-1.7 to -0.6, adjusted p < 0.001) postoperatively. Linear mixed-model
analysis showed that NRS scores for the surgical incision and chest tube
were lower in the ESP+SAP group compared to the ESP group (both p < 0.05).
<br/>Conclusion(s): Compared with ESP block alone, ESP combined with
superficial SAP block reduced pain scores in patients undergoing coronary
artery bypass via mini-thoracotomy.<br/>Copyright &#xa9; 2025

<36>
Accession Number
2038230635
Title
Metabolic cost of physical rehabilitation in mechanically ventilated
patients in critical care: An observational study.
Source
BMJ Open Respiratory Research. 12(1) (no pagination), 2025. Article
Number: e002878. Date of Publication: 05 Apr 2025.
Author
Jenkins T.O.; Karbing D.S.; Rees S.E.; Poulsen M.K.; Patel B.V.; Polkey
M.I.; MacBean V.
Institution
(Jenkins) Royal Brompton and Harefield Hospitals, London, United Kingdom
(Karbing, Rees) Department of Health Science and Technology, Aalborg
Universitet, Aalborg, Denmark
(Poulsen) Intramedic, Aalborg, Denmark
(Patel) Division of Anaesthetics Pain Medicine and Intensive Care,
Imperial College London, Division of Surgery Oncology Reproductive Biology
and Anaesthetics, London, United Kingdom
(Polkey) Department of Respiratory Medicine, Royal Brompton Hospital,
National Heart and Lung Institute, London, United Kingdom
(MacBean) College of Health Medicine and Life Sciences, Brunel University
of London, London, United Kingdom
Publisher
BMJ Publishing Group
Abstract
Background Physical rehabilitation is advocated to improve muscle strength
and function after critical illness, yet interventional studies have
reported inconsistent benefits. A greater insight into patients'
physiological response to exercise may provide an option to prescribe
individualised, targeted rehabilitation, yet there is limited data
measuring oxygen consumption (VO 2) during physical rehabilitation. We
aimed to test the feasibility of measuring VO 2 during seated and standing
exercise using the Beacon Caresystem and quantify within- and
between-patient variability of VO 2 percentage change. Methods We
conducted a prospective observational study on patients mechanically
ventilated for >=72 hours and able to participate in physical
rehabilitation in critical care. Oxygen consumption was measured
continuously using indirect calorimetry. A total of 29 measurements were
taken from ten participants performing active sitting and standing
exercise. Results Median (IQR) first session baseline VO 2 was 3.54
(2.9-3.9) mL/kg/min, increasing significantly to 4.37 (3.96-5.14)
mL/kg/min during exercise (p=0.005). The median (IQR) coefficient of
variation of VO 2 percentage change in participants (n=7) who completed
more than one rehabilitation session (range 2-7 sessions) was 43 (34-61)%
in 26 measurements. The median (IQR) coefficient of variation of VO 2
percentage change was 46 (26-63)% in participants performing >1 sitting
exercise session (six participants, 19 sessions). Conclusions VO 2
increases significantly with exercise but is highly variable between
participants, and in the same participant on separate occasions,
performing the same functional activity. These data suggest that
simplified measures of function do not necessarily relate to oxygen
consumption. Trial registration number NCT05101850.<br/>Copyright &#xa9;
Author(s) (or their employer(s)) 2025.

<37>
[Use Link to view the full text]
Accession Number
2035507555
Title
Culprit vessel revascularization prior to complete angiography as a
strategy to minimize delays in primary percutaneous coronary intervention
for patients with ST-elevation myocardial infarction: a systematic review
and meta-analysis.
Source
Coronary Artery Disease. 36(3) (pp 232-239), 2025. Date of Publication: 01
May 2025.
Author
Bulhoes E.; Antunes V.L.J.; Defante M.L.R.; Mazetto R.; Garcia A.C.;
Garcia T.C.C.; Guida C.
Institution
(Bulhoes) Medicine Department, College of Higher Education of the United
Amazon, Para, Redencao, Brazil
(Antunes) Medicine Department, Federal University of Health Sciences of
Porto Alegre, Porto Alegre, Brazil
(Defante) Medicine Department, Redentor University Center, Itaperuna,
Brazil
(Mazetto) Medicine Department, Amazonas State University, Manaus, Brazil
(Garcia) Division of Cardiology, Goias Military Police Hospital, Goias,
Brazil
(Garcia, Guida) Division of Cardiology, Dante Pazzanese Institute of
Cardiology, Sao Paulo, Brazil
Publisher
Lippincott Williams and Wilkins
Abstract
The rapid restoration of blood flow in patients with acute myocardial
infarction with ST elevation through percutaneous coronary intervention
(PCI) is crucial for the survival of this population. Attempts to decrease
the time from diagnosis of ST-segment elevation myocardial infarction
(STEMI) to arrival at the catheterization laboratory have been extensively
investigated. However, strategies during the procedure aiming to reduce
the time to reperfusion are lacking. We conducted a meta-analysis to
evaluate culprit vessel revascularization prior to complete angiography as
a strategy to minimize delays in primary PCI for patients with STEMI. We
searched PubMed, Embase, and Cochrane Central. <br/>Outcome(s): vascular
access-to-balloon, door-to-balloon, and first medical contact-to-balloon
times; death, reinfarction in 30 days, Bleeding Academic Research
Consortium >=3 type, coronary artery bypass grafting referral, and left
ventricular ejection fraction %. Statistical analysis was performed using
the R program (version 4.3.2). Heterogeneity was assessed with
I² statistics. We included 2050 patients from six studies, of
which two were randomized controlled trials and four were observational
studies. Culprit vessel revascularization prior to complete angiography
was associated with a statistically significant decrease of times:
vascular access-to-balloon time (mean difference -6.79 min; 95% CI: -8.00
to -5.58; P < 0.01; I² = 82%) and door-to-balloon time (mean
difference -9.02 min; 95% CI: -12.83 to -5.22; P < 0.01; I² =
93%). In this meta-analysis, performing PCI on the culprit lesion prior to
complete coronary angiography led to significantly shorter reperfusion
times, with no discernible differences in complication
rates.<br/>Copyright &#xa9; 2024 Wolters Kluwer Health, Inc. All rights
reserved.

<38>
[Use Link to view the full text]
Accession Number
2038463867
Title
Perioperative Outcomes in Patients Undergoing Transcatheter Aortic Valve
Replacement with Concomitant Mitral Regurgitation: A Meta-Analysis.
Source
Cardiology in Review. (no pagination), 2025. Article Number:
10.1097/CRD.0000000000000919. Date of Publication: 2025.
Author
Amani-Beni R.; Darouei B.; Rabiee Rad M.; Ghasempour Dabaghi G.; Eshraghi
R.; Bahrami A.; Amini-Salehi E.; Hashemi S.M.; Mazaheri-Tehrani S.;
Movahed M.R.
Institution
(Amani-Beni, Darouei, Rabiee Rad, Ghasempour Dabaghi) Isfahan
Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan
University of Medical Sciences, Isfahan, Iran, Islamic Republic of
(Eshraghi) Social Determinants of Health Research Center, Isfahan
University of Medical Sciences, Isfahan, Iran, Islamic Republic of
(Bahrami) Kashan University of Medical Sciences, Kashan, Iran, Islamic
Republic of
(Amini-Salehi) School of Medicine, Guilan University of Medical Sciences,
Rasht, Iran, Islamic Republic of
(Hashemi) Cardiovascular Research Center, Hormozgan University of Medical
Sciences, Bandar Abbas, Iran, Islamic Republic of
(Mazaheri-Tehrani) Child Growth and Development Research Center, Research
Institute for Primordial Prevention of Non-Communicable Disease, Isfahan
University of Medical Sciences, Isfahan, Iran, Islamic Republic of
(Movahed) Department of Medicine, University of Arizona, College of
Medicine, Phoenix, United States
(Movahed) Department of Medicine, University of Arizona, Sarver Heart
Center, Tucson, AZ, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Transcatheter aortic valve replacement (TAVR) is widely performed in
high-risk patients with severe aortic stenosis. However, the effects of
baseline concomitant mitral regurgitation (MR) on perioperative outcomes
remain unclear. This study evaluated the impact of concomitant MR severity
on short-term TAVR outcomes. A systematic search of 6 electronic databases
was conducted. Studies that stratified patients based on MR severity (MR
>=2 vs. <2 or MR >=3 vs. <3) and reported perioperative outcomes,
including short-term mortality, in-hospital mortality, acute kidney injury
(AKI), pacemaker implantation, bleeding, vascular complications, and MR
improvement (up to 1 week and 1 month) were eligible. Data from 26 studies
(32,453 patients) demonstrated that patients with baseline
moderate-to-severe MR (MR >=2) had a 49% (95% confidence interval (CI),
1.32-1.70) increased risk of short-term mortality, a 41% (95% CI,
1.22-1.63) higher risk of in-hospital mortality, and a 38% (95% CI,
1.17-1.62) higher risk of AKI than those with none-to-mild MR (MR<2).
Patients with an MR >=3 had an even greater 72% (95% CI, 1.37-2.16)
increase in short-term mortality. No significant differences were observed
in pacemaker implantation, bleeding, or vascular complications between
groups. Additionally, after TAVR, MR improved in 36% of patients by at
least 1 grade within 1 week, increasing to 44% by 1 month. In TAVR
patients, MR >=2 was associated with significantly higher early mortality
and AKI risk, underscoring the need for a comprehensive perioperative risk
assessment. Future studies should examine the differential impact of
functional and degenerative MR.<br/>Copyright &#xa9; 2025 Wolters Kluwer
Health, Inc.

<39>
Accession Number
2036477223
Title
A randomized study of cryoablation of intercostal nerves in patients
undergoing minimally invasive thoracic surgery.
Source
Journal of Thoracic and Cardiovascular Surgery. 169(5) (pp 1375-1382.e1),
2025. Date of Publication: 01 May 2025.
Author
Weksler B.; Maxwell C.; Drake L.; Crist L.; Specht K.; Kuchta P.; DeHaven
K.; Weksler I.; Williams B.A.; Fernando H.C.
Institution
(Weksler, Maxwell, Drake, Crist, Specht, Kuchta, DeHaven, Weksler,
Williams, Fernando) Division of Thoracic and Esophageal Surgery,
Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, United
States
Publisher
Elsevier Inc.
Abstract
Objectives: Minimally invasive thoracic surgery can cause significant
pain, and optimizing pain control after surgery is highly desirable. We
examined pain control after intercostal nerve block with or without
cryoablation of the intercostal nerves. <br/>Method(s): This was a
randomized study (NCT05348447) of adults scheduled for a minimally
invasive thoracic procedure. Each intercostal space near the incision site
was injected with lidocaine and bupivacaine with epinephrine (standard of
care). The cryoanalgesia group also had 5 to 6 intercostal nerves ablated.
The primary outcome was the amount of narcotics (in morphine milligram
equivalents taken during the postoperative hospital stay and the first 2
weeks postdischarge. Secondary outcomes were incentive spirometry volume
and pain scores in the hospital and pain and neuropathy scores at 2 weeks.
<br/>Result(s): Our final cohort contained 103 patients (52 standard of
care and 51 cryoanalgesia). There were no differences between the
treatment groups in morphine milligram equivalents administered during the
hospital stay (44.9 vs 38.4 mg), total morphine milligram equivalents at 2
weeks (108.8 vs 95.2 mg), or pain assessed by visual analog scale on
postoperative day 1 (3.8 and 3.3), postoperative day 2 (2 and 3.5), or 2
weeks (2 and 3.5) for standard of care and cryoanalgesia group patients,
respectively. The decrease in incentive spirometry during the
postoperative period was not significantly different between the 2 groups.
Patients in the cryoanalgesia group had higher neuropathy scores (8 vs 13;
P = .019) 2 weeks after surgery. <br/>Conclusion(s): In this randomized
study, cryoanalgesia did not decrease postoperative pain or narcotic
requirements. Cryoanalgesia increased neuropathic pain 2 weeks after
surgery.<br/>Copyright &#xa9; 2024 The American Association for Thoracic
Surgery

<40>
[Use Link to view the full text]
Accession Number
2035556472
Title
Is the Use of a Buprenorphine Transdermal Patch More Effective Than Oral
Medications for Postoperative Analgesia After Arthroscopic Rotator Cuff
Repair? A Randomized Clinical Trial.
Source
Clinical Orthopaedics and Related Research. 483(5) (pp 857-865), 2025.
Date of Publication: 01 May 2025.
Author
Liu W.; Qin J.; Fang X.; Jiang G.; Wang P.; Ding M.; Xu R.
Institution
(Liu) Department of Pharmacy, Nanjing Drum Tower Hospital, Drum Tower
Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing,
China
(Qin, Jiang, Wang, Xu) Division of Sports Medicine and Adult
Reconstructive Surgery, Department of Orthopedic Surgery, Nanjing Drum
Tower Hospital, Affiliated Hospital of Medical School, Nanjing University,
Nanjing, China
(Fang, Ding) Department of Pharmacy, Nanjing Drum Tower Hospital, School
of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University,
Nanjing, China
(Xu) Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated
Hospital of Medical School, Nanjing University, Nanjing, China
Publisher
Wolters Kluwer Health Inc
Abstract
Background Appropriate analgesic protocols for patients following
arthroscopic rotator cuff repair remain controversial. Although
transdermal buprenorphine patches might potentially provide better pain
control and fewer side effects, it is worth noting that there is limited
evidence for this given a lack of direct comparisons with oral pain
regimens. Questions/purposes Among patients undergoing arthroscopic
rotator cuff repair, and compared with an analgesic approach using oral
tramadol plus celecoxib: (1) Does perioperative use of buprenorphine
patches provide better pain relief by a clinically important margin? (2)
Does perioperative use of buprenorphine patches improve shoulder joint
function recovery? (3) Does perioperative use of buprenorphine patches
have a lower frequency of adverse reactions? Methods This was a
prospective, single-center, randomized controlled trial. We included
patients who underwent arthroscopic rotator cuff repair for partial- or
full-thickness rotator cuff tears < 3 cm in size in the anterior to
posterior direction as estimated by preoperative MRI and excluded those
who had obesity, were pregnant, had opioid dependence, had history of
cardiac bypass surgery or ipsilateral rotator cuff repair, had allergies
to trial medications, were taking anticoagulants or antidepressants, were
being treated with other postsurgical pain management methods, or had
severe liver or kidney dysfunction. Based on these criteria, 64% (72 of
112) of patients were eligible. The patients were randomly assigned into
either the control group (oral tramadol and celecoxib) or the experimental
group (buprenorphine patches). The control group received 100 mg of
tramadol and 200 mg of celecoxib every 12 hours for 2 weeks after surgery.
The experimental group received buprenorphine patches about 48 hours
before surgery without any oral medication. A medication journal was given
to the patients to self-report their compliance in taking the drugs. The
dosage regimen adhered strictly to protocol. After enrollment, 11% (4 of
36) of patients in the control group and 17% (6 of 36) of patients in the
experimental group could not be fully analyzed because of loss to
follow-up or missing data. The surveillance period was 3 months, and there
was no crossover between groups. The groups did not differ at baseline in
terms of demographic parameters and relevant clinical characteristics,
including age, gender, BMI, American Society of Anesthesiologists
classification, tear size, concomitant procedures, and number of anchors.
The outcomes were (1) numeric rating scale (NRS) for pain score at rest or
with movement, which ranges from 0 to 10, where 0 indicates no pain, and
10 indicates the worst pain; (2) the American Shoulder and Elbow Surgeons
(ASES) score for joint function, which ranges from 0 to 100, with higher
scores indicating better shoulder joint function; and (3) the incidence of
postoperative adverse reactions. We defined the minimum clinically
important difference on the NRS as 2 of 10 points and on the ASES score as
15 of 100 points, based on anchor-based approaches reported in other
studies. Results We found no clinically important between-group
differences in NRS pain scores at any time point, either at rest or with
movement. Likewise, we found no clinically important between-group
differences in ASES scores at any time point. Postoperative dizziness or
drowsiness (20% [6 of 30 patients] versus 44% [14 of 32 patients]; p =
0.04) and nausea (10% [3 of 30 patients] versus 34% [11 of 32 patients]; p
= 0.02) during the hospital stay were slightly lower in the experimental
group compared with the control group. Conclusion In this randomized
trial, we found no clinically important advantages in pain or function to
the use of buprenorphine patches after arthroscopic rotator cuff repair,
and insufficient evidence exists to confirm whether the minor differences
in transient side effects could justify the use of a new and largely
untested analgesic approach in this context. That being so, we recommend
against the routine use of buprenorphine patches for this indication. In
general, we found that pain levels were low after the procedure in both
groups. Future studies, therefore, should focus on the efficacy of
buprenorphine patches for more invasive or more painful
procedures.<br/>Copyright &#xa9; 2024 by the Association of Bone and Joint
Surgeons.

<41>
Accession Number
2038513167
Title
The randomized controlled trial to compare temporary permanent pacemaker
vs temporary pacemaker in patients with conduction block after
transcatheter aortic valve replacement: Rationale and design of the
RECOVER trial.
Source
American Heart Journal. 287 (pp 41-49), 2025. Date of Publication: 01 Sep
2025.
Author
Jiang Z.; Chang S.; Tao L.; Luo J.; Fu G.; Wang Y.; Pan W.; Chen L.; Fang
Z.; Li Y.; Bai M.; Yu B.; Cheng X.; Peng X.; Jilaihawi H.; Piazza N.;
Modine T.; Song G.
Institution
(Jiang, Chang, Song) Interventional Center of Valvular Heart Disease,
Beijing AnZhen Hospital, Capital Medical University, National Clinical
Research Centre for Cardiovascular Diseases, Beijing, China
(Tao) Department of Cardiology, Xijing Hospital, Fourth Military Medical
University, Xi'an, China
(Luo) Guangdong Provincial People's Hospital, Guangdong Academy of Medical
Sciences, Guangdong Cardiovascular Institute, Guangzhou, China
(Fu) Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang
University of Medicine, Hangzhou, China
(Wang) Xiamen Heart Center, Xiamen University, Xiamen, China
(Pan) Department of Cardiology, Shanghai Institute of Cardiovascular
Disease, Zhongshan Hospital, Fudan University, Shanghai, China
(Chen) Department of Cardiology, Fujian Medical University Union Hospital,
Fuzhou, China
(Fang) Departments of Cardiology, The Second Xiangya Hospital of Central
South University, Hunan, China
(Li, Yu) Department of Cardiology, Tangdu Hospital, Fourth Military
Medical University, Xi'an, China
(Bai) Department of Cardiology, The First Hospital of Lanzhou University,
Lanzhou, China
(Yu) Department of Cardiology, The Second Affiliated Hospital of Harbin
Medical University, Harbin, China
(Cheng) Department of Cardiology, Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, China
(Peng) Department of Cardiology, The First Affiliated Hospital of Nanchang
University, Nanchang, China
(Jilaihawi) Heart Valve Center, NYU Langone Health, New York, United
States
(Piazza) Division of Cardiology, Department of Medicine, McGill University
Health Centre, Quebec, Canada
(Modine) Hopital Cardiologique de Haut-Leveque, Bordeaux University
Hospital, Bordeaux, France
Publisher
Elsevier Inc.
Abstract
Rationale: Current guidelines and expert consensus recommend different
time thresholds of temporary pacemaker (TM) indwelling in patients with
conduction block after transcatheter aortic valve replacement (TAVR).
Accordingly, this lack of clinical evidence and effective strategies has
resulted in extensive variations in permanent pacemaker (PPM) implantation
patterns, potentially leading to over-early PPM implantation. The use of a
temporary permanent pacemaker (TPPM), which involves an active fixation
pacing lead and an external pulse generator secured to the skin surface,
may be effective and safe in these patients. TPPM may improve
postoperative mobility and facilitate early discharge, while providing
prolonged and stable pacing for the recovery of conduction block, thereby
reducing unnecessary PPM implantation. <br/>Design(s): The RECOVER trial
is a prospective, multicenter, open-label, randomized controlled study
comparing TPPM vs TM in patients with conduction block after TAVR. The
trial will enroll 160 subjects across 13 sites in China. Inclusion
criteria include patients with persistent third-degree atrioventricular
block (AVB), second-degree AVB, first-degree AVB with symptoms (PR
interval >300 ms), alternating bundle branch block or bifascicular block
with syncope/blackness related symptoms occurred during TAVR procedure or
within 1 month after TAVR. Enrolled patients will be randomized 1:1 to the
TPPM group for a 1-month bridge or the TM group for conventional 24 to 48
hours pacing. The primary effectiveness endpoint is the rate of PPM
implantation at 6 months after the occurrence of AVB. Secondary
effectiveness endpoint is the rate of PPM implantation at 1 month after
the occurrence of AVB. Safety endpoints include all-cause mortality and
TPPM/TM/PPM procedure-related complications during the 6-month follow-up.
Key data collected will include sociodemographic information, medical
history, electrocardiograph, HOLTER, echocardiography, contrast-enhanced
cardiac CT, details of procedures and pacemaker interrogation. Indication
for PPM implantation will be adjudicated by an independent pacing
electrophysiologist committee. <br/>Conclusion(s): The RECOVER trial will
evaluate whether TPPM is superior to conventional TM in reducing the rate
of PPM implantation in patients with conduction block after TAVR, with a
buffer period to distinguish whether conduction block is reversible or
persistent. Current status: The trial is still enrolling participants
(with 14 enrolled as of January 1, 2025). Trial registration: Randomized
controlled trial to compare temporary permanent pacemaker vs temporary
pacemaker in patients with conduction block after transcatheter aortic
valve replacement. Chinese Clinical Trial Registry ChiCTR2400087536.
Registered at July 30, 2024.
https://www.chictr.org.cn/showproj.html?proj=227719.<br/>Copyright &#xa9;
2025

<42>
Accession Number
2034346482
Title
Pharmacological Efficacy of Intravenous Magnesium in Attenuating
Remifentanil-Induced Postoperative Hyperalgesia: A Systematic Review and
Meta-Analysis of Randomized Controlled Trials.
Source
Pharmaceuticals. 18(4) (no pagination), 2025. Article Number: 518. Date of
Publication: 01 Apr 2025.
Author
Wu E.-B.; Wu K.-L.; Hsu W.-T.; Yuan W.-C.; Chen K.-B.
Institution
(Wu, Hsu, Yuan, Chen) Department of Anesthesiology, China Medical
University Hospital, China Medical University, 404, Taichung City, Taiwan
(Republic of China)
(Wu) Division of Colorectal Surgery, Department of Surgery, Kaohsiung
Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine,
Kaohsiung City, Taiwan (Republic of China)
(Chen) Department of Anesthesiology, School of Medicine, China Medical
University, 404, Taichung City, Taiwan (Republic of China)
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Remifentanil-based anesthesia is linked to
opioid-induced hyperalgesia (OIH), increasing postoperative pain and
analgesic requirements. Magnesium, an N-methyl-D-aspartate (NMDA) receptor
antagonist, might alleviate OIH. We aimed to assess whether intravenous
magnesium reduces postoperative pain, analgesic requirements, and
hyperalgesia in adults receiving remifentanil-based anesthesia.
<br/>Method(s): We searched PubMed, Embase, the Cochrane Library, and Web
of Science (1 December 2024) for randomized controlled trials (RCTs)
comparing intravenous magnesium vs. placebo. Risk of bias was evaluated
with the Cochrane RoB 2 tool, and random-effects meta-analyses were
conducted. GRADE was used to assess evidence quality. Primary outcomes
were postoperative analgesic requirements and pain scores; secondary
outcomes included intraoperative remifentanil consumption, shivering,
postoperative nausea/vomiting (PONV), extubation time, hypotension, and
bradycardia. PROSPERO registration: CRD42024609911. <br/>Result(s):
Twenty-two RCTs (n = 1362) met eligibility. Magnesium significantly
decreased 24 h analgesic requirements (standardized mean difference [SMD]
-1.51; 95% confidence interval [CI] -2.15 to -0.87; p < 0.0001) and pain
scores (SMD -0.61; 95% CI -0.90 to -0.32; p < 0.0001), with benefits
persisting up to 48 h. It also reduced intraoperative remifentanil use
(SMD -0.52), shivering (odds ratio [OR] 0.25), and PONV (OR 0.66), without
prolonging extubation or increasing hypotension/bradycardia risk. High
heterogeneity, potential publication bias, and moderate-to-very-low
evidence certainty warrant caution. <br/>Conclusion(s): Intravenous
magnesium appears beneficial in remifentanil-based anesthesia, but further
large-scale, methodologically robust trials are needed to confirm optimal
and clarify safety profiles across diverse surgical
populations.<br/>Copyright &#xa9; 2025 by the authors.

<43>
Accession Number
2038409672
Title
Comparative effectiveness of transcatheter vs surgical aortic valve
replacement: A systematic review and meta-analysis.
Source
World Journal of Cardiology. 17(4) (no pagination), 2025. Article Number:
104168. Date of Publication: 26 Apr 2025.
Author
Moradi I.; Mustafa M.S.; Sardar Sheikh J.; Shojai Rahnama B.; Fredericks
M.; Kumar Yennam A.; Arain M.; Saha U.; Richard Ma A.; Nagendran A.; Bin
Omer M.; Armaghan M.; Jaimes D.C.C.; Avinash Bojanki N.L.S.V.; Shafique
M.A.
Institution
(Moradi, Shojai Rahnama, Fredericks, Richard Ma) Department of Medicine,
Saint George's University, Grenada, Grenada
(Mustafa, Shafique) Department of Medicine, Jinnah Sindh Medical
University, Sindh, Karachi, Pakistan
(Sardar Sheikh, Bin Omer, Armaghan) Department of Medicine, CMH Lahore
Medical College, Institute of Dentistry, Punjab, Lahore, Pakistan
(Kumar Yennam) Department of Medicine, Emilio Aguinaldo College, Manila,
Philippines
(Arain) Department of Medicine, Dow University of Health Sciences,
Karachi, Pakistan
(Saha) Department of Medicine, Icahn School of Medicine at Mount Sinai
Queens, New York, NY, United States
(Nagendran) Department of Medicine, Rochester Regional Health-Unity
Hospital, Rochester, NY, United States
(Jaimes) Department of Medicine, Xavierian Pontifical University, Bogota,
Colombia
(Avinash Bojanki) Department of Medicine, Dr. NTR University of Health
Sciences, Andha Pradesh, India
Publisher
Baishideng Publishing Group Inc
Abstract
BACKGROUND The management of severe symptomatic aortic stenosis has been
revolutionized by transcatheter aortic valve replacement (TAVR), offering
a minimally invasive alternative to surgical aortic valve replacement
(SAVR). However, the comparative safety and efficacy of these
interventions remain subjects of ongoing investigation. AIM To compare the
clinical outcomes and safety of TAVR vs SAVR in patients with severe
symptomatic aortic stenosis. METHODS A systematic review and meta-analysis
were conducted according to PRISMA guidelines. Randomized controlled
trials (RCTs) comparing TAVR and SAVR were identified from databases
including PubMed, Scopus, and Web of Science up to May 31, 2024. Data were
extracted on clinical outcomes, including mortality, procedural
complications, and post-procedure adverse events. Risk ratios (RRs) with
95%CIs were calculated using a random-effects model. RESULTS A total of 10
RCTs were included. TAVR demonstrated a significantly lower risk of acute
kidney injury (RR: 0.33; 95%CI: 0.25-0.44), major bleeding (RR: 0.37;
95%CI: 0.30-0.46), and new-onset atrial fibrillation (RR: 0.44; 95%CI:
0.34-0.57) compared to SAVR. However, TAVR was associated with higher
risks of new permanent pacemaker implantation (RR: 3.49; 95%CI:
2.77-4.39), major vascular complications (RR: 2.47; 95%CI: 1.91-3.21), and
paravalvular leaks (RR: 4.15; 95%CI: 3.14-5.48). Mortality at 30 days was
comparable (RR: 0.95; 95%CI: 0.78-1.15), but long-term mortality was
slightly higher with TAVR in some analyses (RR: 1.23; 95%CI: 1.01-1.49).
Rates of stroke (RR: 0.97; 95%CI: 0.81-1.17) and myocardial infarction
(RR: 0.91; 95%CI: 0.67-1.24) were similar between the groups. CONCLUSION
TAVR offers a less invasive option with significant benefits in reducing
acute kidney injury, major bleeding, and new-onset atrial fibrillation,
making it particularly advantageous for high-risk surgical candidates.
However, higher risks of permanent pacemaker implantation, vascular
complications, and paravalvular leaks highlight the need for
individualized patient selection and shared decision-making to optimize
outcomes.<br/>Copyright &#xa9;The Author(s) 2025. Published by Baishideng
Publishing Group Inc. All rights reserved.

<44>
[Use Link to view the full text]
Accession Number
2036069254
Title
Effect of PCSK9 inhibitors on major cardiac adverse events and
lipoprotein-a in patients with coronary heart disease: a meta-analysis.
Source
Coronary Artery Disease. 36(3) (pp 200-210), 2025. Date of Publication: 01
May 2025.
Author
Hu E.; Wan M.
Institution
(Hu) Department of Pharmacy, The Sixth Hospital of Wuhan, Affiliated
Hospital of Jianghan University, Hubei Province, Wuhan, China
(Wan) Department of the Second Clinic, The 940 Hospital of Joint Logistics
Support Force of Chinese PLA, Gansu Province, Lanzhou, China
Publisher
Lippincott Williams and Wilkins
Abstract
Background Lipoprotein(a) [Lp(a)] is an independent risk factor for
cardiovascular disease due to its unique apo(a) component and its
association with atherosclerosis and thrombogenesis. This meta-analysis
was conducted to evaluate the effects of PCSK9 inhibitors on major adverse
cardiac events (MACE) and Lp(a) levels in patients with coronary heart
disease. Methods Randomized controlled trials (RCTs) were systematically
searched in PubMed, the Cochrane Library, and other databases. Stata 15.1
software was used for data analysis, and a random- or fixed-effects model
was selected based on inter-study heterogeneity. Egger's test was applied
to detect publication bias. Results A total of 12 RCTs were included,
involving 48 116 patients with a mean age of 62 years, comprising 65%
males and diverse ethnic backgrounds. The results showed that compared
with the control group, PCSK9 inhibitors significantly reduced low-density
lipoprotein cholesterol (WMD = -1.24 mmol/L, 95% confidence interval (CI):
-1.28 to -1.20), total cholesterol, triglycerides, and Lp(a) levels while
increasing high-density lipoprotein cholesterol levels. In terms of
safety, there was no increased risk of adverse reactions other than
injection site reactions. For MACE, PCSK9 inhibitors significantly reduced
the risk of nonfatal myocardial infarction, stroke, and coronary
revascularization events (RR = 0.87, 95% CI: 0.84-0.89). Conclusion PCSK9
inhibitors not only significantly improve blood lipid profiles and reduce
Lp(a) levels but also reduce the risk of MACE in patients with coronary
heart disease. Therefore, PCSK9 inhibitors offer an effective and safe
treatment option for these patients.<br/>Copyright &#xa9; 2024 Wolters
Kluwer Health, Inc. All rights reserved.

<45>
Accession Number
2038464129
Title
Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients
Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind
Clinical Trial.
Source
Circulation: Cardiovascular Interventions. (no pagination), 2025. Article
Number: e014961. Date of Publication: 2025.
Author
Kjaergaard J.; Moller C.H.; Wiberg S.; Mikkelsen A.D.; Moller-Sorensen H.;
Ravn H.; Ravn J.; Olsen P.S.; Hofsten D.; Boesgaard S.; Kober L.; Nilsson
J.C.; Hassager C.
Institution
(Kjaergaard, Mikkelsen, Hofsten, Boesgaard, Kober, Hassager) Department of
Cardiology, Copenhagen University Hospital Rigshospitalet, Denmark
(Kjaergaard, Wiberg, Kober, Hassager) Department of Clinical Medicine,
Faculty of Health Sciences, University of Copenhagen, Denmark
(Moller, Ravn, Olsen) Department of Cardiothoracic Surgery, Copenhagen
University Hospital Rigshospitalet, Denmark
(Wiberg, Moller-Sorensen, Nilsson) Department of Cardiothoracic
Anesthesiology, Copenhagen University Hospital Rigshospitalet, Denmark
(Ravn) Department of Anesthesiology and Intensive Care, Odense University
Hospital, Copenhagen, Denmark
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: GLP-1 (glucagon-like peptide-1) agonists have been proven
beneficial in reducing the risk of and injury associated with several
cardiovascular diseases. The efficacy in cardiopulmonary bypass-assisted
cardiac surgery is unknown. This trial aimed to investigate the efficacy
of an infusion of the GLP-1 agonist exenatide during and after open-heart
surgery in reducing the risk of death and major organ failure.
<br/>METHOD(S): Randomized, double-blinded, 2-by-2 factorial design,
single-center clinical trial, also including liberal (FiO<inf>2</inf>of
100%) or restrictive (FiO<inf>2</inf>of 50%) oxygenation during and after
bypass. The present article presents the results of the exenatide
intervention. We included adult patients undergoing elective
cardiopulmonary bypass-assisted coronary artery bypass grafting and aortic
valve replacement. Patients were predominantly low risk. The intervention
was an infusion of 17.4 microg of exenatide or placebo during
cardiopulmonary bypass and the first hour after weaning thereof. The main
outcome was time to a composite end point consisting of death, stroke,
renal failure requiring dialysis, or new/worsening heart failure during
follow-up. Secondary end points included occurrence of prespecified
adverse events. <br/>RESULT(S): A total of 1389 patients were included in
the analyses. Within a follow-up period of a median of 5.9 years (min-max;
2.5-8.3 years), 170 (24%) patients in the exenatide group and 165 (24%)
patients experienced a primary end point. We found no difference in time
to the first event between patients randomized to FiO<inf>2</inf>50%
versus FiO<inf>2</inf>100% (hazard ratio, 1.0 [95% CI, 0.83-1.3]; P=0.80).
We found no significant difference in rates of adverse events between the
2 groups. <br/>CONCLUSION(S): Exenatide during cardiopulmonary bypass and
weaning thereof did not significantly reduce the incidence of death,
stroke, renal failure, or new/worsening heart failure in patients
undergoing coronary artery bypass grafting and aortic valve replacement.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier:
NCT02673931.<br/>Copyright &#xa9; 2025 Lippincott Williams and Wilkins.
All rights reserved.

<46>
Accession Number
2038408457
Title
To Compare The Efficacy Of Isobaric Levobupivacaine And Isobaric
Ropivacaine In Patients Undergoing Breast Cancer Surgeries Under Thoracic
Segmental Spinal Anaesthesia.
Source
International Journal of Life Sciences Biotechnology and Pharma Research.
14(4) (pp 851-858), 2025. Date of Publication: 01 Apr 2025.
Author
Kaur H.; Kaur G.; Makhni R.; Ravipaul
Institution
(Kaur, Kaur, Makhni, Ravipaul) Department of anesthesiology, GMC, Punjab,
Amritsar, India
Publisher
International Journal of Life Sciences Biotechnology and Pharma Research
Abstract
Background- Breast cancer is the second most common cause of cancer deaths
in women around the world and the main modality of its treatment is
surgery, which is associated with postoperative nausea-vomiting (PONV) and
pain. It is commonly performed under general anesthesia (GA), but can also
be performed under regional anaesthesia such as thoracic segmental spinal
anaesthesia (TSSA), which is an effective alternative to GA especially in
patients who are at risk under GA. The aim of the study is to compare the
efficacy of isobaric levobupivacaine and ropivacaine in patients
undergoing breast cancer surgeries under TSSA. Methods- The study enrolled
60 patients scheduled for Modified Radical Mastectomy, divided randomly
into two groups of 30 each (group L and R), belonging to the age group
18-60 years of ASA grade l and ll. Group L received 1.8 ml 0.5% isobaric
levobupivacaine and group R received 1.8 ml 0.5% isobaric ropivacaine.
Results- The mean onset of sensory block of group R (7.18+/-0.62 min) was
more than group L (3.66+/-0.51 min). The mean time to attain maximum
sensory level in group R (7.91+/-0.47 min) was more than group L
(5.33+/-0.63 min). Total duration of the sensory block was more in group L
(180.83+/-6.17 min) than group R (129.50+/-6.47 min). Intraoperative and
postoperative hemodynamics were stable and no PONV was seen in either
group. The total number of rescue analgesia doses were more in group R
(2.16+/-0.83) than group L (1.46+/-0.62). Conclusion- Isobaric
levobupivacaine provides adequate subarachnoid block for breast cancer
surgeries under thoracic segmental spinal anaesthesia than isobaric
ropivacaine with longer duration of sensory block.<br/>Copyright
&#xa9;2025Int. J. LifeSci.Biotechnol.Pharma.Res.

<47>
Accession Number
2038418316
Title
Letter by Xu et al Regarding Article, "effect of Delayed Remote Ischemic
Preconditioning on Acute Kidney Injury and Outcomes in Patients Undergoing
Cardiac Surgery: A Randomized Clinical Trial".
Source
Circulation. 151(16) (pp e957-e958), 2025. Date of Publication: 22 Apr
2025.
Author
Xu X.; Zhu H.; Cai L.
Institution
(Xu, Cai) Center of Laboratory Medicine, Hangzhou Red Cross Hospital,
China
(Zhu) Department of Cardiology, Hangzhou Traditional Chinese Medicine
Hospital Affiliated, Zhejiang Chinese Medical University, China
Publisher
Lippincott Williams and Wilkins

<48>
Accession Number
2029622548
Title
Hybrid Cardiac Rehabilitation Program in a Low-Resource Setting: A
Randomized Clinical Trial.
Source
JAMA Network Open. 7(1) (no pagination), 2024. Article Number: e2350301.
Date of Publication: 09 Jan 2024.
Author
Seron P.; Oliveros M.J.; Marzuca-Nassr G.N.; Morales G.; Roman C.; Munoz
S.R.; Galvez M.; Latin G.; Marileo T.; Molina J.P.; Navarro R.; Sepulveda
P.; Lanas F.; Saavedra N.; Ulloa C.; Grace S.L.; Gomez D.; Arancibia M.J.;
Stavros I.; Munoz F.; Arias Y.; Ferrada O.; Gonzalez C.; Verdejo H.;
Segovia M.J.; Adaros K.; Aburto C.; Buzeta F.; Valencia E.; Tomas Ramos
J.; Osorio M.; Diaz F.; Aravena S.; Gatta S.; Figueroa J.L.; Hermosilla
D.; Diaz I.; Maldonado N.; Navarro-Raninao R.; Olea V.; Aravena R.;
Sanchez P.; Morales K.; Saldias M.; Contreras M.M.
Institution
(Seron, Oliveros, Marzuca-Nassr, Sepulveda, Ulloa) Facultad de Medicina,
Departamento de Ciencias de la Rehabilitacion, Universidad de la Frontera,
Temuco, Chile
(Seron, Oliveros, Lanas) Centro de Excelencia CIGES, Universidad de la
Frontera, Temuco, Chile
(Morales, Munoz) Facultad de Medicina, Departamento de Salud Publica,
Universidad de la Frontera, Temuco, Chile
(Roman) Facultad de Medicina, Escuela de Kinesiologia, Pontificia
Universidad Catolica de Chile, Santiago, Chile
(Galvez) Unidad de Kinesiologia, Complejo Hospitalario San Jose, Santiago,
Chile
(Latin) Servicio de Medicina Fisica y Rehabilitacion, Hospital Clinico,
Hospital San Borja Arriaran, Santiago, Chile
(Marileo) Unidad de Rehabilitacion Cardiaca, Hospital Regional de
Antofagasta, Antofagasta, Chile
(Molina) Servicio de Medicina Fisica y Rehabilitacion, Hospital San Juan
de Dios, Santiago, Chile
(Navarro) Servicio de Medicina Fisica y Rehabilitacion, Hospital Clinico
Universidad de Chile, Santiago, Chile
(Lanas) Facultad de Medicina, Departamento de Medicina Interna,
Universidad de la Frontera, Temuco, Chile
(Saavedra) Facultad de Medicina, Departamento de Ciencias Basicas,
Universidad de la Frontera, Temuco, Chile
(Grace) York University, University Health Network, University of Toronto,
Toronto, ON, Canada
(Gomez, Arancibia, Aravena, Sanchez, Morales, Saldias, Contreras)
Universidad de la Frontera Temuco, Region de la Araucania, Chile
(Stavros, Munoz, Arias, Ferrada, Gonzalez, Verdejo, Segovia, Adaros,
Aburto, Buzeta) Hospital de Antofagasta Antofagasta, Region de
Antofagasta, Chile
(Valencia, Tomas Ramos, Osorio, Diaz) Hospital Clinico Universidad de
Chile Santiago, Region Metropolitana, Chile
(Aravena, Gatta, Figueroa, Hermosilla) Hospital San Borja Arriaran
Santiago, Region Metropolitana, Chile
(Diaz, Maldonado, Navarro-Raninao) Hospital San Jose Santiago, Region
Metropolitana, Chile
(Olea) Hospital San Juan de Dios Santiago, Region Metropolitana, Chile
Publisher
American Medical Association
Abstract
Importance: While effective, cardiovascular rehabilitation (CR) as
traditionally delivered is not well implemented in lower-resource
settings. <br/>Objective(s): To test the noninferiority of hybrid CR
compared with traditional CR in terms of cardiovascular events.
<br/>Design, Setting, and Participant(s): This pragmatic, multicenter,
parallel arm, open-label randomized clinical trial (the Hybrid Cardiac
Rehabilitation Trial [HYCARET]) with blinded outcome assessment was
conducted at 6 referral centers in Chile. Adults aged 18 years or older
who had a cardiovascular event or procedure, no contraindications to
exercise, and access to a mobile telephone were eligible and recruited
between April 1, 2019, and March 15, 2020, with follow-up until July 29,
2021. <br/>Intervention(s): Participants were randomized 1:1 in permuted
blocks to the experimental arm, which received 10 center-based supervised
exercise sessions plus counseling in 4 to 6 weeks and then were supported
at home via telephone calls and text messages through weeks 8 to 12, or
the control arm, which received the standard CR of 18 to 22 sessions with
exercises and education in 8 to 12 weeks. <br/>Main Outcomes and Measures:
The primary outcome was cardiovascular events or mortality. Secondary
outcomes were quality of life, return to work, and lifestyle behaviors
measured with validated questionnaires; muscle strength and functional
capacity, measured through physical tests; and program adherence and
exercise-related adverse events, assessed using checklists.
<br/>Result(s): A total of 191 participants were included (mean [SD] age,
58.74 [9.80] years; 145 [75.92%] male); 93 were assigned to hybrid CR and
98 to standard CR. At 1 year, events had occurred in 5 unique participants
in the hybrid CR group (5.38%) and 9 in the standard CR group (9.18%). In
the intention-to-treat analysis, the hybrid CR group had 3.80% (95% CI,
-11.13% to 3.52%) fewer cardiovascular events than the standard CR group,
and relative risk was 0.59 (95% CI, 0.20-1.68) for the primary outcome. In
the per-protocol analysis at different levels of adherence to the
intervention, all 95% CIs crossed the noninferiority boundary (eg, 20%
adherence: absolute risk difference, -0.35% [95% CI, -7.56% to 6.85%]; 80%
adherence: absolute risk difference, 3.30% [95% CI, -3.70% to 10.31%]). No
between-group differences were found for secondary outcomes except
adherence to supervised CR sessions (79.14% [736 of 930 supervised
sessions] in the hybrid CR group vs 61.46% [1201 of 1954 sessions] in the
standard CR group). <br/>Conclusions and Relevance: The results suggest
that a hybrid CR program is noninferior to standard center-based CR in a
low-resource setting, primarily in terms of recurrent cardiovascular
events and potentially in terms of intermediate outcomes. Hybrid CR may
induce superior adherence to supervised exercise. Clinical factors and
patient preferences should inform CR model allocation.<br/>Copyright
&#xa9; 2024 American Medical Association. All rights reserved.

<49>
[Use Link to view the full text]
Accession Number
2038415710
Title
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune
or Inflammatory Diseases: An Analysis of the FOURIER Trial.
Source
Circulation. (no pagination), 2025. Date of Publication: 2025.
Author
Zimerman A.; Kunzler A.L.F.; Weber B.N.; Ran X.; Murphy S.A.; Wang H.;
Honarpour N.; Keech A.C.; Sever P.S.; Sabatine M.S.; Giugliano R.P.
Institution
(Zimerman, Kunzler) Hospital Moinhos de Vento, Moinhos de Vento College of
Health Sciences, Porto Alegre, Brazil
(Ran, Murphy, Sabatine, Giugliano) TIMI Study Group, Brigham and Women's
Hospital, Harvard Medical School, Boston, MA, United States
(Weber) Division of Cardiovascular Medicine, Brigham and Women's Hospital,
Harvard Medical School, Boston, MA, United States
(Wang) Amgen, Thousand Oaks, CA, United States
(Honarpour) Global Development, Amgen, Thousand Oaks, CA, United States
(Keech) Sydney Medical School, National Health and Medical Research
Council Clinical Trials Centre, University of Sydney, Australia
(Sever) National Heart and Lung Institute, Imperial College London, United
Kingdom
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: Patients with an autoimmune or inflammatory disease (AIID) are
at increased cardiovascular risk and may benefit more from statin therapy.
In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9
Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein
convertase subtilisin/kexin type 9) inhibitor evolocumab lowered
low-density lipoprotein cholesterol levels, but not hsCRP
(high-sensitivity C-reactive protein) levels, and reduced the risk of
cardiovascular events. <br/>METHOD(S): FOURIER was a randomized trial of
evolocumab versus placebo in 27 564 patients with stable atherosclerosis
who were taking statins. This analysis focused on the effect of evolocumab
in patients with or without an AIID, defined as any autoimmune or chronic
inflammatory condition. The primary end point was a composite of
cardiovascular death, myocardial infarction, stroke, unstable angina, or
coronary revascularization. <br/>RESULT(S): At baseline, 889 patients
(3.2%) had an AIID, most commonly rheumatoid arthritis (33.7%) or
psoriasis (15.6%). Median (interquartile range) low-density lipoprotein
cholesterol levels were 90.0 mg/dL (79.5-105.5) and 91.5 mg/dL
(79.5-108.5) in patients with or without an AIID, respectively (P=0.025),
and the placebo-adjusted percent reduction with evolocumab was consistent
(60.2% versus 59.0%; P=0.57). Baseline hsCRP was higher in patients with
an AIID (median 2.1 versus 1.7 mg/L; P<0.001) and did not significantly
change with evolocumab in either group. Compared with placebo, evolocumab
reduced the rate of the primary end point by 14% in patients without an
AIID (hazard ratio, 0.86 [95% CI, 0.80-0.93]) and by 42% in patients with
an AIID (hazard ratio, 0.58 [95% CI, 0.38-0.89];
P<inf>interaction</inf>=0.066). Likewise, evolocumab reduced the key
secondary end point of cardiovascular death, myocardial infarction, or
stroke by 19% in patients without an AIID (hazard ratio, 0.81 [95% CI,
0.74-0.89]) and 58% in those with an AIID (hazard ratio, 0.42 [95% CI,
0.24-0.74]; P<inf>interaction</inf>=0.022). <br/>CONCLUSION(S): Intensive
lowering of low-density lipoprotein cholesterol levels with evolocumab may
lead to greater relative reduction in cardiovascular events in patients
with an AIID.<br/>Copyright &#xa9; 2025 American Heart Association, Inc.

<50>
Accession Number
2032696733
Title
Randomized Trial of Pulsatile and Nonpulsatile Flow in Cyanotic and
Acyanotic Congenital Heart Surgery.
Source
World Journal for Pediatric and Congenital Heart Surgery. 16(3) (pp
329-337), 2025. Date of Publication: 01 May 2025.
Author
Patel K.; Lin T.K.; Clark J.B.; Ceneviva G.D.; Imundo J.R.; Spear D.;
Kunselman A.R.; Thomas N.J.; Myers J.L.; Undar A.
Institution
(Patel, Lin, Clark, Ceneviva, Imundo, Spear, Kunselman, Thomas, Myers,
Undar) Penn State Hershey Pediatric Cardiovascular Research Center, Penn
State College of Medicine, Hershey, PA, United States
(Patel, Clark, Imundo, Myers, Undar) Division of Pediatric Cardiology,
Department of Pediatrics, Penn State College of Medicine, Hershey, PA,
United States
(Patel, Clark, Myers, Undar) Department of Surgery, Penn State College of
Medicine, Hershey, PA, United States
(Lin) Division of Pediatric Critical Care Medicine, Department of
Pediatrics, University of Virginia Children's Hospital, Charlottesville,
VA, United States
(Ceneviva, Spear, Thomas) Division of Pediatric Critical Care Medicine,
Department of Pediatrics, Penn State College of Medicine, Hershey, PA,
United States
(Kunselman, Thomas) Department of Public Health Sciences, Penn State
College of Medicine, Hershey, PA, United States
(Undar) Department of Biomedical Engineering, College of Engineering, The
Pennsylvania State University, University Park, PA, United States
Publisher
SAGE Publications Inc.
Abstract
Background: The study objective was to determine the impact of
cardiopulmonary bypass perfusion modalities on cerebral hemodynamics and
clinical outcomes in congenital cardiac surgery patients stratified by
acyanotic versus cyanotic heart disease. <br/>Method(s): A total of 159
pediatric (age <18 years) cardiac surgery patients were prospectively
randomized to pulsatile or nonpulsatile cardiopulmonary bypass and
stratified by type of congenital heart disease: acyanotic versus cyanotic.
Intraoperative cerebral gaseous microemboli counts and middle cerebral
artery pulsatility index were assessed. Organ injury was quantified by
Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score at 24, 48, and 72 h
postoperatively. Additional outcomes included Pediatric Risk of
Mortality-3 score, vasoactive-inotropic score, duration of mechanical
ventilation, intensive care and hospital length of stay, and 180-day
mortality. Heterogenous variance linear models (ie, ANOVA and mixed
models) and chi² tests were used to compare groups for
continuous and categorical variables, respectively. <br/>Result(s): Within
congenital heart disease subgroups, patients randomized to nonpulsatile
versus pulsatile bypass had similar preoperative and operative
characteristics. While the intraoperative pulsatility index was higher in
the pulsatile subset of both acyanotic and cyanotic groups (P <.05),
regional cerebral oxygen saturation, mean arterial pressure, and gaseous
microemboli counts were similar. Postoperative PELOD-2 scores decreased at
similar rates in the acyanotic and cyanotic subgroups regardless of the
perfusion modality utilized. There were also no significant between-group
differences in the additional postoperative outcomes by perfusion modality
in either acyanotic or cyanotic groups. <br/>Conclusion(s): Despite
patients undergoing pulsatile cardiopulmonary bypass experiencing a more
physiologic pulsatility index in both acyanotic and cyanotic groups, no
significant differences in cerebral hemodynamics or clinical outcomes were
appreciated.<br/>Copyright &#xa9; The Author(s) 2024.

<51>
Accession Number
2034262482
Title
Short-Term, Mid-Term, and Long-Term Outcomes of Transcatheter Aortic Valve
Replacement With Balloon-Expandable Versus Self-Expanding Valves: A
Meta-Analysis of Randomized Controlled Trials.
Source
Clinical Cardiology. 48(4) (no pagination), 2025. Article Number: e70134.
Date of Publication: 01 Apr 2025.
Author
Tavakoli K.; Mohammadi N.S.H.; Bahiraie P.; Saeidi S.; Shaker F.; Moghadam
A.S.; Namin S.M.; Rahban H.; Pawar S.; Tajdini M.; Soleimani H.; Jenab Y.;
Ahmad Y.; Iskander F.H.; Alkhouli M.; Makkar R.; Gupta A.; Hosseini K.
Institution
(Tavakoli, Mohammadi, Saeidi, Shaker, Moghadam, Namin, Tajdini, Soleimani,
Jenab, Hosseini) Tehran Heart Center, Cardiovascular Diseases Research
Institute, Tehran University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Bahiraie) School of Medicine, Shahid Beheshti University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Rahban) Cardiovascular Research Foundation of Southern California,
Beverly Hills, CA, United States
(Rahban) Department of Cardiovascular Disease, Creighton University School
of Medicine, St. Joseph Hospital and Medical Center, Phoenix, AZ, United
States
(Pawar, Makkar, Gupta) Cedars Sinai Medical Center, California, United
States
(Tajdini, Soleimani, Jenab, Hosseini) Cardiac Primary Prevention Research
Center, Cardiovascular Diseases Research Institute, Tehran University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Ahmad) Yale School of Medicine, Yale University, New Haven, CT, United
States
(Iskander) Department of Cardiology, Medstar Union Memorial Hospital,
Baltimore, MD, United States
(Alkhouli) Department of Cardiology, Mayo Clinic School of Medicine,
Rochester, MN, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Comparisons of outcomes after transcatheter aortic valve
replacement with balloon-expandable (BEV) versus self-expanding (SEV)
valves are limited. Hypothesis: This study aimed to compare clinical and
hemodynamic outcomes of BEV and SEV at short-term (30 days), midterm (1
year), and long-term (> 1 year) endpoints. <br/>Method(s): PubMed, Embase,
Scopus, and Cochrane Library databases were searched until July 2024 for
randomized controlled trials. Random-effect model (DerSimonian-Laird
method) was used to pool the risk ratios (RR), mean differences, and 95%
confidence intervals (CI). <br/>Result(s): A total of 10 studies
comprising 4325 patients (2295 BEV, 2030 SEV) were included. In
short-term, cardiovascular (RR: 0.56, 95% CI: 0.36-0.87) and all-cause
mortality (RR: 0.54, 95% CI: 0.35-0.81) were lower in the BEV group. Risk
of moderate to severe paravalvular leak (PVL) was lower among BEV patients
in short-term (RR: 0.28, 95% CI: 0.17-0.49) and long-term (RR: 0.28, 95%
CI: 0.1-0.79). A limited number of studies showed a greater risk of
clinical valve thrombosis on BEV in midterm and long-term. The need for
permanent pacemaker implantation was lower in BEV at both short-term (RR:
0.56, 95% CI: 0.37-0.87), and midterm (RR: 0.78, 95% CI: 0.64-0.94). The
SEV group had a larger effective orifice area with lower mean
transvalvular pressure gradient at all endpoints. <br/>Conclusion(s): BEV
is associated with reduced risk of clinical outcomes in short-term;
however, most differences diminish in longer evaluations, except for
moderate to severe PVL, which remains elevated for SEV. SEVs had better
hemodynamic results and lower risk of clinical valve
thrombosis.<br/>Copyright &#xa9; 2025 The Author(s). Clinical Cardiology
published by Wiley Periodicals, LLC.

<52>
Accession Number
2038263878
Title
Comparative Outcomes of Mitral Valve Repair Versus Replacement in
Infective Endocarditis: A 16-Year Meta-Analysis of Time-to-Event Data From
Over 4000 Patients.
Source
American Journal of Cardiology. 246 (pp 33-42), 2025. Date of Publication:
01 Jul 2025.
Author
Comentale G.; Ahmadi-Hadad A.; Moldon H.J.; Carbone A.; Manzo R.; Calanni
Macchio C.; Damiano A.; Bossone E.; Esposito G.; Pilato E.
Institution
(Comentale, Ahmadi-Hadad, Moldon, Calanni Macchio, Damiano, Pilato)
Division of Cardiac Surgery, Department of Advanced Biomedical Sciences,
University of Naples "Federico II", Naples, Italy
(Manzo, Bossone, Esposito) Division of Cardiology, Department of Advanced
Biomedical Sciences, University of Naples "Federico II", Naples, Italy
(Carbone) Division of Cardiology, University of Campania "Luigi
Vanvitelli", Naples, Italy
Publisher
Elsevier Inc.
Abstract
Mitral valve (MV) repair for infective endocarditis (IE) has proven to be
a good and safe option, but current trends favor replacement; the
available data, in addition, don't allow to reach a general consensus on
the preferred first-line approach. The present metanalysis, aimed to
compare short- and long-term outcomes between MV repair (MVRep) and MV
replacement (MVR) in patients with IE. A search of PubMed was conducted on
30th August 2024, yielding 120 results. (PROSPERO CRD: CRD42023490612).
Four additional suitable studies were identified and added from Embase and
Medline (via Ovid). Statistical analyses were performed using RStudio,
SPSS, and RevMan. Pseudoindividual patient data were extracted from
Kaplan-Meier curves by converting the graphical plots into raw data
coordinates through WebPlotDigitizer. A total of 21 studies were eligible
for inclusion. The 16-year reconstructed analysis revealed that patients
undergoing MVRep have higher survival compared to the MVR group (HR: 1.41,
95% Cl: 1.30-1.53, p < 0.001). Moreover, IE recurrence was significantly
lower in MVRep (95% CI, RR:0.46, 12 = 41%, p = 0.03). Reoperation rates,
however, were similar between MVRep and MVR (95% CI, RR: 0.78, 12 = 0%, p
= 0.27). In-hospital mortality was similar between the groups (95% CI,
RR:0.40, 12 = 34%, p = 0.07). In conclusion, MV repair should be favored
over replacement in IE when there is no evidence of local extension of the
infections and if valve leaflets have not degenerated. This approach is
associated with improved overall survival and a reduced risk of IE
recurrence, making it particularly advantageous for younger
patients.<br/>Copyright &#xa9; 2025 The Author(s)

<53>
Accession Number
2034219574
Title
Effectiveness of a Rotating-Leg Prepper for Reducing Pressure Injury and
Preventing Surgical Site Infection in Patients Undergoing Heart Surgery:
Paired Matching Randomised Controlled Trial.
Source
International Wound Journal. 22(4) (no pagination), 2025. Article Number:
e70371. Date of Publication: 01 Apr 2025.
Author
Chiannilkulchai N.; Pichaiphanupatt P.
Institution
(Chiannilkulchai) Ramathibodi School of Nursing, Faculty of Medicine
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
(Pichaiphanupatt) Division of Perioperative Nursing, Department of
Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
Publisher
John Wiley and Sons Inc
Abstract
This study aims to evaluate the effectiveness of a rotating-leg prepper
(intervention) compared with a rolled gauze bandage (control) in reducing
pressure injury and preventing surgical site infection in the legs of
patients undergoing heart surgery. The paired-matched, open, randomised
controlled trial was conducted from September 2022 to July 2024. The
participants were composed of the patient and the staff groups. Sixty
patients were paired-matched to the intervention and control groups.
Before painting the resting area with an antiseptic, the ankle presented
non-blanchable erythema, which was recorded as a pressure injury. The
intervention group showed significantly lower pressure injury (0% vs.
76.6%, p = 0.001) than the control group, with a relative risk of 5.29
(95% CI: 2.71-10.30). Both groups exhibited no significant difference in
surgical site infection. However, the relative risk of surgical site
infection in the control group was 2.03 (95% CI: 1.57-2.64). Thirty staff
participants were purposively sampled to evaluate the effects of both leg
lifting methods and assess their satisfaction with the leg prepper. The
overall satisfaction with the rotating-leg prepper was 4.87 +/- 0.22.
Rotating-leg preppers can reduce pressure injury and prevent surgical site
infections in patients' legs during heart surgery.<br/>Copyright &#xa9;
2025 The Author(s). International Wound Journal published by
Medicalhelplines.com Inc and John Wiley & Sons Ltd.

<54>
Accession Number
2030824099
Title
Minimally invasive extracorporeal circulation versus conventional
cardiopulmonary bypass in patients undergoing cardiac surgery (MiECS):
Rationale and design of a multicentre randomised trial.
Source
Perfusion (United Kingdom). 40(4) (pp 923-932), 2025. Date of Publication:
01 May 2025.
Author
Anastasiadis K.; Antonitsis P.; Papazisis G.; Haidich B.; Liebold A.;
Punjabi P.; Gunaydin S.; El-Essawi A.; Rao V.; Serrick C.; Condello I.;
Nasso G.; Bozok S.; Daylan A.; Argiriadou H.; Deliopoulos A.;
Karapanagiotidis G.; Ashkanani F.; Moorjani N.; Cale A.; Erdoes G.;
Bennett M.; Starinieri P.; Carrel T.; Murkin J.
Institution
(Anastasiadis, Antonitsis, Argiriadou, Deliopoulos, Karapanagiotidis)
Cardiothoracic Department, School of Medicine, Aristotle University of
Thessaloniki, Thessaloniki, Greece
(Papazisis) Special Unit for Biomedical Research and Education, Aristotle
University of Thessaloniki School of Medicine, Thessaloniki, Greece
(Haidich) Department of Hygiene, Social-Preventive Medicine and Medical
Statistics, School of Medicine, Aristotle University of Thessaloniki,
Thessaloniki, Greece
(Liebold, Ashkanani) Department of Cardio-thoracic Surgery, University
Hospital Ulm, Ulm, Germany
(Punjabi) Department of Cardiothoracic Surgery, Hammersmith Hospital,
Imperial College Healthcare NHS Trust, London, United Kingdom
(Gunaydin) Department of Cardiovascular Surgery, Ankara City Hospital,
University of Health Sciences, Ankara, Turkey
(El-Essawi) Department of Thoracic and Cardiovascular Surgery, University
Medical Center Gottingen, Gottingen, Germany
(Rao, Serrick) Peter Munk Cardiac Centre, Toronto General Hospital,
Toronto, ON, Canada
(Condello, Nasso) Cardiac Surgery, Anthea Hospital Gvm Care & Research,
Bari, Italy
(Bozok, Daylan) Department of Cardiovascular Surgery, Izmir Bakircay
University, Izmir, Turkey
(Moorjani) Department of Cardiothoracic Surgery, Royal Papworth Hospital,
University of Cambridge, Cambridge, United Kingdom
(Cale) Department of Cardiac Surgery, Hull and East Yorkshire Hospitals
NHS Trust, Hull, United Kingdom
(Erdoes) Department of Anesthesiology and Pain Medicine, Inselspital, Bern
University Hospital, Bern, Switzerland
(Bennett) Department of Anesthesia, Morriston Hospital, Swansea Bay
University Health Board, Swansea, United Kingdom
(Starinieri) Department of Clinical Perfusion, Jessa Hospital, Hasselt,
Belgium
(Carrel) Department of Cardiac Surgery, University Hospital Zurich,
Switzerland
(Murkin) Department of Anesthesia and Perioperative Medicine, Schulich
School of Medicine and Dentistry, University of Western Ontario, London,
ON, Canada
Publisher
SAGE Publications Ltd
Abstract
Introduction: The ultimate answer to the question whether minimal invasive
extracorporeal circulation (MiECC) represents the optimal perfusion
technique in contemporary clinical practice remains elusive. The present
study is a real-world study that focuses on specific perfusion-related
clinical outcomes after cardiac surgery that could potentially be
favourably affected by MiECC and thereby influence the future clinical
practice. <br/>Method(s): The MiECS study is an international,
multi-centre, two-arm randomized controlled trial. Patients undergoing
elective or urgent coronary artery bypass grafting (CABG), aortic valve
replacement (AVR) or combined procedure (CABG + AVR) using extracorporeal
circulation will be randomized to MiECC or contemporary conventional
cardiopulmonary bypass (cCPB). Use of optimized conventional circuits as
controls is acceptable. The study design includes a range of features to
prevent bias and is registered at clinicaltrials.gov (NCT05487612).
<br/>Result(s): The primary outcome is a composite of postoperative
serious adverse events that could be related to perfusion technique
occurring up to 30 days postoperatively. Secondary outcomes include use of
blood products, ICU and hospital length of stay (30 days) as well as
health-related quality of life (30 and 90 days). <br/>Conclusion(s): The
MiECS trial has been designed to overcome perceived limitation of previous
trials of MiECC. Results of the proposed study could affect current
perfusion practice towards advancement of patient care.<br/>Copyright
&#xa9; The Author(s) 2024.

<55>
Accession Number
2038380833
Title
Non-invasive monitoring strategies for atrial fibrillation detection in
adult cardiac surgery patients after hospital discharge: A scoping review.
Source
Heart and Lung. 73 (pp 9-18), 2025. Date of Publication: 01 Sep 2025.
Author
Jaradat O.; Drury P.; Rihari-Thomas J.; Frost S.
Institution
(Jaradat, Drury, Frost) School of Nursing, University of Wollongong,
Northfields Avenue, Wollongong, NSW, Australia
(Rihari-Thomas) Susan Wakil School of Nursing and Midwifery, The
University of Sydney, Susan Wakil Health Building, Camperdown, NSW,
Australia
Publisher
Elsevier Inc.
Abstract
Background: Atrial fibrillation (AF) is a common complication after
cardiothoracic surgery, affecting up to 50 % of patients. It can develop
after discharge, leading to frequent hospital readmissions. There is a
growing need for effective monitoring strategies to detect AF in the
post-discharge period. <br/>Objective(s): To synthesis the available
literature on various mobile monitoring devices used to detect AF in adult
cardiac surgery patients post-discharge from the hospital. <br/>Method(s):
Following Arksey and O'Malley's framework and the PRISMA-ScR guidelines. A
comprehensive search of six databases (PubMed; MEDLINE; CINAHL; Scopus;
ProQuest; and Web of Science) was performed, including studies published
between 2009 and 2024. The risk of bias was assessed using the
Newcastle-Ottawa Scale (NOS). <br/>Result(s): A total of 1256
de-duplicated studies were screened, and 102 studies underwent full-text
review. Five studies were included: four prospective cohort studies, and
one randomised clinical trial. Samples sizes ranged from 23 to 730 adults
undergoing cardiac surgery, with follow-up between four weeks to three
months post-discharge. Handheld and wearable ECG-based devices were the
most used tools for AF detection, demonstrating high sensitivity and
specificity. Their use effectively reduced unplanned hospital visits and
improved clinical outcomes. Patient adherence to monitoring protocols was
generally high, though variability in engagement was noted.
<br/>Conclusion(s): Handheld and wearable ECG- based devices, are
effective for post-discharge AF detection in cardiac surgery patients.
Integrating these tools into routine post-discharge care can improve
patient outcomes. Future research should focus on long-term effectiveness
and strategies to optimise patient engagement and implementation in
clinical practice.<br/>Copyright &#xa9; 2025 The Author(s)

<56>
Accession Number
2037330610
Title
Effect of del Nido Cardioplegia on Isolated Coronary Artery Bypass
Grafting: A Study-level Meta-analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 39(6) (pp 1538-1546),
2025. Date of Publication: 01 Jun 2025.
Author
Yamashita Y.; Baudo M.; Magouliotis D.E.; Sicouri S.; Wertan M.A.C.;
Spragan D.D.; Torregrossa G.; Ramlawi B.; Sutter F.P.
Institution
(Yamashita, Wertan, Spragan, Torregrossa, Ramlawi, Sutter) Department of
Cardiothoracic Surgery, Lankenau Heart Institute, Wynnewood, PA, United
States
(Yamashita, Baudo, Magouliotis, Sicouri, Ramlawi) Department of
Cardiothoracic Surgery Research, Lankenau Institute for Medical Research,
Wynnewood, PA, United States
Publisher
W.B. Saunders
Abstract
The purpose of this study was to evaluate the effect of del Nido
cardioplegia versus conventional cardioplegic solutions on early outcomes
of isolated coronary artery bypass grafting (CABG). PubMed, Scopus, and
the Cochrane Central Register of Controlled Trials were searched through
July 2024 to conduct a meta-analysis for a comparison between del Nido and
other cardioplegic solutions in isolated CABG. Major end points of the
study included operative mortality and morbidities. A random effects model
was used to estimate the pooled effect size. For subgroup analyses,
meta-analyses were conducted for outcomes derived from either randomized
controlled-trials, propensity score analysis, or multivariable analysis.
Twenty-four studies met our eligibility criteria, including 4 randomized
controlled trials and 5 propensity score-matched studies with a total of
34,737 patients. Operative mortality was not significantly associated with
cardioplegic solutions (del Nido vs other solutions; p = 0.262). The
incidence of postoperative stroke, reoperation, deep wound infection, and
atrial fibrillation was also comparable between the 2 groups. The
incidence of postoperative myocardial infarction and renal failure was
significantly lower in the del Nido group with a pooled odds ratio of 0.43
(95% confidence interval, 0.24-0.77) and 0.61 (95% confidence interval,
0.45-0.81), respectively. Subgroup analyses also demonstrated these
significant differences. In patients undergoing isolated CABG, del Nido
cardioplegia provides comparable mortality compared with other
cardioplegic solutions. Del Nido solution was significantly protective
against myocardial infarction and renal failure.<br/>Copyright &#xa9; 2025
Elsevier Inc.

<57>
Accession Number
2032973050
Title
Machine-learning approaches for risk prediction in transcatheter aortic
valve implantation: Systematic review and meta-analysis.
Source
Journal of Thoracic and Cardiovascular Surgery. 169(5) (pp 1460-1470.e15),
2025. Date of Publication: 01 May 2025.
Author
Jacquemyn X.; Van Onsem E.; Dufendach K.; Brown J.A.; Kliner D.; Toma C.;
Serna-Gallegos D.; Sa M.P.; Sultan I.
Institution
(Jacquemyn, Van Onsem) Department of Cardiovascular Sciences, KU Leuven,
Leuven, Belgium
(Dufendach, Brown, Serna-Gallegos, Sa, Sultan) Department of
Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, United
States
(Dufendach, Brown, Kliner, Toma, Serna-Gallegos, Sa, Sultan) UPMC Heart
and Vascular Institute, University of Pittsburgh Medical Center,
Pittsburgh, PA, United States
(Kliner, Toma) Department of Interventional Cardiology, University of
Pittsburgh, Pittsburgh, PA, United States
Publisher
Elsevier Inc.
Abstract
Objectives: With the expanding integration of artificial intelligence (AI)
and machine learning (ML) into the structural heart domain, numerous ML
models have emerged for the prediction of adverse outcomes after
transcatheter aortic valve implantation (TAVI). We aim to identify,
describe, and critically appraise ML prediction models for adverse
outcomes after TAVI. Key objectives consisted in summarizing model
performance, evaluating adherence to reporting guidelines, and
transparency. <br/>Method(s): We searched PubMed, SCOPUS, and Embase
through August 2023. We selected published machine learning models
predicting TAVI outcomes. Two reviewers independently screened articles,
extracted data, and assessed the study quality according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Outcomes included summary C-statistics and model risk of bias assessed
with the Prediction Model Risk of Bias Assessment Tool. C-statistics were
pooled using a random-effects model. <br/>Result(s): Twenty-one studies
(118,153 patients) employing various ML algorithms (76 models) were
included in the systematic review. Predictive ability of models varied:
11.8% inadequate (C-statistic <0.60), 26.3% adequate (C-statistic
0.60-0.70), 31.6% acceptable (C-statistic 0.70-0.80), and 30.3%
demonstrated excellent (C-statistic >0.80) performance. Meta-analyses
revealed excellent predictive performance for early mortality
(C-statistic: 0.81; 95% confidence interval [CI], 0.65-0.91), acceptable
performance for 1-year mortality (C-statistic: 0.76; 95% CI, 0.67-0.84),
and acceptable performance for predicting permanent pacemaker implantation
(C-statistic: 0.75; 95% CI, 0.51-0.90). <br/>Conclusion(s): ML models for
TAVI outcomes exhibit adequate-to-excellent performance, suggesting
potential clinical utility. We identified concerns in methodology and
transparency, emphasizing the need for improved scientific reporting
standards.<br/>Copyright &#xa9; 2024 The American Association for Thoracic
Surgery

<58>
[Use Link to view the full text]
Accession Number
2031563339
Title
Impact of Early Mobilization Within the Intensive Care Unit after Coronary
Artery Bypass Grafting: A Systematic Review.
Source
Cardiopulmonary Physical Therapy Journal. 35(2) (pp 56-70), 2024. Date of
Publication: 01 Apr 2024.
Author
Thomas B.; Morgan S.; Smith J.M.
Institution
(Thomas) School of Physical Therapy and Rehabilitation Sciences,
University of South Florida, Tampa, FL, United States
(Morgan) College of Nursing, University of South Florida, Tampa, FL,
United States
(Smith) Department of Physical Therapy, University of Connecticut, Storrs,
CT, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Purpose:Coronary artery bypass grafting (CABG) surgery treats
complications from coronary artery diseases, and its recovery
traditionally consisted of bedrest. Recent research emphasizes the
benefits of early mobilization for hospitalized patients. However, the
functional outcomes and effectiveness of early mobilization for persons
within the intensive care units after CABG has not been investigated thus
far. The objective of this review was to determine the effectiveness of
early mobilization in reducing hospital and intensive care unit length of
stay (LoS) and improving functional outcomes of persons after CABG.
<br/>Method(s):This study was registered with PROSPERO and followed PRISMA
guidelines. PubMed, Embase, CINAHL, and PEDro databases were searched
using MeSH terms. Studies with early mobilization interventions for adults
in the intensive care unit after CABG that recorded outcomes of LoS or
functioning were included. Methodological quality was measured using the
PEDro scale and Oxford Level of Evidence. <br/>Result(s):This systematic
review collectively addressed 2280 participants through 14 studies in 7
countries. The initiation time frames for early mobilization varied, with
the majority beginning within 24 to 48 hours after surgery and
interventions were heterogenous. Early mobility was found to be effective
in reducing atelectasis, improving oxygen saturation, and decreasing time
spent on mechanical ventilation. Among early mobilization participants,
the LoS was reduced in all studies; intensive care unit LoS decreased by
one day or greater in 6 of 14 studies, and hospital LoS decreased by one
day or greater in 5 of 7 studies. <br/>Conclusion(s):Data analysis found
that early mobilization achieved better functional outcomes. It was found
that implementing early mobilization led to decreased intensive care and
hospital lengths of stay, reduced atelectasis and pleural effusion, and
improved functional and respiratory outcomes in persons who underwent CABG
surgery.<br/>Copyright &#xa9; Cardiovascular and Pulmonary Section, APTA.

<59>
Accession Number
2030125027
Title
Statin therapy improves outcomes in infective endocarditis: evidence from
a meta-analysis.
Source
Egyptian Heart Journal. 76(1) (no pagination), 2024. Article Number: 70.
Date of Publication: 01 Dec 2024.
Author
Yaghoobi M.H.; Heidari E.; Shafiee A.; Seighali N.; Maghsoodi M.R.;
Bakhtiyari M.
Institution
(Yaghoobi, Shafiee, Seighali, Maghsoodi, Bakhtiyari) School of Medicine,
Alborz University of Medical Sciences, Karaj, Iran, Islamic Republic of
(Heidari) School of Pharmacy, Shahid Beheshti University of Medical
Sciences, Tehran, Iran, Islamic Republic of
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Beyond its ability to decrease cholesterol, statin medication
has been proved to have a variety of pleiotropic effects, such as
anti-inflammatory and immunomodulatory effects. Statins are an appealing
therapeutic option for individuals with infective endocarditis because of
these effects, as the condition is linked to a strong inflammatory
response. <br/>Method(s): A comprehensive search was done in
Medline/PubMed, Cochrane database (CENTRAL), and Google Scholar to
identify relevant studies reporting outcomes of interest (rate of
mortality, intensive care unit admission, and embolic events) comparing
those who are on statin therapy to nonusers were included. We performed a
random effect meta-analysis to pool each study's individual results.
<br/>Result(s): Three articles were included in the study. The pooled
results regarding our primary endpoint showed there was a significant
reduction in mortality among statin users in all time points (1-year
mortality: OR 0.69, 95% CI 0.61-0.79, I2: 0%; Chi2 = 0.01; p < 0.0001).
Meta-analysis for the secondary outcome showed statin users are less
frequently admitted to the intensive care unit (OR 0.73, 95% CI 0.59-0.90,
I2: 0%; Chi2 = 0.00; p = 0.0004). The rate of mortality was significantly
lower for those with a previous history of cerebrovascular disease who
were on statin therapy compared to those without cerebrovascular diseases
(CVD). <br/>Conclusion(s): The results of the present study support a
significant association with statin therapy as a potential treatment
proposed for individuals at risk of infective endocarditis.<br/>Copyright
&#xa9; The Author(s) 2024.

<60>
Accession Number
2038382602
Title
Effect of Transesophageal Echocardiography Probe Insertion on Endotracheal
Tube Cuff Pressure in Patients Undergoing Coronary Artery Bypass Graft
(CABG) Surgery. A Prospective Randomized Control Trial.
Source
Annals of Cardiac Anaesthesia. 28(2) (pp 143-148), 2025. Date of
Publication: 01 Apr 2025.
Author
Kireeti A.; Pula R.; Nagarjuna T.; Rabbani T.; Gopinath R.
Institution
(Kireeti) Department of Anaesthesia, Govt Medical College, Telangana,
Wanaparthy, India
(Pula, Nagarjuna, Rabbani, Gopinath) Department of Anaesthesia, ESIC MC
and SSH, Sanathnagar, Telangana, Hyderabad, India
Publisher
Wolters Kluwer Medknow Publications
Abstract
Introduction: Elevated endotracheal tube (ETT) cuff pressures during
surgery can lead to tracheal ischemia and airway complications, including
postoperative sore throat, subglottic edema, and tracheal stenosis. The
insertion of a transesophageal echocardiography (TEE) probe, commonly used
in cardiac surgeries, may increase ETT cuff pressure due to its proximity
to the trachea. This study assesses the impact of TEE probe insertion on
ETT cuff pressures and related postoperative airway complications in
patients undergoing coronary artery bypass graft (CABG) surgery.
<br/>Method(s): In this prospective, randomized controlled trial, 40
patients undergoing CABG were assigned to either a control group (Group C,
n = 20) or an intervention group (Group T, n = 20). Cuff pressures were
monitored at baseline (T1), during TEE probe manipulation (T2), after
initial examination (T3), and during recovery (T4). In Group T, cuff
pressures were adjusted to 20-30 cmH2O if they exceeded 30 cmH2O during T2
and T3. Postoperative complications, including sore throat, hoarseness,
and cough, were assessed using standardized scales. <br/>Result(s): TEE
probe manipulation significantly increased ETT cuff pressures in both
groups, with lower pressures consistently observed in Group T (P < 0.05).
At T3, the mean cuff pressure in Group C was 41.00 cmH2O versus 33.30
cmH2O in Group T (P < 0.001). The control group experienced more severe
postoperative airway complications, while Group T had a significantly
reduced risk of severe complications (odds ratio < 0.2).
<br/>Conclusion(s): TEE probe manipulation significantly increases ETT
cuff pressures, but cuff deflation during manipulation effectively reduces
these pressures and lowers the risk of postoperative airway
complications.<br/>Copyright &#xa9; 2025 Annals of Cardiac Anaesthesia.

<61>
Accession Number
2038382604
Title
Randomized Comparison of Oblique versus Transverse Orientation for
Ultrasound-Guided Internal Jugular Venous Cannulation in Pediatric Heart
Surgery Patients.
Source
Annals of Cardiac Anaesthesia. 28(2) (pp 149-155), 2025. Date of
Publication: 01 Apr 2025.
Author
Heriwardito A.; Manggala S.K.; Christina A.
Institution
(Heriwardito, Manggala, Christina) Department of Anesthesiology and
Intensive Care, Cipto Mangunkusumo General Hospital, Faculty of Medicine
Universitas Indonesia, DKI Jakarta, Indonesia
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: Ultrasound-guided internal jugular venous access improves the
rate of successful cannulation of the internal jugular vein in both adult
and pediatric patients. Internal jugular venous cannulation in pediatric
patients is anatomically and technically more challenging than in adults.
The oblique method is a novel approach for guiding central venous
cannulation. There is currently a scarcity of research on central venous
cannulation techniques for pediatric patients. <br/>Aim(s): The purpose of
this study was to compare the success rates between the oblique and
transverse approach of jugular venous cannulation in pediatric cardiac
surgery patients. <br/>Method(s): A prospective randomized clinical trial
of pediatric patients who underwent cardiac surgery at Cipto Mangunkusumo
Hospital was conducted between February and May 2021. Sixty patients were
randomized into two groups: 30 in the oblique group and 30 in the
transverse group. <br/>Result(s): There was no difference in the first
needle pass success rate between the oblique and transversal approaches
(86.7% vs. 73.3%; P = 0.19). There is no difference in the total number of
attempts between the two groups (1.3 vs 1.43; P > 0.05).
<br/>Conclusion(s): There was no difference between oblique and transverse
orientations for internal jugular venous cannulation in pediatric cardiac
surgery patients in terms of successful cannulation on the first needle
pass and total number of attempts.<br/>Copyright &#xa9; 2025 Annals of
Cardiac Anaesthesia.

<62>
Accession Number
2038174047
Title
Outcomes After CABG Compared With FFR-Guided PCI in Patients Presenting
With Acute Coronary Syndrome.
Source
JACC: Cardiovascular Interventions. 18(7) (pp 838-848), 2025. Date of
Publication: 14 Apr 2025.
Author
Takahashi K.; Otsuki H.; Zimmermann F.M.; Ding V.Y.; Piroth Z.; Oldroyd
K.G.; Wendler O.; Reardon M.J.; Desai M.; Woo Y.J.; Yeung A.C.; De Bruyne
B.; Pijls N.H.J.; Fearon W.F.
Institution
(Takahashi, Otsuki, Yeung, Fearon) Stanford University School of Medicine
and Stanford Cardiovascular Institute, Stanford University, CA, United
States
(Zimmermann) St. Antonius Hospital, Nieuwegein, Netherlands
(Zimmermann, Pijls) Catharina Hospital, Eindhoven, Netherlands
(Ding, Desai) Quantitative Sciences Unit, Stanford University, Stanford,
CA, United States
(Piroth) Gottsegen National Cardiovascular Center, Hungary
(Oldroyd) Golden Jubilee National Hospital, Glasgow, United Kingdom
(Wendler) Cleveland Clinic London, London, United Kingdom
(Reardon) Houston Methodist Debakey Heart & Vascular Center, Houston, TX,
United States
(Woo) Department of Cardiothoracic Surgery, Division of Cardiovascular
Medicine and Stanford Cardiovascular Institute, Stanford University, CA,
United States
(De Bruyne) Cardiovascular Center Aalst, Belgium
(Fearon) VA Palo Alto Medical Systems, Palo Alto, CA, United States
Publisher
Elsevier Inc.
Abstract
Background: There are limited data comparing coronary artery bypass
grafting (CABG) with percutaneous coronary intervention (PCI) in patients
presenting with non-ST-segment elevation acute coronary syndrome
(NSTE-ACS). <br/>Objective(s): The aim of this study was to evaluate
differences in outcomes in patients presenting with or without NSTE-ACS
after CABG compared with fractional flow reserve (FFR)-guided PCI using
current generation drug-eluting stents. <br/>Method(s): The FAME 3 trial
(Fractional flow reserve versus Angiography for Multivessel Evaluation;
NCT02100722) was an investigator-initiated, randomized controlled trial to
attest noninferiority of FFR-guided PCI using the current-generation
drug-eluting stents to CABG with respect to the primary endpoint, defined
as a composite of death, myocardial infarction (MI), stroke, or repeat
revascularization at 1 year, in 1,500 patients with 3-vessel coronary
artery disease. The prespecified key secondary endpoint was a composite of
death, MI, or stroke at 3 years. <br/>Result(s): Of 1,500 patients
enrolled, 587 (39.2%) presented with NSTE-ACS. Patients were followed up
for a median of 1,080 days (Q1-Q3: 1,080-1,080 days). At 3 years, the risk
of the composite of death, MI, or stroke was similar between patients
presenting with NSTE-ACS and with chronic coronary syndrome (CCS) (11.8%
vs 10.0%; adjusted HR [aHR]: 1.20; 95% CI: 0.81-1.77; P = 0.37). Patients
presenting with NSTE-ACS had a similar risk of death, MI, or stroke at 3
years after CABG as compared with PCI (aHR: 0.98; 95% CI: 0.60-1.60; P =
0.94), whereas patients presenting with CCS had a significantly reduced
risk after CABG compared with PCI (aHR: 0.58; 95% CI: 0.38-0.90; P = 0.02;
P<inf>interaction</inf> = 0.11), which was driven by a lower risk of MI
(aHR: 0.32; 95% CI: 0.15-0.64; P = 0.002; P<inf>interaction</inf> = 0.01).
<br/>Conclusion(s): The risk of death, MI, or stroke at 3 years was
similar after CABG compared with FFR-guided PCI in patients presenting
with NSTE-ACS, but reduced by CABG in patients presenting with CCS.
(Fractional flow reserve versus Angiography for Multivessel Evaluation
[FAME 3]; NCT02100722)<br/>Copyright &#xa9; 2025

<63>
Accession Number
2034179969
Title
Myocardial Revascularization in Patients with Diabetes and Heart Failure-A
Narrative Review.
Source
International Journal of Molecular Sciences. 26(7) (no pagination), 2025.
Article Number: 3398. Date of Publication: 01 Apr 2025.
Author
Zivkovic S.; Mandic A.; Krupnikovic K.; Obradovic A.; Misevic V.; Farkic
M.; Ilic I.; Tesic M.; Aleksandric S.; Juricic S.; Beleslin B.; Dobric M.
Institution
(Zivkovic, Mandic, Krupnikovic, Obradovic, Misevic, Farkic, Ilic, Dobric)
Cardiology Clinic, Institute for Cardiovascular Diseases "Dedinje",
Belgrade, Serbia
(Ilic, Tesic, Aleksandric, Beleslin, Dobric) Faculty of Medicine,
University of Belgrade, Belgrade, Serbia
(Tesic, Aleksandric, Juricic, Beleslin) Cardiology Clinic, University
Clinical Center of Serbia, Belgrade, Serbia
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Heart failure and diabetes mellitus are major contributors to global
morbidity and mortality, with their prevalence continuously rising,
primarily due to aging populations and improvements in healthcare. These
conditions often coexist or develop sequentially, leading to complex
interactions that significantly influence the progression and management
of both diseases. Furthermore, heart failure and diabetes are commonly
associated with coronary artery disease, which presents a unique challenge
in clinical management, particularly in the context of myocardial
revascularization. The presence of diabetes exacerbates atherosclerotic
progression and impairs endothelial function, while heart failure
complicates the perfusion and recovery of myocardial tissue
post-intervention. This narrative review delves into the underlying
mechanisms contributing to revascularization failure in patients with
heart failure and diabetes, emphasizing the importance of understanding
these interactions for optimal treatment. The review also summarizes key
findings from randomized controlled trials, examining evidence both in the
general population and in specific subgroups, including the elderly and
patients with left main coronary artery disease, chronic kidney disease,
peripheral artery disease, and chronic obstructive pulmonary disease.
Understanding these complexities is critical for improving patient
outcomes.<br/>Copyright &#xa9; 2025 by the authors.

<64>
Accession Number
2034220669
Title
Combined Catheter Ablation and Left Atrial Appendage Occlusion in Atrial
Fibrillation: From Data to Clinical Reality.
Source
Cardiovascular Drugs and Therapy. (no pagination), 2025. Date of
Publication: 2025.
Author
Dimitriadis K.; Adamopoulou E.; Pyrpyris N.; Iliakis P.; Beneki E.;
Konstantinidis D.; Fragkoulis C.; Antonopoulos A.; Papanikolaou A.;
Aznaouridis K.; Aggeli K.; Tsioufis K.
Institution
(Dimitriadis, Adamopoulou, Pyrpyris, Iliakis, Beneki, Konstantinidis,
Fragkoulis, Antonopoulos, Papanikolaou, Aznaouridis, Aggeli, Tsioufis)
First Department of Cardiology, School of Medicine, National and
Kapodistrian University of Athens, Hippokration General Hospital, Vas
Sofias 114, Athens, Greece
Publisher
Springer
Abstract
Purpose: Atrial fibrillation (AF) requires treatment that focuses on two
main goals: symptom control and prevention of thromboembolic events.
Catheter ablation and left atrial appendage occlusion (LAAO) constitute
two well-established treatment methods in selected patients that
accomplish these two goals correspondingly. Recently, there is increasing
interest in performing the two procedures concomitantly in a so-called
"combined" or "one-stop" procedure. This review aims to summarize the
current data on the combined procedure, from the rationale and the
techniques to its clinical efficacy, indications and future directions.
<br/>Method(s): An extensive search has been conducted using the
MEDLINE/PubMed database to identify the relevant studies. <br/>Result(s):
The reported success rates of the combined procedure are very high and
frequently reach 100% when performed by experienced operators. The
periprocedural and follow-up complications are low, the procedure is
cost-effective, while there is significant stroke, bleeding and arrhythmia
incidence reduction that does not seem to be undermined by interference
between the two interventions. There are also a few indications that the
one-stop procedure has a positive effect on left atrial mechanical
function as it has been correlated with left atrial reverse remodeling. On
the other hand, some studies suggest possible increase in peri-device
leaks (PDLs), compared with LAAO alone, which could in turn negatively
affect the clinical outcomes. Most available studies are small and
observational, with a lack of randomized controlled trials.
<br/>Conclusion(s): Catheter ablation and left atrial appendage occlusion
can be safely and effectively combined in a cost-effective single
procedure in carefully selected patients.<br/>Copyright &#xa9; The
Author(s) 2025.

<65>
Accession Number
2034316412
Title
Redo aortic root-complexity vs simplicity with choice of device selected.
Source
Expert Review of Medical Devices. (no pagination), 2025. Date of
Publication: 2025.
Author
He C.; Norton E.L.; Chen E.P.
Institution
(He, Norton) Division of Cardiothoracic Surgery, Department of Surgery,
Emory University School of Medicine, Atlanta, GA, United States
(Chen) Division of Cardiovascular and Thoracic Surgery, Department of
Surgery, Duke University Medical Center, Durham, NC, United States
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: The field of cardiac surgery continues to evolve
significantly and one such example of advancement is aortic root
replacement. In the setting of prior cardiac surgery, operative complexity
increases due to adhesions, surgically-altered anatomy, and previously
implanted prosthetic graft material. Device choice plays a significant
role in balancing operative complexity with achieving simplicity and
optimal clinical outcomes. Areas covered: This review explores the
critical considerations necessary in performing redo aortic root surgery
and the impact that device selection can have on the procedural complexity
and clinical outcomes. This review was formulated by a systematic
identification of published and unpublished laboratory and clinical
studies evaluating these technologies. Expert opinion: Redo aortic root
surgery represents one of the most challenging procedures in cardiac
surgery, and the choice of both surgical technique and prosthetic device
used are critical factors which influence the clinical success of the
operation and the long-term outcomes for patients. By understanding the
unique challenges of root replacement in a reoperative setting and the
characteristics of different prosthetic devices, a tailored approach must
be employed toward the best possible outcomes.<br/>Copyright &#xa9; 2025
Informa UK Limited, trading as Taylor & Francis Group.

<66>
[Use Link to view the full text]
Accession Number
2038224547
Title
Cost-Effectiveness of Aortic Valve Replacement in Low- and
Intermediate-Risk Chinese Patients With Severe Aortic Stenosis.
Source
Circulation: Cardiovascular Quality and Outcomes. 18(4) (pp e010858),
2025. Date of Publication: 01 Apr 2025.
Author
Peng J.; Zheng X.; Jiang M.; Yao X.; Ma Y.; Fu M.; Ma T.; Shang X.; Yan
Y.; Thourani V.H.; Fang Y.
Institution
(Peng, Jiang, Yao, Ma, Fu, Fang) Department of Pharmacy Administration and
Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, China
(Peng, Jiang, Yao, Ma, Fu, Fang) Center for Drug Safety and Policy
Research, Xi'an Jiaotong University, China
(Peng, Jiang, Yao, Ma, Fu, Fang) Shaanxi Center for Health Reform and
Development Research, Xi'an, China
(Peng, Jiang, Yao, Ma, Fu, Fang) Research Institute for Drug Safety and
Monitoring, Institute of Pharmaceutical Science and Technology, Western
China Science and Technology Innovation Harbor, Xi'an, China
(Zheng, Ma, Shang, Yan) Department of Cardiovascular Surgery, First
Affiliated Hospital of Xi'an Jiaotong University, China
(Jiang) Institute for Global Health and Development, Peking University,
Beijing, China
(Thourani) Department of Cardiovascular Surgery, Marcus Heart and Vascular
Center, Piedmont Heart Institute, Atlanta, GA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: Transcatheter aortic valve replacement (TAVR) remains debated
as an alternative to surgical aortic valve replacement (SAVR). We aimed to
evaluate the cost-effectiveness of aortic valve replacement strategies in
low- and intermediate-risk patients with severe aortic stenosis in China.
<br/>METHOD(S): A decision-analytic model combining decision tree and
Markov model was developed to compare outcomes of universal SAVR,
universal TAVR, and a risk-based strategy (SAVR in low-risk patients and
TAVR in intermediate-risk patients) in a hypothetical cohort of
75-year-old patients with aortic stenosis within the perspective of the
Chinese health care system. A meta-analysis was performed to derive the
clinical inputs; the 2019 to 2021 claims data from Shaanxi Province were
used for cost analysis, and quality of life was measured using EuroQoL-5D.
One-way and probabilistic (10 000 Monte Carlo simulations) sensitivity
analyses were conducted to examine the robustness of model results.
Primary outcomes included total costs, quality-adjusted life-years
(QALYs), and incremental cost-effectiveness ratio (ICER). <br/>RESULT(S):
Universal TAVR gained the most QALYs (6.76 QALYs) with the highest costs
(USD 58 949). Compared with universal SAVR, the risk-based strategy gained
0.12 additional QALYs at higher costs (USD 14 046); the ICER (117 048
USD/QALY) exceeded the willingness-to-pay threshold (37 657 USD/QALY,
3-fold gross domestic product per capita in China). The ICER of universal
TAVR versus universal SAVR (80 526 USD/QALY) also exceeded the
willingness-to-pay threshold. Sensitivity analysis showed that universal
TAVR would be cost-effective if TAVR valve costs were <USD 21 477 (>44.23%
cost reduction). Subgroup analysis showed that universal TAVR and
risk-based strategy remained not cost-effective compared with universal
SAVR in both low-risk (ICER of 64 414 USD/QALY) and intermediate-risk
(ICER of 124 851 USD/QALY) patients. In 10 000 Monte Carlo simulations,
the probabilities of being cost-effective for universal SAVR, universal
TAVR, and risk-based strategy were 89.81%, 10.14%, and 0.05%,
respectively. <br/>CONCLUSION(S): The risk-based strategy and universal
TAVR appeared not to be cost-effective versus universal SAVR in low- and
intermediate-risk patients with severe aortic stenosis in
China.<br/>Copyright &#xa9; 2025 American Heart Association, Inc.

<67>
Accession Number
2036504016
Title
Sex-related differences in patients with acute myocardial infarction
complicated by cardiogenic shock: A systematic review and meta-analysis.
Source
American Journal of the Medical Sciences. 369(5) (pp 599-604), 2025. Date
of Publication: 01 May 2025.
Author
Karamat M.; Patel B.; Khanal R.; Hamza M.; Fakhra S.; Yadav R.; Patel
N.N.; Mir J.; Kumar N.; Harmouch K.M.; Naseem M.; Bahar Y.; Riasat M.;
Thyagaturu H.; Sattar Y.; Alraies M.C.
Institution
(Karamat) Department of Internal Medicine, Ascension Saint Francis
Hospital, Evanston, IL, United States
(Patel) Department of Internal Medicine, West Virginia University,
Morgantown, WV, United States
(Khanal) Department of Internal Medicine, Promedica Physician Group,
Toledo, OH, United States
(Hamza) Department of Internal Medicine, Guthrie Medical Group, NY, United
States
(Fakhra) Department of Internal Medicine, University of Nevada Las Vegas
Kirk Krikorian School of Medicine, NV, United States
(Yadav) Department of Internal Medicine, Midwest University GME/Verde
Valley Medical Center, AZ, United States
(Patel) Department of Internal Medicine, New York Medical College /
Landmark Medical Center, Woonsocket, RI, United States
(Mir) Department of Internal Medicine, University of Missouri, Columbia,
MO, United States
(Kumar, Harmouch) Department of Internal Medicine, Detroit Medical
Center/Wayne State University, Detroit, MI, United States
(Naseem) Ziauddin Medical College, Ziauddin University, Karachi, Pakistan
(Bahar) Wayne State University, Detroit, MI, United States
(Riasat) Department of Cardiology, Ichan School of Medicine Mount Sinai
Morningside, New York City, NY, United States
(Thyagaturu, Sattar) Department of Cardiology, West Virginia University,
Morgantown, WV, United States
(Alraies) Cardiovascular Institute, Detroit Medical Center, DMC Heart
Hospital, Detroit, MI, United States
Publisher
Elsevier B.V.
Abstract
Background: This review aims to analyze sex-related differences in
patients with acute myocardial infarction (AMI) complicated by cardiogenic
shock (CS). <br/>Method(s): 10 studies were retrieved from PubMed and
Embase comparing outcomes between men and women admitted with AMI
complicated by CS. Pooled log odds ratios (OR) were calculated for binary
outcomes using the Mantel-Haenszel method, and Hedges' g with the
inverse-variance method was used for continuous outcomes. <br/>Result(s):
The primary endpoints were in-hospital mortality and 30-day mortality. The
secondary endpoints were reinfarction rate, length of hospital stay (LOS),
requirement of renal replacement therapy (RRT), and stroke (ischemic and
hemorrhagic). Males exhibited a lower risk of in-hospital mortality (OR
0.77, 95 % CI 0.69-0.85, I² = 97 %, p < 0.0001), 30-day
mortality (OR 0.69, 95 % CI: 0.61-0.78, I2 = 0 %, p < 0.0001) and stroke
(OR 0.91, 95 % CI 0.87-0.95, I² = 36 %, p < 0.0001) compared to
females. In contrast, males were more likely to require renal replacement
therapy (RRT) (OR 1.27, 95 % CI 1.09-1.48, I² = 69 % p =
0.0017). However, there were no statistically significant differences
between females and males in terms of reinfarction rate (OR 0.88, 95 % CI
0.66-1.18, I² = 56 %, p = 0.3936) or length of hospital stay
during hospitalization (Hedges's g 0.35 days, 95 % CI -0.38-1.07,
I² = 100 %, p = 0.34). <br/>Conclusion(s): Females with AMI and
CS have higher in-hospital mortality, 30-day mortality, and stroke risk
than men. Men are more likely to require RRT. Further research is needed
to understand underlying mechanisms and improve outcomes for both
genders.<br/>Copyright &#xa9; 2024

<68>
Accession Number
2033639537
Title
Transcatheter aortic valve replacement outcomes in patients with high
gradient versus low ejection fraction low gradient severe aortic stenosis:
A meta-analysis of randomized controlled trials.
Source
Cardiovascular Revascularization Medicine. 73 (pp 1-7), 2025. Date of
Publication: 01 Apr 2025.
Author
Al-Bayati A.; Alrifai A.; Darmoch F.; Alkhaimy H.; Fanari Z.
Institution
(Al-Bayati, Fanari) University of California San Francisco, Fresno, CA,
United States
(Alrifai) Advocate Aurora Health, Chicago, IL, United States
(Darmoch) Northside Hospital Cardiovascular Institute, Cumming, GA, United
States
(Alkhaimy) University of Arkansas for Medical Sciences, Little Rock, AR,
United States
Publisher
Elsevier Inc.
Abstract
Background: The outcome of Low Flow-Low Gradient (LF-LG) severe aortic
stenosis (AS) patients who underwent Transcatheter Aortic Valve
Replacement (TAVR) procedure is not well defined. We conducted a
systematic review of the literature to compare the outcomes of TAVR in
LF-LG AS patients to the more traditional high gradient (HG) aortic
stenosis. <br/>Method(s): We comprehensively searched for controlled
randomized and non-randomized studies from 4 online databases. We are
presenting the data using risk ratios (95 % confidence intervals) and
measuring heterogeneity using Higgins' I² index.
<br/>Result(s): Our analysis included 4380 patients with 3425 HG patients
and 955 LF-LG patients from 6 cohort (5 retrospective and 1 prospective)
studies. When compared to LFLG; TAVR was associated with significantly
lower 30 days mortality in HG patients (5.1 % vs 7.4 %; relative risk
[RR]: 0.55; 95 % confidence interval [CI]: 0.35 to 0.86; p < 0.01).
Similar findings were also observed in 12-month cardiovascular (CV)
mortality (5.5 % vs. 10.4 %; RR: 0.47; 95 % CI: 0.38 to 0.60; p < 0.01 and
12-month all-cause mortality (15.9 % vs 20.9 %; RR: 0.70; 95 % CI: 0.49 to
1.00; p < 0.05). There was no significant difference in myocardial
infarction (MI) after TAVR between HG and LF-LG at 30 days (0.16 % vs.
0.95 %; p < 0.09) or 12 months (0.43 % vs. 0.95 %; p = 0.20). Similarly,
there was no difference in stroke rates at 30 days (2.9 % vs. 2.86 %) or
at 12 months (3.6 % vs. 3.06 %). Conclusions and relevance: Patients with
LF-LG severe AS who underwent TAVR had worse 1-year all-cause mortality,
30-day all-cause, and 1-year CV mortality when compared to TAVR in HG
severe AS. There was no difference in MI or stroke rates. Therefore, with
heart team discussion and informed patient decision regarding the risk and
benefit, TAVR would still offer better outcomes in LFLG AS compared to
conservative medical management.<br/>Copyright &#xa9; 2024 The Authors

<69>
Accession Number
2037453363
Title
Benzodiazepine-Free Cardiac Anesthesia for Reduction of Postoperative
Delirium: A Cluster Randomized Crossover Trial.
Source
JAMA Surgery. 160(3) (pp 286-294), 2025. Date of Publication: 12 Mar 2025.
Author
Spence J.; Devereaux P.J.; Lee S.-F.; D'Aragon F.; Avidan M.S.; Whitlock
R.P.; Mazer C.D.; Rousseau-Saine N.; Rajamohan R.R.; Pryor K.O.; Klein R.;
Tan E.; Cameron M.J.; Di Sante E.; Deborba E.; Mustard M.E.; Couture E.J.;
Zamper R.P.C.; Law M.W.Y.; Djaiani G.; Saha T.; Choi S.; Hedlin P.;
Pikaluk D.R.; Lam W.; Deschamps A.; Ramasundarahettige C.F.; Vincent J.;
McIntyre W.F.; Oczkowski S.J.W.; Dulong B.J.; Beaver C.; Kloppenburg S.A.;
Lamy A.; Jacobsohn E.; Belley-Cote E.P.
Institution
(Spence, Devereaux, Lee, Whitlock, Di Sante, Deborba, Ramasundarahettige,
Vincent, McIntyre, Beaver, Kloppenburg, Lamy, Belley-Cote) Population
Health Research Institute, Hamilton, ON, Canada
(Spence) Department of Anesthesia and Critical Care, McMaster University,
Hamilton, ON, Canada
(Spence, Devereaux, Lee, Whitlock, Oczkowski, Belley-Cote) Department of
Health Research Methods, Evidence, and Impact, McMaster University,
Hamilton, ON, Canada
(Spence, Devereaux, Whitlock, McIntyre, Lamy, Belley-Cote) World Health
Research Trust, Hamilton, ON, Canada
(Devereaux, McIntyre, Lamy) Department of Medicine, Cardiology, McMaster
University, Hamilton, ON, Canada
(D'Aragon) Departement d'Anesthesiologie, Universite de Sherbrooke,
Sherbrooke, QC, Canada
(Avidan) Department of Anesthesia, Washington University, St Louis School
of Medicine, St Louis, MO, United States
(Whitlock) Department of Surgery, Cardiac Surgery, McMaster University,
Hamilton, ON, Canada
(Mazer) Department of Anesthesia, Li Ka Shing Knowledge Institute, St.
Michael's Hospital, Toronto, ON, Canada
(Mazer) Departments of Anesthesiology and Pain Medicine, Physiology, and
Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
(Rousseau-Saine, Deschamps) Departement d'Anesthesie, Institut de
Cardiologie de Montreal, Universite de Montreal, Montreal, QC, Canada
(Rajamohan) Department of Anesthesia, St Paul's Hospital, University of
British Columbia, Vancouver, BC, Canada
(Pryor) Department of Anesthesiology, Weill Cornell Medical College, New
York, NY, United States
(Klein) Department of Anesthesia, Vancouver General Hospital, University
of British Columbia, Vancouver, BC, Canada
(Tan, Dulong) Department of Anesthesia and Critical Care Medicine, Queen
Elizabeth II Health Sciences, Dalhousie University, Halifax, NS, Canada
(Cameron) Department of Anesthesia, Jewish General Hospital, McGill
University, Montreal, QC, Canada
(Mustard) St Michael's Hospital, Toronto, ON, Canada
(Couture) Institut Universitaire de Cardiologie et de Pneumologie de
Quebec, Universite Laval, Quebec, QC, Canada
(Zamper) Department of Anesthesia, University of Western Ontario, London,
ON, Canada
(Law) Department of Anesthesiology, Royal Columbian Hospital, Department
of Anesthesiology, Pharmacology & Therapeutics, University of British
Columbia, Vancouver, BC, Canada
(Djaiani, Choi) Department of Anesthesiology and Pain Medicine, University
of Toronto, Toronto, ON, Canada
(Saha) Department of Anesthesia, Queen's University, Kingston, ON, Canada
(Choi) Department of Anesthesia, Sunnybrook Health Sciences Centre,
Toronto, ON, Canada
(Hedlin, Pikaluk) Department of Anesthesia, University of Saskatchewan,
Saskatoon, SK, Canada
(Lam) Department of Anesthesia, University of Alberta, Mazankowski Alberta
Heart Institute, Edmonton, AB, Canada
(Oczkowski) Department of Medicine, Critical Care, McMaster University,
Hamilton, ON, Canada
(Lamy, Belley-Cote) Department of Medicine, Cardiology and Critical Care,
McMaster University, Hamilton, ON, Canada
(Jacobsohn) Departments of Anesthesia and Perioperative Medicine and
Medicine, Critical Care, University of Manitoba, Winnipeg, MB, Canada
Publisher
American Medical Association
Abstract
Importance: Delirium is common after cardiac surgery and associated with
adverse outcomes. Intraoperative benzodiazepines may increase
postoperative delirium but restricting intraoperative benzodiazepines has
not yet been evaluated in a randomized trial. <br/>Objective(s): To
determine whether an institutional policy of restricted intraoperative
benzodiazepine administration reduced the incidence of postoperative
delirium. <br/>Design, Setting, and Participant(s): This pragmatic,
multiperiod, patient- and assessor-blinded, cluster randomized crossover
trial took place at 20 North American cardiac surgical centers. All adults
undergoing open cardiac surgery at participating centers during the trial
period were included through a waiver of individual patient consent
between November 2019 and December 2022. <br/>Intervention(s):
Institutional policies of restrictive vs liberal intraoperative
benzodiazepine administration were compared. Hospitals (clusters) were
randomized to cross between the restricted and liberal benzodiazepine
policies 12 to 18 times over 4-week periods. <br/>Main Outcomes and
Measures: The primary outcome was the incidence of delirium within 72
hours of surgery as detected in routine clinical care, using either the
Confusion Assessment Method-Intensive Care Unit or the Intensive Care
Delirium Screening Checklist. Intraoperative awareness by patient report
was assessed as an adverse event. <br/>Result(s): During the trial, 19768
patients (mean [SD] age, 65 [12] years; 14528 [73.5%] male) underwent
cardiac surgery, 9827 during restricted benzodiazepine periods and 9941
during liberal benzodiazepine periods. During restricted periods,
clinicians adhered to assigned policy in 8928 patients (90.9%), compared
to 9268 patients (93.2%) during liberal periods. Delirium occurred in 1373
patients (14.0%) during restricted periods and 1485 (14.9%) during liberal
periods (adjusted odds ratio [aOR], 0.92; 95% CI, 0.84-1.01; P =.07). No
patient spontaneously reported intraoperative awareness. <br/>Conclusions
and Relevance: In intention-to-treat analyses, restricting benzodiazepines
during cardiac surgery did not reduce delirium incidence but was also not
associated with an increase in the incidence of patient-reported
intraoperative awareness. Given that smaller effect sizes cannot be ruled
out, restriction of benzodiazepines during cardiac surgery may be
considered. Research is required to determine whether restricting
intraoperative benzodiazepines at the patient level can reduce the
incidence of postoperative delirium. Trial Registration:
ClinicalTrials.gov Identifier: NCT03928236.<br/>Copyright &#xa9; 2025
American Medical Association. All rights reserved, including those for
text and data mining, AI training, and similar technologies.

<70>
[Use Link to view the full text]
Accession Number
2038244062
Title
Effect of Disclosing a Polygenic Risk Score for Coronary Heart Disease on
Adverse Cardiovascular Events.
Source
Circulation: Genomic and Precision Medicine. 18(2) (pp e004968), 2025.
Date of Publication: 01 Apr 2025.
Author
Naderian M.; Hamed M.E.; Vaseem A.A.; Norland K.; Dikilitas O.;
Teymourzadeh A.; Bailey K.R.; Kullo I.J.
Institution
(Naderian, Hamed, Vaseem, Norland, Teymourzadeh, Kullo) Department of
Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States
(Dikilitas) Department of Internal Medicine, Mayo Clinic, Rochester, MN,
United States
(Bailey) Department of Quantitative Health Sciences, Mayo Clinic,
Rochester, MN, United States
(Kullo) Gonda Vascular Center, Mayo Clinic, Rochester, MN, United States
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: In the Myocardial Infarction Genes clinical trial (URL:
https://www.clinicaltrials.gov; Unique identifier: NCT01936675),
participants at intermediate risk of coronary heart disease (CHD) were
randomized to receive a Framingham risk score (Framingham risk score
group, n=103) or an integrated risk score (integrated risk score group
[IRSg], n=104) that additionally included a polygenic risk score. After 6
months, IRSg participants had higher statin initiation and lower
low-density lipoprotein cholesterol. We conducted a post hoc 10-year
follow-up analysis to investigate whether disclosure of a polygenic risk
score for CHD was associated with a reduction in major adverse
cardiovascular events (MACE). <br/>METHOD(S): Participants were followed
from randomization in October 2013 to September 2023 to ascertain MACE,
testing for CHD, and changes in risk factors. The primary outcome was time
to first MACE, defined as cardiovascular death, nonfatal myocardial
infarction, coronary revascularization, and nonfatal stroke. Statistical
analyses included Cox proportional hazards regression and linear
mixed-effects models. <br/>RESULT(S): We followed all participants who
completed the trial, 100 in Framingham risk score group and 103 in IRSg
(mean age at the end of follow-up, 68.2+/-5.2; 48% male). During a median
follow-up of 9.5 years, 9 MACEs occurred in Framingham risk score group
and 2 in IRSg (hazard ratio, 0.20 [95% CI, 0.04-0.94]; P=0.042). In
Framingham risk score group, 47 (47%) underwent at least 1 diagnostic test
for CHD, compared with 30 (29%) in IRSg (hazard ratio, 0.51 [95% CI,
0.32-0.81]; P=0.004). A higher proportion of IRSg participants were on
statin therapy during the first 4 years postrandomization and had a
greater reduction in low-density lipoprotein cholesterol for up to 3 years
postrandomization. No significant differences were observed between 2
groups in other traditional cardiovascular risk factors during follow-up.
<br/>CONCLUSION(S): Disclosure of an integrated risk score that included a
polygenic risk score to individuals at intermediate risk for CHD was
associated with lower MACE incidence after 10 years, likely due to higher
statin initiation, leading to lower low-density lipoprotein cholesterol
levels.<br/>Copyright &#xa9; 2025 American Heart Association, Inc.

<71>
Accession Number
2038523873
Title
Ultrasound-guided ulnar versus radial artery cannulation in children
undergoing major non-cardiac surgery: a randomized controlled
non-inferiority trial.
Source
Minerva Anestesiologica. 91(4) (pp 356-358), 2025. Date of Publication: 01
Apr 2025.
Author
Sarhan K.A.; Mohamed R.; El Ghobashy M.; Elkholy M.; Alkonaiesy R.; Nawwar
K.; Seif N.
Institution
(Sarhan, Mohamed, Elkholy, Alkonaiesy, Nawwar, Seif) Department of
Anesthesia and Critical Care Medicine, Faculty of Medicine, Cairo
University, Cairo, Egypt
(El Ghobashy) Radiology Department, Cairo University, Cairo, Egypt
Publisher
Edizioni Minerva Medica

<72>
Accession Number
2034459476
Title
Role of nicorandil in preventing contrast-induced nephropathy in patients
undergoing cardiac catheterization procedures: an updated systematic
review and meta-analysis.
Source
International Urology and Nephrology. (no pagination), 2025. Date of
Publication: 2025.
Author
Khan A.A.; Tahir M.Z.; Maryam K.U.E.; Uzair M.; Haram; Faheem M.S.B.;
Zainab; Abdullah A.; Anwer A.; Ashraf D.A.; Ahmed A.K.; Rahim S.; Arshad
M.S.
Institution
(Khan, Maryam, Ashraf) Department of Internal Medicine, Foundation
University Medical College Islamabad, Islamabad, Pakistan
(Tahir) Department of Internal Medicine, Punjab Medical College,
Faisalabad, Pakistan
(Uzair) Ziauddin Medical College, Karachi, Pakistan
(Haram) Rehman Medical College, Peshawar, Pakistan
(Faheem) Department of Internal Medicine, Karachi Institute of Medical
Sciences, KIMS, Sindh, Karachi, Pakistan
(Zainab) Allama Iqbal Medical College, Lahore, Pakistan
(Abdullah, Anwer) Amna Inayat Medical College, Sheikhupura, Pakistan
(Ahmed) Jinnah Medical and Dental College, Karachi, Pakistan
(Rahim) King Edward Medical University, Lahore, Pakistan
(Arshad) Dow University of Health Sciences, Islamabad, Pakistan
Publisher
Springer Science and Business Media B.V.
Abstract
Background: Contrast-induced nephropathy (CIN) is a major risk for
patients undergoing coronary angiography (CAG) and percutaneous coronary
intervention (PCI). <br/>Method(s): PubMed, MEDLINE, Embase, Google
Scholar, and Web of Science were searched through May 2024 to include
randomized controlled trials (RCTs) assessing the efficacy and safety of
nicorandil administration in patients following CAG or PCI. Outcomes of
interest included the CIN incidence, major adverse events, serum
creatinine, serum cystatin C, BUN and eGFR. Risk ratios (RRs) and standard
mean differences (SMDs) with 95% confidence intervals (CIs) were
calculated using random-effects model. Statistical heterogeneity was
assessed using I2 statistics. <br/>Result(s): Twelve studies (n = 2931
patients) were included in the final analysis. Nicorandil significantly
reduced the CIN incidence (RR: 0.40 [0.31,0.52]; p < 0.00001), with
consistent results for oral (RR: 0.35 [0.25,0.48]; p < 0.00001) and
intravenous administration (RR: 0.52 [0.30,0.92]; p = 0.02) (p-interaction
= 0.22). Oral nicorandil reduced the risk of major adverse events (RR:
0.71 [0.51,0.99]; p = 0.05). Among patients on nicorandil, serum
creatinine levels were significantly lower at 48 h (SMD: -0.30
[-0.52,-0.07]; p = 0.009), and 72 h post-intervention (SMD: -0.42
[-0.71,-0.13]; p = 0.004). Nicorandil significantly reduced serum cystatin
C levels at 48 h post-intervention (SMD: -0.56 [-1.01,-0.01]; p = 0.02).
However, nicorandil did not significantly affect eGFR values at 24-h (SMD:
0.12 [-0.21,0.45]; p = 0.46), 48-h (SMD: 0.08 [-0.19,0.35]; p = 0.58), and
72-h (SMD: 0.34 [-0.13,0.81]; p = 0.16). <br/>Conclusion(s): Nicorandil
administration reduces the CIN incidence and improves renal biomarkers in
patients undergoing CAG and PCI. Large-scale trials with longer follow-up
periods are warranted to confirm renoprotective effects of
nicorandil.<br/>Copyright &#xa9; The Author(s), under exclusive licence to
Springer Nature B.V. 2025.

<73>
Accession Number
2038571551
Title
Weekly Journal Scan: is transcatheter replacement therapy for tricuspid
regurgitation ready for prime time?.
Source
European Heart Journal. 46(17) (pp 1687-1688), 2025. Date of Publication:
01 May 2025.
Author
Pedicino D.; Vergallo R.
Institution
(Pedicino) Intensive Cardiac Care Unit, Department of Cardiovascular
Medicine, Fondazione Policlinico Universitario A. Gemelli - IRCCS,
Catholic University of the Sacred Heart, Largo A. Gemelli 8, Rome, Italy
(Vergallo) Department of Internal Medicine and Medical Specialties (DIMI),
Universita di Genova, Genova, Italy
(Vergallo) Interventional Cardiology Unit, Cardiothoracic and Vascular
Department (DICATOV), IRCCS Ospedale Policlinico San Martino, Genova,
Italy
Publisher
Oxford University Press
Abstract
The TRISCEND II trial (EVOQUE Transcatheter Tricuspid Valve Replacement:
Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a
Novel Device) was an international, multicentre, industry-funded,
randomized controlled trial (RCT) aiming to compare safety and
effectiveness of transcatheter tricuspid valve replacement (TTVR) using
the EVOQUE system (Edwards Lifesciences) along with medical therapy to
medical therapy alone in the treatment of patients with symptomatic,
severe tricuspid regurgitation (TR).1 Patients with functional and/or
degenerative TR graded as at least severe on transthoracic echocardiogram
(assessed by the echo core lab using a 5-grade classification)2 who had
signs or symptoms of TR or had been hospitalized for associated heart
failure (HF) despite medical therapy were included. Exclusion criteria
included severe right ventricular (RV) systolic dysfunction, prior heart
transplantation, anatomy that precluded proper device delivery, deployment
and/or function, estimated glomerular filtration rate = 25 mL/min/1.73 m2
or long-term renalreplacement therapy, and life expectancy < 12 months.
The primary endpoint, assessed at 12 months, was a hierarchical composite
of all-cause death, durable implantation of a RV assist device or heart
transplantation, tricuspid valve surgery or percutaneous intervention,
annualized rate of HF hospitalization, an improvement of =10 points in the
Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) score,
an improvement of at least one New York Heart Association (NYHA)
functional class, and an increase in the 6-min walk distance (6MWD) of =30
m. A win ratio analysis was performed for the primary endpoint. Secondary
endpoints were a composite of death and HF hospitalization; all-cause
hospitalizations; all-cause death; reduction in TR of =1 grade; reduction
in NYHA functional class by =1 grade; change in KCCQ-OS from baseline; and
change in 6MWD from baseline. From May 2021 through April 2023, a total
of 400 patients (mean age, 79 years; 76% female) were enrolled at 45
centres in the USA and Germany and randomized in a 2:1 ratio to undergo
either TTVR plus medical therapy (n = 267) or medical therapy alone (n =
133); 73% of patients had functional TR, with 57% showing parameters for
massive or torrential TR; 94% of patients had atrial fibrillation. The
mean pulmonary artery systolic pressure was 38 mmHg, and the mean
tricuspid annular plane systolic excursion was 16 mm. Medical therapy was
determined by the heart team and included stable oral diuretic
medications. In the TTVR group, warfarin or another anticoagulant plus
aspirin was recommended for at least 6 months after the procedure. At 12
months, the win ratio favouring TTVR was 2.0 (95% confidence interval,
1.6-2.6; P < .001). In comparisons of patient pairs, those in the TTVR
group showed more wins than the medical therapy group with respect to
all-cause death (14.8% vs. 12.5%), tricuspid valve intervention (3.2% vs.
0.6%), and improvement in KCCQ-OS score (23.1% vs. 6.0%), NYHA class
(10.2% vs. 0.8%), and 6MWD (1.1% vs. 0.9%). As compared with the medical
therapy group, the TTVR group showed fewer wins with respect to the
annualized rate of HF hospitalization (9.7% vs. 10.0%). As compared with
patients in the medical therapy group, those in the TTVR group more
frequently showed an increase of =10 points in the KCCQ-OS score (66% vs.
37%), a decrease of =1 NYHA class (79% vs. 24%), and an increase of =30 m
in 6MWD (48% vs. 32%). At 12 months, 73% of the patients in the TTVR group
had no residual TR, and 23% had mild TR. In the medical therapy group,
most patients had severe (41%), massive (20%), or torrential TR (23%) at
12 months. The incidence of severe bleeding was higher in the TTVR group
than in the medical therapy group (15.4% vs. 5.3%, P = .003), as well as
the rate of permanent pacemaker implantation (17.4% vs. 2.3%, P <
.001).<br/>Copyright &#xa9; The Author(s) 2025. Published by Oxford
University Press on behalf of the European Society of Cardiology.

<74>
Accession Number
2034368011
Title
Combined Use of Dexmedetomidine and Hydrocortisone to Prevent New-Onset
Atrial Fibrillation After Coronary Artery Bypass Grafting Surgery: A
Randomized Clinical Trial.
Source
Seminars in Cardiothoracic and Vascular Anesthesia. (no pagination),
2025. Date of Publication: 2025.
Author
Alhadidy M.A.; Alansary A.M.; Elghareeb S.H.
Institution
(Alhadidy, Alansary, Elghareeb) Department of Anesthesiology, ICU and Pain
Management, Ain Shams University, Cairo, Egypt
Publisher
SAGE Publications Inc.
Abstract
Objective: Postoperative atrial fibrillation (POAF) occurs in 20%-40% of
patients following coronary artery bypass grafting (CABG), contributing to
significant morbidity. POAF is linked to elevated catecholamines,
oxidative stress, and inflammatory mediators. Dexmedetomidine, a centrally
acting alpha-2 agonist with sympatholytic and anti-inflammatory effects,
and hydrocortisone, which suppresses inflammatory mediators, may reduce
the incidence of POAF. <br/>Method(s): A prospective, double-blind
randomized controlled trial was conducted on 248 patients undergoing
elective on-pump CABG at Ain Shams University Hospital. Patients were
randomized into 2 groups: the Treatment Group received dexmedetomidine and
hydrocortisone, and the Placebo Group received standard care. The primary
endpoint was the occurrence of POAF within 7 days postoperatively.
<br/>Result(s): All 248 patients (124 per group) completed the study. The
combined use of dexmedetomidine and hydrocortisone reduced POAF incidence
(4.8% vs 12.9%). ICU and hospital length of stay were also shorter in the
Treatment Group (2.77 +/- 1.12 vs 3.16 +/- 1.34 days, P =.012, and 6.63
+/- 1.56 vs 7.11 +/- 2 days, P =.035, respectively). No differences in
hypotension, bradycardia, or wound infections were observed.
Hyperglycemia, defined as blood glucose >180 mg/dl, occurred in 8.1% of
the Treatment Group and 6.5% of the Placebo Group. <br/>Conclusion(s):
Combining dexmedetomidine and hydrocortisone effectively reduces POAF
incidence after CABG, with manageable side effects. Multicenter trials are
warranted to confirm these findings. Date and Number of IRB Approval and
Clinical Trial Registry Number. Ain Shams University Protocol Record
(FMASU R 261/2022), ClinicalTrials.gov Identifier:
NCT05674253.<br/>Copyright &#xa9; The Author(s) 2025.

<75>
Accession Number
2038528332
Title
Myocardial Revascularization in Heart Failure With Reduced Ejection
Fraction.
Source
Deutsches Arzteblatt International. 122(4) (pp 103-108), 2025. Date of
Publication: 21 Feb 2025.
Author
Haring B.; Bauersachs J.; Frey N.; Hoppe U.C.; Doenst T.; Bohm M.
Institution
(Haring, Bohm) Department of Internal Medicine III, Cardiology, Angiology,
and Internal Intensive Care Medicine, University of the Saarland, Homburg,
Germany
(Bauersachs) Department of Cardiology and Angiology, Medical School
Hanover, Germany
(Frey) Department of Internal Medicine III, Cardiology, Angiology, and
Pulmonology, University Hospital Heidelberg, Germany
(Hoppe) Department of Internal Medicine II, Cardiology, Paracelsus Medical
University, Salzburg, Austria
(Doenst) Department of Cardiothoracic Surgery, University Hospital Jena,
Friedrich Schiller University of Jena, Germany
Publisher
Deutscher Arzte-Verlag GmbH
Abstract
Background: Heart failure (HF) patients with reduced ejection fraction
(HFrEF) now more commonly die of non-cardiovascular causes than they did
in the past. In patients with both HFrEF and ischemic cardiomyopathy (as
the cause of HFrEF or as an accompanying condition), the effect of
myocardial revascularization-i.e. percutaneous coronary intervention (PCI)
or coronary artery bypass grafting (CABG)-on long-term outcome is unclear.
<br/>Method(s): This review is based on publications that were retrieved
by a selective search of the literature for pertinent clinical studies and
current guidelines. <br/>Result(s): Drug treatment for HFrEF has markedly
prolonged these patients' survival. In a comparative study, HF
pharmacotherapy was found to add an average of 8.3 years to the lifespan
of a 55-year-old patient with HFrEF. Three of the four randomized
controlled trials on revascularization procedures were conducted prior to
the major pharmacotherapy improvements leading to better outcomes in HF
patients over the past decade. These trial data indicate a long-term
benefit from CABG compared to medical treatment alone in patients with
HFrEF and severe coronary heart disease. For example, in the STICH trial,
the hazard ratio for death from any cause after a follow-up time of nearly
10 years was 0.84 (95% confidence interval, [0.73; 0.97]). The role of
pre-procedural myocardial viability and ischemia testing remains to be
fully determined. The choice of method for myocardial revascularization
should be discussed within an interdisciplinary cardiac team in
consideration of the patient's symptoms and ischemic burden, the
complexity of the coronary findings, as well as the patient's
perioperative risk and current medical HF therapy. No RCTs comparing CABG
to PCI are yet available. <br/>Conclusion(s): Optimal guideline-directed
medical therapy is a key determinant of long-term survival in patients
with HFrEF.<br/>Copyright &#xa9; 2025 Deutscher Arzte-Verlag GmbH. All
rights reserved.

<76>
Accession Number
2038606045
Title
Age and sex-related outcomes in cardiovascular magnetic resonance versus
computed tomography-guided transcatheter aortic valve replacement: a
secondary analysis of a randomized clinical trial.
Source
Journal of Cardiovascular Magnetic Resonance. 27(1) (no pagination), 2025.
Article Number: 101882. Date of Publication: 01 Jun 2025.
Author
Lechner I.; Oberhollenzer F.; Tiller C.; Holzknecht M.; Kaser A.; Binder
R.K.; Gollmann-Tepekoylu C.; Klug G.; Mayr A.; Bauer A.; Metzler B.;
Reindl M.; Reinstadler S.J.
Institution
(Lechner, Oberhollenzer, Tiller, Holzknecht, Kaser, Bauer, Metzler,
Reindl, Reinstadler) University Clinic of Internal Medicine III,
Cardiology and Angiology, Medical University of Innsbruck, Innsbruck,
Austria
(Binder) Department of Cardiology and Intensive Care, University Teaching
Hospital Klinikum Wels-Grieskirchen, Wels, Austria
(Gollmann-Tepekoylu) University Clinic of Cardiac Surgery, Medical
University of Innsbruck, Innsbruck, Austria
(Klug) Department of Internal Medicine, County Hospital Bruck an der Mur,
Bruck an der Mur, Austria
(Mayr) University Clinic of Radiology, Medical University of Innsbruck,
Innsbruck, Austria
Publisher
Elsevier B.V.
Abstract
Background: Transcatheter aortic valve replacement (TAVR) is the preferred
treatment for older patients with severe aortic stenosis with outcomes
influenced by age and sex. Computed tomography (CT) is the reference
imaging modality for TAVR planning, while cardiovascular magnetic
resonance (CMR) is an emerging alternative for this indication. The aim of
this study was to evaluate the impact of age and sex on implantation
success in patients undergoing CT- or CMR-guided TAVR. <br/>Method(s):
This was a secondary analysis of the randomized TAVR-CMR trial comparing
TAVR planning by CT or CMR (NCT03831087). Patients were categorized
according to the median age (82 years) and sex. Implantation success,
defined using the Valve Academic Research Consortium-2 definition (absence
of procedural mortality, correct positioning of a single prosthetic valve,
and proper prosthetic valve performance), was compared at hospital
discharge between age groups and sex for each imaging strategy. All-cause
mortality at 6 months was compared between imaging strategies across age
groups and sex. <br/>Result(s): A total of 267 patients (median age 82
[IQR 80-85] years, 50% (133/267) female) underwent TAVR at two heart
centers in Austria between September 2017 and December 2022. Implantation
success did not differ significantly between imaging strategies across age
and sex subgroups. For patients <=82 years, success rates were 92.1%
(58/63) (CT) vs. 94.7% (72/76) (CMR) (p = 0.524), and for those >82 years,
89.4% (59/66) (CT) vs. 91.9% (57/62) (CMR) (p = 0.622). Among female
patients, success rates were 84.7% (50/59) (CT) vs. 93.2% (69/74) (CMR) (p
= 0.113), and among male patients, 95.7% (67/70) (CT) vs. 93.8% (60/64)
(CMR) (p = 0.610). All-cause mortality at 6 months did not differ
significantly between imaging strategies across age and sex subgroups.
Mortality rates for patients <=82 and >82 years were 4.8% (3/63) vs. 5.3%
(4/76) (p = 0.839) and 9.1% (6/66) vs. 12.9% (8/62) (p = 0.490) for CT and
CMR, respectively. Similarly, female and male patients had comparable
mortality rates (10.2% (6/59) vs. 8.1% (6/74), p = 0.680; 4.3% (3/70) vs.
9.4% (6/64), p = 0.240). <br/>Conclusion(s): In this secondary analysis of
the TAVR-CMR trial, CMR-guided TAVR was associated with similar outcomes
compared with CT-guided TAVR irrespective of age and sex.<br/>Copyright
&#xa9; 2025 The Author(s)

<77>
Accession Number
647220683
Title
Percutaneous Coronary Intervention or Minimally Invasive Coronary Bypass
for Isolated Left Anterior Descending Artery Disease.
Source
The American journal of cardiology. (no pagination), 2025. Date of
Publication: 22 Apr 2025.
Author
Gallingani A.; Pampuri G.; Diab N.; Grassa G.; Hernandez-Vaquero D.;
Tuttolomondo D.; Carino D.; Singh G.; Nicolini F.; Formica F.
Institution
(Gallingani) Cardiac Surgery Unit, University Hospital of Parma, Parma,
Italy
(Pampuri, Diab, Grassa, Carino, Nicolini) Cardiac Surgery Unit, University
Hospital of Parma, Parma, 43123, Italy; Cardiac Surgery Unit, Department
of Medicine and Surgery, University of Parma, University Hospital of
Parma, 43123, Italy
(Hernandez-Vaquero) Cardiac Surgery Department, Hospital Universitario
Central de Asturias, Oviedo, Spain
(Tuttolomondo) Cardiology Unit, University Hospital of Parma, Italy
(Singh) Department of Critical Care Medicine and Division of Cardiac
Surgery, Mazankowski Alberta Heart Institute, University of Alberta,
Edmonton, Canada
(Formica) Department of Experimental Medicine, University of Salento,
Lecce, Italy
Abstract
The optimal revascularization strategy for isolated left anterior
descending (LAD) artery disease, minimally invasive direct coronary artery
bypass (MIDCAB) and percutaneous coronary intervention (PCI), remains a
subject of debate. This updated meta-analysis aimed to compare the long-
term outcomes of MIDCAB versus PCI for patients with isolated LAD artery
disease. Three databases were systematically searched to identify
randomized controlled trials (RCTs) and adjusted studies. Primary outcomes
included long-term survival and repeat target vessel revascularization
(TVR). The secondary endpoint was long-term major adverse cardiovascular
events (MACEs). Hazards ratios (HR) and Confidence Intervals (CI) were
calculated for long-term outcomes and a random effects model was used.
Sensitivity analyses included subgroups analysis of stent-type. Nine
articles, comprising four RCTs, totaling 2,168 patients (MIDCAB=1,086 and
PCI=1,080) were included. The weighted mean follow-up was 4.35+/-4.9
years. Long-term survival was comparable between MIDCAB and PCI (HR=0.76;
95% CI, 0.58-1.00; p=0.05). MIDCAB was associated with a significantly
lower rate of repeat TVR (HR=0.35; 95% CI, 0.25-0.49; p<0.0001) and a
reduced risk of MACEs (HR=0.59; 95% CI, 0.43-0.81; p<0.0001), although the
difference was not evident in subgroup analysis comparing MIDCAB and PCI
with drug-eluting stent (HR=0.66; 95% CI, 0.46-1.06; p=0.09). In
conclusion, this meta-analysis of RCTs and adjusted studies shows that in
patients with isolated LAD lesion, MIDCAB and PCI exhibit comparable
long-term survival. However, MIDCAB is associated with a significantly
reduced risk of long-term repeat TVR and MACEs compared to
PCI.<br/>Copyright &#xa9; 2025. Published by Elsevier Inc.

<78>
Accession Number
2038589842
Title
Postoperative physiotherapy interventions in hospitalized adults
undergoing pulmonary resection surgery. A protocol for a scoping review.
Source
MethodsX. 14 (no pagination), 2025. Article Number: 103349. Date of
Publication: 01 Jun 2025.
Author
Gutierrez-Arias R.; Fernandez-Fuentes J.; Rios-Ossandon J.; Vasquez-Gatica
F.; Yanez-Cartes M.; Guajardo-Latorre N.; Moreno-Huircaleo A.;
Salinas-Barahona F.; Seron P.
Institution
(Gutierrez-Arias, Guajardo-Latorre, Moreno-Huircaleo, Salinas-Barahona)
Departamento de Apoyo en Rehabilitacion Cardiopulmonar Integral, Instituto
Nacional del Torax, Santiago, Chile
(Gutierrez-Arias, Guajardo-Latorre, Moreno-Huircaleo, Salinas-Barahona)
INTRehab Research Group, Instituto Nacional del Torax, Santiago, Chile
(Gutierrez-Arias, Fernandez-Fuentes, Rios-Ossandon, Vasquez-Gatica,
Yanez-Cartes) Exercise and Rehabilitation Sciences Institute, Faculty of
Rehabilitation Sciences, Universidad Andres Bello, Santiago, Chile
(Salinas-Barahona) Escuela de Kinesiologia, Facultad de Ciencia de la
Salud, Universidad Autonoma de Chile, Santiago, Chile
(Seron) Departamento de Ciencias de la Rehabilitacion, Facultad de
Medicina, Universidad de La Frontera, Temuco, Chile
(Seron) Centro de Excelencia CIGES, Facultad de Medicina, Universidad de
La Frontera, Temuco, Chile
Publisher
Elsevier B.V.
Abstract
Patients undergoing lung resection surgery (LRS) may experience various
postoperative complications, which can be prevented or managed through
physiotherapy interventions. The current evidence concerning physiotherapy
interventions for individuals undergoing LRS is inconsistent and
disorganised. Our objective is to outline the methods we will employ to
collect, describe, and analyse studies that have assessed the effects of
physiotherapy interventions in the immediate postoperative period for
hospitalized adults undergoing LRS. We will conduct our scoping review
following the Joanna Briggs Institute. We will include primary studies
that have enrolled hospitalized adults undergoing LRS where the effects,
efficacy, effectiveness or cost-effectiveness of postoperative
physiotherapy interventions has been evaluated. A systematic search of
MEDLINE (Ovid), Embase (Ovid), CENTRAL (Cochrane Library), CINAHL
(EBSCOhost), LILACS (BVS), and PEDro will be carried out. Additionally, we
will perform forward and backward citation searches. Data selection and
extraction will be done in duplicate. Conflicts will be resolved by
consensus or through a third reviewer. We will utilise the Word Frequency
Analyser, The Polyglot Search Translator, Citationchaser, and Catchii
tools to enhance the efficiency of our review. Outlining our strategies to
conduct our review will help uphold scientific rigour and enable readers
to identify any deviations from our plan. * We will conduct our scoping
review following the Joanna Briggs Institute. We will include primary
studies that have enrolled hospitalized adults undergoing LRS and
evaluated postoperative physiotherapy interventions' effects, efficacy,
effectiveness or cost-effectiveness. * To enhance the efficiency of our
review, we will use artificial intelligence tools such as Word Frequency
Analyser, The Polyglot Search Translator, Citationchaser, and Catchii. *
Understanding applications of postoperative physiotherapy interventions in
hospitalized adults undergoing LRS can aid in implementing treatment
strategies. It will also highlight existing research gaps that require
attention from primary studies.<br/>Copyright &#xa9; 2025 The Author(s)

<79>
Accession Number
647214710
Title
Advancements in Aortic Stenosis Imaging: The Emerging Role of PET/CT and
PET/MRI.
Source
Journal of Nuclear Medicine. Conference: Society of Nuclear Medicine and
Molecular Imaging Annual Meeting, SNMMI 2024. Toronto, ON Canada.
65(Supplement 2) (no pagination), 2024. Date of Publication: 01 Jun 2024.
Author
Khanal K.; Singh A.; Ashfaq F.; Singh S.
Institution
(Khanal) Memorial HealthCare System, United States
(Singh) Vibrant MBBS Entrance Preparation Pvt Ltd, United States
(Ashfaq, Singh) Stanford University, United States
Publisher
Society of Nuclear Medicine Inc.
Abstract
Introduction: Aortic stenosis (AS), prevalent in developed countries,
shares pathophysiological similarities with atherosclerosis, involving
endothelial damage, lipid infiltration, and progressive calcification
leading to valvular fibrosis, stiffening, and stenosis. This progression
can result in left ventricular hypertrophy, heart failure, and potentially
fatal outcomes without valve replacement. While echocardiography remains
the diagnostic standard, CT calcium scoring and cardiac MRI offer
additional insights into stenosis severity and myocardial condition. Given
the limitations of conventional imaging in early detection and the
potential mismatch between disease severity and echocardiographic
findings, there's increasing interest in exploring molecular imaging,
particularly PET/CT and PET/MRI, in AS evaluation. Our focus is to assess
the effectiveness of these modalities in AS. <br/>Method(s): Utilizing
keywords "PET/CT, PET/MRI, Aortic Stenosis, 18F-FDG, and 18F-NaF,"we
conducted a focused search on Google Scholar and PubMed for literature on
AS evaluation via PET/CT and PET/MRI. Our analysis centered on highly
cited articles from the past five years, synthesizing their results and
conclusions for a comprehensive understanding. <br/>Result(s): PET/CT and
PET/MRI are becoming crucial in the comprehensive assessment of Aortic
Stenosis (AS), blending anatomical and molecular data. While CT and MRI
components provide detailed images of the aortic valve and myocardium, PET
adds a unique dimension by using tracers like 18F-fluorodeoxyglucose
(18F-FDG) and 18Fsodium fluoride (18F-NaF) to highlight areas of active
inflammation and calcification. 18F-FDG is particularly adept at
identifying inflammation, as it accumulates in glucose-dependent
macrophages present in inflamed tissues.18FFDG baseline SUV<inf>max</inf>
was significantly higher in patients who subsequently developed (2.28 +/-
0.42 vs. 1.73 +/- 0.36) or had increased (2.03 +/- 0.52 vs.1.74 +/- 0.36)
AV calcification as compared to patients who did not have a change in
calcification. However, its utility in AS is somewhat hindered by its
physiological uptake in the myocardium and a lack of specificity.
Additionally, 18F-FDG uptake does not consistently align with AS severity,
limiting its diagnostic value. Contrastingly, 18F-NaF shines in detecting
valve calcification, closely correlating with AS severity and progression.
In patients with aortic sclerosis and stenosis, 18F-NaF uptake, as
measured by TBRmax, is significantly higher compared to the control group.
This is substantiated by its alignment with echocardiographic findings and
CT calcium scores. 18F-NaF's ability to detect early microcalcifications
makes it a powerful tool for early diagnosis and prognostication of
potential adverse outcomes in AS. PET/MRI, in particular, offers superior
tissue characterization, effective motion correction, and reduced
radiation exposure compared to PET/CT. Despite these advantages, the
application of PET/MRI in AS remains limited. Factors like high cost,
limited availability, and technical challenges constrain its widespread
adoption in the clinical assessment of AS, suggesting a need for further
development and accessibility improvements in this technology.
<br/>Conclusion(s): 18F-FDG and 18F-NaF PET/CT are emerging as
complementary imaging modalities in Aortic Stenosis (AS), offering
insights into valve inflammation and calcification and aiding in
diagnosis, progression assessment, and adverse event prediction. PET/MRI
further enhances this evaluation with detailed valve and myocardial
analysis, coupled with lower radiation exposure. However, defining the
specific clinical roles and integration of PET/CT and PET/MRI in AS
requires further research to optimize their use in clinical practice.

<80>
Accession Number
647214742
Title
Advancing the Detection of Cardiac Allograft Vasculopathy: The Role of
PET/CT Imaging in Post-Heart Transplant Patients.
Source
Journal of Nuclear Medicine. Conference: Society of Nuclear Medicine and
Molecular Imaging Annual Meeting, SNMMI 2024. Toronto, ON Canada.
65(Supplement 2) (no pagination), 2024. Date of Publication: 01 Jun 2024.
Author
Khanal K.; Singh A.; Ashfaq F.; Singh S.
Institution
(Khanal) Memorial HealthCare System, United States
(Singh) Vibrant MBBS Entrance Preparation Pvt Ltd, United States
(Ashfaq, Singh) Stanford University, United States
Publisher
Society of Nuclear Medicine Inc.
Abstract
Introduction: Cardiac allograft vasculopathy (CAV) is a predominant cause
of late graft failure in heart transplant recipients, affecting half of
these patients. This condition significantly increases morbidity and
mortality. Currently, CAV screening post-transplantation primarily depends
on invasive methods like coronary angiography and intravascular ultrasound
(IVUS), which carry risks of adverse complications. Non-invasive
diagnostic approaches for CAV pose challenges due to their widespread
impact on both the coronary macro-and microvasculature and their limited
sensitivity in the early detection of coronary intimal hyperplasia. We aim
to explore the potential of advanced molecular imaging in the early and
accurate detection of CAV. <br/>Method(s): To investigate the efficacy of
positron emission tomography/computed tomography (PET/CT) in cardiac
allograft vasculopathy (CAV), we conducted a comprehensive review of
highly cited articles from the past five years indexed in PubMed and
Google Scholar. The data extracted from these relevant sources were
meticulously synthesized to formulate this abstractResults: In the domain
of cardiac allograft vasculopathy (CAV) detection, Positron Emission
Tomography (PET) imaging has emerged as a promising non-invasive modality,
particularly in the precise quantification of myocardial blood flow (MBF)
and myocardial flow reserve (MFR). These parameters are pivotal for
discerning regional perfusion anomalies indicative of CAV. Specifically,
Rubidium-82 (Rb82) PET/CT has shown significant promise in posttransplant
CAV surveillance. Comparative analyses with traditional techniques such as
coronary angiography and intravascular ultrasound (IVUS) have demonstrated
Rb82 PET/CT's elevated sensitivity (88% and 83%) and specificity (88% and
90%). This efficacy is attributed to the utilization of pre-defined
advanced PET metrics, including combined rate-pressure-product-corrected
myocardial flow reserve (cMFR < 2.9), stress MBF (< 2.3), and coronary
vascular resistance (CVR > 55). Further, retrospective investigations have
established a PET-derived MFR threshold of 2.0, correlating it with
critical clinical outcomes such as mortality, re-transplantation, or
cardiovascularrelated hospitalizations. This threshold serves as a crucial
indicator for proactive intervention strategies. In addition, studies
utilizing N-13 ammonia PET/CT have elucidated an inverse relationship
between IVUS-assessed intimal thickness and PET MFR. This is complemented
by a modest yet significant correlation between MFR and plaque volume
within the left coronary system. Most notably, MFR, as assessed by PET
imaging, has been identified as an independent prognostic factor for
adverse cardiovascular outcomes. These include cardiovascular death,
incidents of acute coronary syndrome, the necessity for coronary
revascularization, and hospitalization due to heart failure. This
predictive capability holds even after adjusting for key variables such as
summed stress score, left ventricular ejection fraction, and the duration
post-transplant. Such insights affirm the indispensability of PET imaging,
particularly Rb82 PET/CT, in the nuanced assessment and management of
cardiac allograft vasculopathy in the post-transplant clinical setting.
<br/>Conclusion(s): PET/CT demonstrates potential in detecting cardiac
allograft vasculopathy (CAV) and forecasting adverse clinical outcomes in
post-cardiac transplant patients. Yet, to fully establish its clinical
utility alongside existing tools such as IVUS and optical coherence
tomography, rigorously designed randomized controlled trials are essential
for validating its effectiveness in the prompt diagnosis of CAV.

<81>
Accession Number
2038526166
Title
Clarifications on a prospective randomized controlled trial evaluating
adhesion prevention using oxidized regenerated cellulose sheets in
thoracic surgery.
Source
Journal of Thoracic Disease. 17(4) (pp 2747-2748), 2025. Date of
Publication: 30 Apr 2025.
Author
Ochi T.; Suzuki H.; Sata Y.; Toyoda T.; Inage T.; Tanaka K.; Sakairi Y.;
Matsui Y.; Shiko Y.; Yoshino I.
Institution
(Ochi, Suzuki, Sata, Toyoda, Inage, Tanaka, Sakairi, Matsui, Yoshino)
Department of General Thoracic Surgery, Chiba University Graduate School
of Medicine, Chiba, Japan
(Shiko) Clinical Research Center, Chiba University Hospital, Chiba, Japan
(Yoshino) Department of Thoracic Surgery, International University Health,
Welfare School of Medicine, Narita, Japan
Publisher
AME Publishing Company

<82>
Accession Number
2034454307
Title
Cardiac benign metastatic leiomyoma- a comprehensive review.
Source
Cardio-Oncology. 11(1) (no pagination), 2025. Article Number: 41. Date of
Publication: 01 Dec 2025.
Author
Garg P.; Ali M.; Alomari M.; Schoolmeester J.K.; Edgar M.; Landolfo C.K.;
Attia S.; Landolfo K.P.
Institution
(Garg, Ali, Alomari, Landolfo) Department of Cardiothoracic Surgery, Mayo
Clinic, Jacksonville, FL, United States
(Schoolmeester, Edgar) Laboratory Medicine and Pathology Department, Mayo
Clinic, Jacksonville, FL, United States
(Landolfo) Cardiovascular Diseases Department, Mayo Clinic, Jacksonville,
FL, United States
(Attia) Hematology and Oncology Department, Mayo Clinic, Jacksonville, FL,
United States
Publisher
BioMed Central Ltd
Abstract
Cardiac benign metastatic leiomyoma (BML) is a rare cardiac tumor that is
usually asymptomatic, frequently misdiagnosed and may result in serious
complications, including embolization, heart failure and death. This
review highlights the importance of considering cardiac BML in the
differential diagnosis of cardiac masses, especially in women with a
history of uterine leiomyomas. This review summarizes the current
knowledge about cardiac BML, including its demographics, clinical
presentation, etio-pathogenesis, diagnosis, and management. The authors
discuss the challenges associated with diagnosing cardiac BML and
emphasize the importance of a thorough history, physical examination, and
imaging studies. They also review the different treatment options for
cardiac BML, including surgical resection and role of medical and surgical
castration. Early diagnosis and management of cardiac BML is crucial to
prevent complications. This review provides valuable insights for
clinicians who may encounter this rare condition. By raising awareness of
cardiac BML and its management strategies, this review can improve patient
care and outcomes.<br/>Copyright &#xa9; The Author(s) 2025.

<83>
Accession Number
2038540234
Title
The role of impaired iron transport on exercise performance and prognosis
in patients with chronic heart failure.
Source
IJC Heart and Vasculature. 59 (no pagination), 2025. Article Number:
101685. Date of Publication: 01 Aug 2025.
Author
Campodonico J.; Bonomi A.; Alimento M.; Apostolo A.; Piotti A.; Mattavelli
I.; Salvioni E.; Mapelli M.; Vignati C.; Gugliandolo P.; Pezzuto B.;
Grilli G.; Rusconi V.; Poggio P.; Agostoni P.
Institution
(Campodonico, Bonomi, Alimento, Apostolo, Piotti, Mattavelli, Salvioni,
Mapelli, Vignati, Gugliandolo, Pezzuto, Grilli, Rusconi, Poggio, Agostoni)
Centro Cardiologico Monzino, IRCCS, Milan, Italy
(Campodonico, Mapelli, Vignati, Agostoni) Department of clinical sciences
and community health, University of Milan, Cardiovascular section, Milan,
Italy
(Poggio) University of Milan, Department of Biomedical, Surgical and
Dental Sciences, Milan, Italy
Publisher
Elsevier Ireland Ltd
Abstract
Background: Iron deficiency (ID) is frequent in chronic heart failure
(HF). Among HF-ID patients those with impaired iron transport (IIT)
(Transferrin saturation (TSAT) < 20 %) have the worst prognosis. In HF
survival is strictly related to exercise limitation but the link between
IIT, exercise limitation and survival is at present undefined.
<br/>Method(s): We evaluated in 999 consecutive patients hospitalized for
worsening HF whether IIT affects prognosis through cardiopulmonary
exercise test (CPET), i.e. peak oxygen uptake (VO<inf>2</inf>) and
ventilation vs. carbon dioxide (VE/VCO<inf>2</inf>) slope. In all patients
at stabilization iron metabolism and maximal CPET were performed. Survival
was assessed as all cause death, urgent LVAD and heart transplant were
considered death equivalents. The causal relationship between survival and
IIT, peakVO<inf>2</inf> and VE/VCO<inf>2</inf>slope was assessed applying
path analysis. <br/>Result(s): PeakVO<inf>2</inf> VE/VCO<inf>2</inf>slope
and TSAT were 68 +/- 44 %pred, 35 +/- 9 and 24.4 +/- 12.9, respectively.
PeakVO<inf>2</inf> and VE/VCO<inf>2</inf>slope were 61 +/- 18 vs. 72 +/-
53 %pred and 38 +/- 10 vs. 33 +/- 8, in IIT vs. non IIT patients (p <
0.0001 in both). At univariable and multivariable analysis a correlation
between survival and VO<inf>2</inf>, VE/VCO<inf>2</inf>slope and TSAT was
observed; at Kaplan-Myer lower peakVO<inf>2</inf>, higher
VE/VCO<inf>2</inf>slope and lower TSAT showed worst survival; at path
analysis IIT showed both an important effect on survival independent from
peakVO<inf>2</inf> and VE/VCO<inf>2</inf>slope (48 %) and an effect on
survival independently mediated by VE/VCO<inf>2</inf>slope and
peakVO<inf>2</inf> (52 %), contributing to the IIT negative effect on
survival. <br/>Conclusion(s): The adverse impacts of low TSAT on prognosis
are in part direct and in part mediated by mechanisms related to reduced
peakVO<inf>2</inf> and increased @VE/VCO<inf>2</inf>slope<br/>Copyright
&#xa9; 2025 The Authors

<84>
Accession Number
647203840
Title
Five-Year Mortality of Surgical and Transcatheter Aortic Valve Replacement
in the Real-World Scenario: A Systematic Review and Meta-Analysis of
Propensity Score Matching Studies.
Source
Brazilian journal of cardiovascular surgery. 40(4) (pp e20240048), 2025.
Date of Publication: 23 Apr 2025.
Author
Marin-Cuartas M.; Dalbesio B.; Pollari F.; Scarpanti M.; Anselmi A.;
Cuesta M.; Uva M.S.; Verhoye J.-P.; Musumeci F.; Barili F.; Parolari A.
Institution
(Marin-Cuartas, Cuesta) University Department of Cardiac Surgery, Leipzig
Heart Center, Leipzig, Germany
(Dalbesio) Department of Cardiac Surgery, S. Croce Hospital, Cuneo, Italy
(Pollari) Cardiac Surgery, Klinikum Nurnberg-Paracelsus Medical
University, Nuremberg, Germany
(Scarpanti, Parolari) University Cardiac Surgery Unit, IRCCS Policlinico
San Donato, San Donato, Italy
(Anselmi, Verhoye) Department of Thoracic and Cardiovascular Surgery,
University Hospital of Rennes, Rennes, France
(Uva) Department of Cardiac Surgery, Hospital Santa Cruz, Carnaxide,
Portugal
(Uva) Department of Cardiac Surgery and Physiology, Porto University
Medical School, Porto, Portugal
(Musumeci) Department of Cardiac Surgery, ISMETT, Palermo, Italy
(Barili) University Cardiac Surgery Unit, IRCCS Ospedale Galeazzi
Sant'Ambrogio, Milan, Italy
(Barili) Department of Epidemiology, Harvard T.H. Chan School of Public
Health, Boston, MA, United States
(Parolari) Department of Biomedical and Clinical Sciences, University of
Milan, Milan, Italy
(Parolari) on behalf of the INTernational Evidence Grading Initiative
Targeting Transparency and qualitY - INTEGRITTY
Abstract
INTRODUCTION: Randomized controlled trials (RCTs) provide evidence of
efficacy, while real-world data (RWD) demonstrate effectiveness in
real-world practice. We designed a systematic review and meta-analysis of
reconstructed time-to-event (RTE) data from propensity score matching
studies comparing transcatheter aortic valve implantation (TAVI) and
surgical aortic valve replacement (SAVR) to compare their effectiveness
and evaluate the generalizability of TAVI indications. <br/>METHOD(S):
Systematic review of literature between 2007 and 2023 including propensity
score matching studies comparing TAVI or SAVR that reported at least
one-year Kaplan-Meier curves of endpoints. <br/>RESULT(S): Twenty-one
studies were included (39538 participants). TAVI shows a higher all-cause
mortality (hazard ratio [HR] 1.41; 95% confidence interval [CI] 1.34-1.47,
P-value < 0.001), with a significant heterogeneity. The analysis of HR
trend over time shows that TAVI superiority is limited to the first month
with a steep reversal afterwards, when SAVR becomes clearly superior.
All-cause mortality is significantly higher in TAVI in low-risk (HR 1.35;
95% CI 1.08-1.69, P-value < 0.001) as well as in intermediate (HR 1.73;
95% CI 1.35-2.22, P-value < 0.001) and high-risk (HR 1.61; 95% CI
1.38-1.88, P-value < 0.001) patients. The HR trend in the subgroups of
risk confirms the data from the whole mixed population.
<br/>CONCLUSION(S): In a real-word setting, TAVI is associated with higher
incidence of all-cause death and maintains a survival benefit only in the
first month after implantation. These results show that TAVI effectiveness
may not reflect the efficacy demonstrated by RCTs and pose a threat to
their external validity.

<85>
Accession Number
647204107
Title
Twice-a-day administration of aspirin in patients with diabetes mellitus
or aspirin resistance after acute coronary syndrome: Rationale and design
of the randomized ANDAMAN trial.
Source
American heart journal. (no pagination), 2025. Date of Publication: 21
Apr 2025.
Author
Dillinger J.-G.; Pezel T.; Batias L.; Angoulvant D.; Goralski M.; Ferrari
E.; Cayla G.; Silvain J.; Gilard M.; Lemesle G.; Souteyrand G.; Lim P.;
Roubille F.; Georges J.-L.; Bal Dit Sollier C.; Petroni T.; Morel O.;
Delarche N.; Elbaz M.; Puymirat E.; Toupin S.; Montalescot G.; Drouet L.;
Vicaut E.; Henry P.
Institution
(Dillinger) Universite Paris Cite, Department of Cardiology, Hopital
Lariboisiere, Assistance Publique-Hopitaux de Paris, Inserm MASCOT - UMRS
942, Paris, France.; MIRACL.ai laboratory, Multimodality Imaging for
Research and Artificial Intelligence Core Laboratory, University Hospital
of Lariboisiere (AP-HP), 75010, Paris, France.; CREATIF, Centre de
Reference et d'Education des antithrombotiques d'Ile de France, Hopital
Lariboisiere, Assistance Publique-Hopitaux de Paris, Paris, France.
(Pezel, Toupin) Universite Paris Cite, Department of Cardiology, Hopital
Lariboisiere, Assistance Publique-Hopitaux de Paris, Inserm MASCOT - UMRS
942, Paris, France.; MIRACL.ai laboratory, Multimodality Imaging for
Research and Artificial Intelligence Core Laboratory, University Hospital
of Lariboisiere (AP-HP), 75010, Paris, France
(Batias) Centre Hospitalier Metropole Savoie, Service de Cardiologie,
Place Lucien Biset, 73000 Chambery, France
(Angoulvant) Cardiology Department, CHU Tours, Universite de Tours, Tours,
France
(Goralski) Cardiology Department, Orleans, France
(Ferrari) Cardiology Department, Pasteur University Hospital, 30 avenue de
la Voie Romaine ,CS 51069, France
(Cayla) Cardiology department, Nimes university Hospital, Montpellier
University, ACTION group, Nimes, France
(Silvain, Montalescot) Sorbonne Universite, ACTION Group, INSERM UMRS1166,
Hopital Pitie-Salpetriere (AP-HP), Paris, France
(Gilard) Chest Diseases, Brest, France
(Lemesle) Heart and Lung Institute, University hospital of Lille, CHU
Lille, F-59000 Lille, France. Univ. Lille, F-59000, France. Institut
Pasteur of Lille, Inserm U1011-EGID, F-59000 Lille, France. FACT (French
Alliance for Cardiovascular Trials), F-75000 Paris, France
(Souteyrand) Institut Pascal, CNRS SIGMA UCA UMR 6602 University Hospital
Gabriel Montpied, Clermont-Ferrand, France
(Lim) Service de Cardiologie, Univ Paris Est Creteil, INSERM, IMRB, AP-HP,
Hopital Universitaire Henri-Mondor, Creteil, France
(Roubille) PhyMedExp, Cardiology Department, Universite de Montpellier,
INSERM, CNRS, CHU de Montpellier, France
(Georges) Service de cardiologie, cardiologie interventionnelle, Centre
Hospitalier de Versailles, Hopital Andre Mignot, France
(Bal Dit Sollier, Drouet) Centre de Reference et d'Education des
antithrombotiques d'Ile de France, Hopital Lariboisiere, Assistance
Publique-Hopitaux de Paris, Paris, France
(Petroni) Cardiology Department, Clinique Pont de Chaume, Montauban,
France
(Morel) Division of Cardiovascular Medicine, Nouvel Hopital Civil,
Strasbourg University Hospital, UR 3074 Translational CardioVascular
Medicine CRBS, Strasbourg, France
(Delarche) Cardiology Department, Hopital Francois Mitterrand, Pau, France
(Elbaz) Center for Clinical Investigation (CIC1436)/CARDIOMET, Rangueil
University Hospital, Toulouse, France
(Puymirat) Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Europeen
Georges Pompidou, Department of Cardiology, 75015 Paris, France;
Universite de Paris Cite, 75006 Paris, France
(Vicaut) Unite de Recherche Clinique, ACTION Group, Paris, France
(Henry) Department of Cardiology, Hopital Lariboisiere, Assistance
Publique-Hopitaux de Paris, Paris, France
Abstract
BACKGROUND: Patients with diabetes mellitus (DM) or aspirin resistance are
exposed to recurrent atherothrombotic events after acute coronary syndrome
(ACS). Aspirin once-daily can allow the recovery of platelet
cyclooxygenase activity before the next intake in these patients.
Twice-daily administration provides more stable inhibition of platelet
aggregation and may improve prognosis in these patients. AIM: To
demonstrate the superiority of twice-daily aspirin compared to once daily
in reducing major adverse cardiovascular events (MACE) in patients with DM
or aspirin resistance after ACS. <br/>METHOD(S): The ANDAMAN trial is a
randomized, multicenter study including patients (aged >=18 years) with DM
or with aspirin resistance defined as: i) index event occurring under
aspirin; ii) body mass index >= 27 kg/m2); iii) increased waist
circumference (>= 88 cm for women or >= 102 cm for men). The patients will
be recruited in 39 centers after an ACS (with or without ST elevation)
with at least one significant coronary stenosis and will be randomized
before hospital discharge between twice-daily versus once daily low-dose
aspirin (100 mg bid versus od). The primary composite endpoint will be the
occurrence of MACE including all-cause death, myocardial infarction,
stroke, urgent coronary revascularization or acute arterial thrombotic
event during a follow-up of 18 months. To achieve a 20% reduction in the
relative risk of MACE in the twice-daily aspirin group, a total of 2,574
patients will be included in the trial. The main secondary endpoint will
be major bleeding (type 3-5 following BARC classification).
<br/>CONCLUSION(S): The trial will evaluate the prognostic impact of
twice-daily aspirin for ACS patients with DM or aspirin resistance and may
change the way aspirin is administered to these patients. TRIAL
REGISTRATION: ClinicalTrials.gov Identifier: NCT02520921.<br/>Copyright
&#xa9; 2025. Published by Elsevier Inc.

<86>
Accession Number
2038523869
Title
Randomized study assessing the effectiveness and safety of a novel scoring
balloon for percutaneous coronary intervention: the Wedge NC trial.
Source
Journal of Thoracic Disease. 17(4) (pp 2101-2112), 2025. Date of
Publication: 30 Apr 2025.
Author
Chen H.; Xu J.; Chen D.; Gao F.; Liu Y.; Cui H.; Wang J.; Guo S.; Du Z.;
Huang J.; Zhang X.; Jiang W.; Cheng Z.; Jiang J.
Institution
(Chen, Xu, Chen, Gao, Liu, Jiang) Department of Cardiology, The Second
Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou,
China
(Cui) Department of Cardiology, The First Affiliated Hospital of Ningbo
University, Ningbo, China
(Wang) Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun
Yat-sen University, Guangzhou, China
(Guo) Department of Cardiology, Dongguan People's Hospital, The Tenth
Affiliated Hospital of Southern Medical University, Dongguan, China
(Du) Department of Cardiology, Dongguan Songshan Lake Tungwah Hospital,
Dongguan, China
(Huang) Department of Cardiology, Affiliated Hangzhou First People's
Hospital, Westlake University School of Medicine, Hangzhou, China
(Zhang) Department of Cardiology, The Affiliated Hospital of Hangzhou
Normal University, Hangzhou, China
(Jiang) Department of Cardiology, Wenzhou Hospital of Integrated
Traditional Chinese, Western Medicine Affiliated to Zhejiang Chinese
Medicine University, Wenzhou, China
(Jiang) Department of Cardiology, Wenzhou Central Hospital, The Second
Affiliated Hospital of Shanghai University, Wenzhou, China
(Cheng) Department of Cardiology, Huzhou Central Hospital, Affiliated
Huzhou Hospital, Zhejiang University School of Medicine, Huzhou, China
Publisher
AME Publishing Company
Abstract
Background: Scoring balloon angioplasty catheters are designed to induce
high focal stress at low inflation pressure for better lesion
modification. We aimed to assess the effectiveness and safety of a newly
developed Wedge NC scoring balloon catheter compared to the ScoreFlex
coronary dilatation catheter for treating coronary artery lesions.
<br/>Method(s): The Wedge NC trial was a prospective, multicenter,
open-label, randomized controlled noninferiority trial conducted during
August 2021 and February 2022. There were 198 patients with indication for
percutaneous coronary intervention (PCI) enrolled at nine centers in
China. Patients undergoing angioplasty were randomly assigned to treatment
with the Wedge NC scoring balloon or the ScoreFlex scoring balloon. The
primary endpoint was procedure success, defined as the residual stenosis
of the target lesion <=30% immediately after PCI procedure, without
complications (limited to death, Q-wave or non-Q-wave myocardial
infarction, or emergent coronary artery bypass grafting during
postoperative hospitalization). The secondary endpoints included rate of
clinical success, device procedural success, balloon slippage, and
angiographic traits measured by quantitative coronary analysis.
<br/>Result(s): Baseline parameters showed no differences between the two
groups. Procedure success was achieved in 98 of 99 patients in both
groups. The mean difference between the Wedge group and the ScoreFlex
group was 0 (95% confidence interval: -2.79% to 2.79%, 1-sided P<0.001
with both Wald method and minimum risk weights method). Noninferiority at
a predefined margin of 7% was established. Immediately after the balloon
inflation, minimal lumen diameter in the Wedge group was significantly
larger than that of the ScoreFlex group (1.71+/-0.39 vs. 1.56+/-0.36 mm,
P=0.02), resulting in a lower percent diameter stenosis and a higher acute
lumen gain (36.04+/-11.43 vs. 41.14+/-10.63, P=0.004; 0.82+/-0.39 vs.
0.69+/-0.37 mm, P=0.02, respectively). There was comparable and low rate
of procedural complications for both treatment groups. <br/>Conclusion(s):
In patients undergoing PCI, the Wedge NC scoring balloon dilatation
catheter was noninferior to the ScoreFlex coronary dilatation catheter
regarding procedure success and had comparably low procedural complication
rate. (Sponsored by BrosMed Medical.)<br/>Copyright &#xa9; AME Publishing
Company.

<87>
Accession Number
2038569416
Title
Transcatheter aortic valve replacement in low-risk patients: an updated
meta-analysis of randomized controlled trials.
Source
IJC Heart and Vasculature. 59 (no pagination), 2025. Article Number:
101692. Date of Publication: 01 Aug 2025.
Author
Meeus R.; Dhondt P.; Hariyanto J.; Ashraf H.; Lecchi C.; Fischer-Bacca
C.O.; Langenhoven L.V.; Minten L.; Dubois C.
Institution
(Meeus, Dhondt, Minten, Dubois) Department of Cardiovascular Medicine,
University Hospitals Leuven, Leuven, Belgium
(Hariyanto) Gedung Fakultas Kedokteran UPH, Tangerang, Indonesia
(Ashraf) Rawalpindi Medical University, Rawalpindi, Pakistan
(Lecchi) University of Trieste, Trieste, Italy
(Fischer-Bacca) UNIDAVI, Rio do Sul, Brazil
(Langenhoven) Leuven Biostatistics and Statistical Bioinformatics Centre,
KU Leuven, Leuven, Belgium
(Dubois) Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium
Publisher
Elsevier Ireland Ltd
Abstract
Background: Transcatheter aortic valve replacement (TAVR) is increasingly
used in patients with aortic valve stenosis (AS) at low risk for surgical
aortic valve replacement (SAVR), despite uncertainty regarding medium and
long-term clinical outcomes. <br/>Objective(s): We performed an updated
meta-analysis comparing TAVR with SAVR in this population. <br/>Method(s):
We searched PubMed, EMBASE and Cochrane Central for randomized controlled
trials (RCT) comparing TAVR with SAVR in low-risk patients with either
bicuspid or tricuspid AS. Outcomes of interest were all-cause mortality,
rehospitalization and stroke at 30 days, 1 year and up to 5 years
follow-up. <br/>Result(s): We included six RCTs with in total 4487
patients, mean age 74.2 +/- 5.5y and of which 50.1 % underwent TAVR. The
STS-PROM Score was similar for TAVR and SAVR (2.1 +/- 0.7 vs. 2.2 +/- 0.8
%). Thirty-day all-cause mortality showed a borderline significant
difference favoring TAVR (RR 0.55; 95 % CI 0.30-1.01; p = 0.05). One-year
all-cause mortality was significantly lower for TAVR (RR 0.60; 95 % CI
0.41-0.98; p = 0.01), while no differences were seen at 5-year follow up
(RR 1.02; 95 % CI 0.81-1.29; p = 0.85). TAVR was associated with reduced
30-day (RR 0.67; 95 % CI 0.46-0.95; p = 0.03) and one-year
rehospitalization rates (RR 0.72; 95 % CI 0.53-0.98; p = 0.04). Stroke
rates at 30 days (RR 0.78; 95 % CI 0.48-1.32; p = 0.37), one-year (RR
0.79; 95 % CI 0.48-1.32; p = 0.37) and 5-year follow-up (RR 1.09; 95 % CI
0.81-1.46; p = 0.56) were not significantly different. <br/>Conclusion(s):
TAVR in low-risk patients with AS results in reduced 1-year all-cause
mortality and rehospitalization rates as compared with SAVR. This benefit
is attenuated during protracted follow-up.<br/>Copyright &#xa9; 2025 The
Author(s)

<88>
Accession Number
647204052
Title
Comparison of Outcomes Between Total Arterial Off-Pump Versus On-Pump
Coronary Artery Bypass Surgery: a Meta-Analysis and Meta-Regression.
Source
The American journal of cardiology. (no pagination), 2025. Date of
Publication: 21 Apr 2025.
Author
Comanici M.; Bithi N.; Raja S.G.
Institution
(Comanici, Bithi, Raja) Department of Cardiac Surgery, Harefield Hospital,
London, United Kingdom
Abstract
An essential aspect of achieving early optimal outcomes in coronary artery
bypass grafting (CABG) is the careful selection of conduits. Total
arterial grafting (TAG) has been debated, and recent studies suggest its
benefits, especially when combined with off-pump coronary artery bypass
grafting (OPCAB). We conducted a systematic review and meta-analysis of
studies comparing outcomes of TAG in OPCAB versus on-pump CABG (ONCAB),
using data from OVID MEDLINE, EMBASE, SCOPUS, and PUBMED. Seven studies
with a total of 5417 patients were included. Short-term outcomes showed no
significant differences in perioperative complications between TAG-OPCAB
and TAG-ONCAB, but TAG-OPCAB was associated with reduced short-term
mortality (OR 0.48, 95% CI [0.26, 0.89], P=0.02), lower incidence of
postoperative low cardiac output, atrial fibrillation, and MACCEs, as well
as shorter intubation duration and hospital stay. Meta-regression did not
reveal any associations between pre- or intra-operative variables and
short-term mortality. In conclusion, TAG-OPCAB demonstrates favourable
short-term outcomes and may be considered a safe and effective strategy in
selected patients, while long-term outcomes remain inconclusive due to
limited data.<br/>Copyright &#xa9; 2025. Published by Elsevier Inc.

<89>
Accession Number
2038524694
Title
Expert consensus on cancer treatment-related lung injury.
Source
Journal of Thoracic Disease. 17(4) (pp 1844-1875), 2025. Date of
Publication: 30 Apr 2025.
Author
Lin X.; Guo H.; Zhao W.; Li M.; Lin G.; Chu Q.; Chen E.; Chen L.; Chu T.;
Deng H.; Deng Y.; Dong H.; Dong W.; Dong Y.; Fang W.; Gan X.; Gong L.; Gu
Y.; Han Q.; Hao Y.; He Y.; Hu C.; Hu J.; Hu Y.; Jiang Y.; Jin Y.; Lan F.;
Li W.; Liang W.; Liu A.; Liu D.; Liu M.; Liu Z.; Luo Q.; Miao L.; Mu C.;
Pan P.; Peng P.; Qin J.; Qin Y.; Shen P.; Shi M.; Song Y.; Su C.; Su J.;
Su X.; Tan X.; Tang K.; Tang X.; Tian P.; Wang B.; Wang H.; Wang K.; Wang
M.; Wang Q.; Wang W.; Wang Z.; Wu D.; Xu F.; Xu Y.; Xu C.; Xie Z.; Xie X.;
Yang B.; Yang M.; Ye F.; Ye X.; Yu Z.; Zhang J.; Zhang X.; Zhao F.; Zheng
X.; Zhu B.; Zhu Z.; Zhou J.; Zhou M.; Zhou Q.; Zou Z.; Kidane B.; Bignami
E.; Sakamaki F.; Roviello G.; Taniguchi H.; Jeon K.; Saric L.; Ariza-Prota
M.; La-Beck N.M.; Kanaji N.; Watanabe S.; Shukuya T.; Akaba T.; Leong
T.L.; Gesierich W.; Koga Y.; Tanino Y.; Uehara Y.; Li S.; Chen R.; Zhou C.
Institution
(Lin, Deng, Deng, Gu, Han, Liang, Liu, Luo, Qin, Shen, Xie, Xie, Li, Zhou)
State Key Laboratory of Respiratory Disease, National Clinical Research
Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health,
First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
(Guo, Chen) Department of Medical Oncology, The Second Affiliated Hospital
of Xi'an Jiaotong University, Xi'an, China
(Zhao) Department of Respiratory and Critical Care Medicine, Chinese
People's Liberation Army (PLA) General Hospital, Beijing, China
(Li) Department of Respiratory Medicine, Xiangya Cancer Center, Xiangya
Hospital, Central South University, Changsha, China
(Lin) Department of Medical Oncology, Beijing Chest Hospital, Capital
Medical University, Beijing, China
(Chu) Department of Oncology, Tongji Hospital, Huazhong University of
Science and Technology, Wuhan, China
(Chen) Department of Pulmonary and Critical Care Medicine, Sir Run Run
Shaw Hospital of Zhejiang University, Hangzhou, China
(Chen) Department of Medical Oncology, Sun Yat-sen University Cancer
Center, Guangzhou, China
(Chu) Department of Respiratory Medicine, Shanghai Chest Hospital,
Shanghai Jiao Tong University, Shanghai, China
(Dong) Chronic Airways Diseases Laboratory, Department of Respiratory and
Critical Care Medicine, Nanfang Hospital, Southern Medical University,
Guangzhou, China
(Dong) Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin
Medical University Cancer Institute and Hospital, National Clinical
Research Center for Cancer, Key Laboratory of Cancer Prevention and
Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China
(Dong) Department of Pulmonary and Critical Care Medicine, Shanghai
Changhai Hospital, Second Military Medical University, Shanghai, China
(Fang) Department of Medical Oncology, State Key Laboratory of Oncology in
South China, Collaborative Innovation Center for Cancer Medicine, Sun
Yat-sen University Cancer Center, Guangzhou, China
(Gan) Department of Respiration, The First Affiliated Hospital of Nanchang
University, Nanchang, China
(Gong) Department of Respiratory and Critical Care Medicine, The First
Affiliated Hospital, the Army Medical University, Chongqing, China
(Hao) Department of Clinical Trial, Chinese Academy of Sciences University
Cancer Hospital, Zhejiang Cancer Hospital, Hangzhou, China
(He) Department of Pulmonary and Critical Care Medicine, Daping Hospital,
Army Medical University, Chongqing, China
(Hu) Department of Pulmonary Medicine, Xiangya Hospital, Central South
University, Changsha, China
(Hu) Department of Respiratory Medicine, Zhongshan Hospital, Fudan
University, Shanghai, China
(Hu) Department of Medical Oncology, Chinese People's Liberation Army
(PLA) General Hospital, Beijing, China
(Jiang) Department of Respiratory Medicine, Hunan Provincial People's
Hospital, The First Affiliated Hospital of Hunan Normal University,
Changsha, China
(Jin) Department of Respiratory and Critical Care Medicine, NHC Key
Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, China
(Lan, Wang) Department of Respiratory Medicine, The Second Affiliated
Hospital of Zhejiang University of Medicine, Hangzhou, China
(Li) Department of Respiratory and Critical Care Medicine, Clinical
Research Center for Respiratory Disease, West China Hospital, Sichuan
University, Chengdu, China
(Li) Department of Respiratory Medicine, General Hospital of Guangzhou
Military Command of PLA, Guangzhou, China
(Liu) Department of Oncology, The Second Affiliated Hospital of Nanchang
University, Nanchang, China
(Liu) Department of Respiratory and Critical Care Medicine, West China
Hospital, Sichuan University, Chengdu, China
(Liu) Phase I Clinical Trial Research Ward, The Second Affiliated Hospital
of Xi'an Jiaotong University, Xi'an, China
(Liu) Department of Respiratory and Critical Care Medicine, The First
Affiliated Hospital of Dalian Medical University, Dalian, China
(Liu) Department of Oncology, General Hospital of Chinese PLA, Beijing,
China
(Miao, Su) Department of Respiratory and Critical Care Medicine, Nanjing
Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical
School, Nanjing, China
(Mu) Department of Respiratory Medicine, The First Affiliated Hospital of
Soochow University, Suzhou, China
(Pan) Department of Respiratory Medicine, National Key Clinical Specialty,
Branch of National Clinical Research Center for Respiratory Disease,
Xiangya Hospital, Central South University, Changsha, China
(Peng) Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, China
(Qin) Department of Respiratory and Critical Care Medicine, Tianjin Chest
Hospital, Tianjin, China
(Shi) Department of Respiratory Medicine, The Second Affiliated Hospital
of Suzhou University, Suzhou, China
(Song) Department of Respiratory and Critical Care Medicine, Jinling
Hospital, Nanjing, China
(Su) Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji
University School of Medicine, Shanghai, China
(Su) Department of Respiratory and Critical Care Medicine, Nanfang
Hospital, Southern Medical University, Guangzhou, China
(Tan) Pulmonary and Critical Care Medicine, the Second Affiliated
Hospital, Hengyang Medical School, University of South China, Hengyang,
China
(Tang) Division of Pulmonary and Critical Care Medicine, The First
Affiliated Hospital of Sun Yat-sen University, Institute of Pulmonary
Diseases, Sun Yat-sen University, Guangzhou, China
(Tang) Department of Oncology, Jiangxi Provincial Chest Hospital,
Nanchang, China
(Tian) Lung Cancer Center, Lung Cancer Institute, West China Hospital,
Sichuan University, Chengdu, China
(Wang) Guangdong Lung Cancer Institute, Guangdong General Hospital,
Guangdong Academy of Medical Sciences, Guangzhou, China
(Wang) Department of Medical Oncology, The Affiliated Cancer Hospital of
Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
(Wang, Xu) Department of Respiratory and Critical Care Medicine, Peking
Union Medical College Hospital, Beijing, China
(Wang) Department of Respiratory Medicine, The Second Affiliated Hospital
of Dalian Medical University, Dalian, China
(Wang) Department of Chemotherapy, Chinese Academy of Sciences University
Cancer Hospital, Zhejiang Cancer Hospital, Hangzhou, China
(Wang) Department of Medical Oncology, National Cancer Center, National
Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of
Medical Sciences, Peking Union Medical College, Beijing, China
(Wu) Department of Respiratory Medicine, Shenzhen People's Hospital,
Shenzhen, China
(Xu) Department of Respiratory Medicine, The First Affiliated Hospital of
Nanchang University, Nanchang, China
(Xu) Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences,
Hangzhou, China
(Yang) Department of Comprehensive Oncology, National Cancer Center,
National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen
Hospital, Chinese Academy of Medical Sciences, Peking Union Medical
College, Shenzhen, China
(Yang) Department of Respiratory Disease, China-Japan Friendship Hospital,
Beijing, China
(Ye) Department of Medical Oncology, Xiamen Key Laboratory of Antitumor
Drug Transformation Research, First Affiliated Hospital of Xiamen
University, School of Medicine, Xiamen University, Xiamen, China
(Ye) Department of Respiratory Diseases, The Second Affiliated Hospital of
Nanchang University, Nanchang, China
(Yu) Department of Pulmonary and Critical Care Medicine, The 900th
Hospital of Joint Logistic Support Force, PLA, Fuzhou, China
(Zhang) Department of Pulmonary and Critical Care Medicine, Xijing
Hospital, Fourth Military Medical University, Xi'an, China
(Zhang) Second Department of Respiratory and Critical Care Medicine, First
Affiliated Hospital of Kunming Medical University, Kunming, China
(Zhang) Department of Respiratory and Critical Care Medicine, Henan
Provincial People's Hospital, People's Hospital of Zhengzhou University,
Zhengzhou, China
(Zhao) Department of Respiratory and Critical Care Medicine, Changsha
Hospital of Traditional Chinese Medicine, Changsha Eighth Hospital,
Changsha, China
(Zheng, Zou) Department of Thoracic Oncology, Clinical Oncology School of
Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
(Zhu) Chongqing Key Laboratory of Immunotherapy, Xinqiao Hospital, Third
Military Medical University, Chongqing, China
(Zhu) Department of Radiation Oncology, Fudan University Shanghai Cancer
Center, Shanghai, China
(Zhou) Department of Respiratory Disease, Thoracic Disease Center, The
First Affiliated Hospital, College of Medicine, Zhejiang University,
Hangzhou, China
(Zhou) Department of Respiratory Diseases, The First Affiliated Hospital
of College of Medicine, Zhejiang University, Hangzhou, China
(Zhou) Department of Pulmonary and Critical Care Medicine, Ruijin
Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
China
(Zhou) Guangdong Lung Cancer Institute, Guangdong Provincial People's
Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
(Kidane) Section of Thoracic Surgery, Department of Surgery, Department of
Physiology & Pathophysiology, University of Manitoba, Winnipeg, Canada
(Bignami) Anesthesiology, Critical Care and Pain Medicine Division,
Department of Medicine and Surgery, University of Parma, Parma, Italy
(Sakamaki) Department of Respiratory Medicine, Tokai University Hachioji
Hospital, Tokai University School of Medicine, Tokyo, Japan
(Roviello) Department of Health Sciences, University of Florence,
Florence, Italy
(Taniguchi) Clinical Oncology Center, Nagasaki University Hospital,
Nagasaki, Japan
(Jeon) Division of Pulmonary and Critical Care Medicine, Department of
Medicine, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, South Korea
(Saric) Department of Anesthesiology, Reanimatology and Intensive Care,
University Hospital Split, Split, Croatia
(Saric) University Department of Health Studies, University of Split,
Split, Croatia
(Saric) Medical School, University of Split, Split, Croatia
(Ariza-Prota) Division of Respiratory Medicine, Interventional Pulmonology
Unit, Hospital Universitario Central de Asturias, Oviedo, Spain
(La-Beck) Department of Immunotherapeutics and Biotechnology, Jerry H.
Hodge School of Pharmacy, Texas Tech University Health Sciences Center,
Abilene, TX, United States
(Kanaji) Division of Hematology, Rheumatology and Respiratory Medicine,
Department of Internal Medicine, Faculty of Medicine, Kagawa University,
Kagawa, Japan
(Watanabe) Department of Respiratory Medicine and Infectious Diseases,
Niigata University Graduate School of Medical and Dental Sciences,
Niigata, Japan
(Shukuya) Department of Respiratory Medicine, Juntendo University Graduate
School of Medicine, Tokyo, Japan
(Akaba) Department of Respiratory Medicine, Tokyo Women's Medical
University, Tokyo, Japan
(Leong) Department of Respiratory Medicine, Austin Hospital, Heidelberg,
VIC, Australia
(Gesierich) Department of Pulmonology, Asklepios Lung Clinic Gauting,
Center for Respiratory Medicine and Thoracic Surgery, Gauting, Germany
(Koga) Department of Respiratory Medicine, Gunma University Graduate
School of Medicine, Maebashi, Japan
(Tanino) Department of Pulmonary Medicine, Fukushima Medical University
School of Medicine, Fukushima, Japan
(Uehara) Department of Thoracic Oncology and Respiratory Medicine, Tokyo
Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital,
Tokyo, Japan
(Uehara) Division of Cancer Evolution, National Cancer Center Japan
Research Institute, Tokyo, Japan
(Chen) Shenzhen Institute of Respiratory Diseases, Shenzhen People's
Hospital, Shenzhen, China
(Chen) Shenzhen Institute of Respiratory Diseases, Shenzhen People's
Hospital, 1017 Dongmen North Road, Luohu District, Shenzhen, China
Publisher
AME Publishing Company
Abstract
Background: Although advancements in cancer therapies have substantially
improved the survival of cancer patients, these treatments may also result
in acute or chronic lung injury. Cancer treatment-related lung injury
(CTLI) presents with a diverse array of clinical manifestations and can
involve multiple sites. Due to the lack of specific diagnostic protocols,
CTLI can deteriorate rapidly and may be life-threatening if not promptly
addressed. Unfortunately, there is no universally accepted consensus
document on the diagnosis and management of CTLI. <br/>Method(s): A
multidisciplinary panel comprising experts from respiratory and critical
care medicine, oncology, radiation oncology, thoracic surgery, radiology,
pathology, infectious diseases, pharmacy, and rehabilitation medicine
participated in this consensus development. Through a systematic
literature review and detailed panel discussions, the team formulated nine
key recommendations. <br/>Result(s): This consensus document addresses the
concept, epidemiology, pathogenesis, risk factors, diagnostic approach,
evaluation workflow, management strategies, differential diagnosis,
type-specific management and clinical staging of CTLI. Emphasis is placed
on raising awareness among clinicians and therapeutic practices through
comprehensive guidelines. <br/>Conclusion(s): The consensus provides a
detailed diagnostic protocol for CTLI and introduces a structured
management framework based on grading, typing, and staging. It highlights
the critical role of multidisciplinary team (MDT) collaboration and
emphasizes the need for individualized, whole-process patient care
strategies to optimize clinical outcomes.<br/>Copyright &#xa9; AME
Publishing Company.

<90>
Accession Number
2038543385
Title
Predictive Effect of GDF-15 on Adverse Outcomes After Cardiovascular
Interventions: A Systematic Review and Meta-Analysis.
Source
Reviews in Cardiovascular Medicine. 26(4) (no pagination), 2025. Article
Number: 28279. Date of Publication: 01 Apr 2025.
Author
Jia X.; Gao J.; Qi Z.; Ma J.
Institution
(Jia, Gao, Qi, Ma) Department of Anesthesiology, Beijing Anzhen Hospital,
Capital Medical University, Beijing, China
Publisher
IMR Press Limited
Abstract
Background: This systematic review and meta-analysis aimed to evaluate the
predictive effect of Growth Differentiation Factor-15 (GDF-15) on adverse
outcomes in patients undergoing cardiovascular interventions.
<br/>Method(s): A comprehensive literature search was performed across
PubMed, EMBASE, Cochrane Library, and Web of Science databases. The
meta-analysis used hazard ratios (HR) and odds ratios (OR) to compare
outcomes such as all-cause mortality, cardiovascular death, postoperative
atrial fibrillation (AF), acute kidney injury (AKI), and spontaneous
myocardial infarction (MI) between high GDF-15 levels and control groups.
Subgroup analyses were conducted based on study design and GDF-15 cutoff
levels. Publication bias was evaluated using funnel plot and Egger's test.
<br/>Result(s): A total of 13 studies were included in the meta-analysis.
The study revealed a significant association between elevated GDF-15
levels and increased all-cause mortality. Subgroup analysis showed a
significant association in retrospective studies but not in prospective
studies. Higher GDF-15 cutoff levels (>2 ng/mL) were more strongly
associated with increased mortality than lower cutoff levels (<=2 ng/mL).
Elevated GDF-15 levels were found to be significantly associated with
increased risks of cardiovascular death, AKI, and spontaneous MI. No
significant difference was observed in the incidence of postoperative AF.
The overall adverse outcomes analysis showed no significant difference.
Subgroup analyses suggested significant associations primarily observed in
studies with higher GDF-15 cutoffs. <br/>Conclusion(s): Elevated GDF-15
levels are associated with increased risks of all-cause mortality,
cardiovascular death, AKI, and spontaneous MI in patients undergoing
cardiovascular interventions. Due to the heterogeneity of the studies,
including variations in surgical techniques, the conclusions should be
interpreted with caution. The PROSPERO Registration: CRD42024582279,
https://www.crd.york.ac.uk/PROSPERO/view/CRD42024582279.<br/>Copyright
&#xa9; 2025 The Author(s).

<91>
Accession Number
2034454647
Title
Intravenous leiomyomatosis: A case report and narrative literature review.
Source
International Journal of Gynecology and Obstetrics. (no pagination),
2025. Date of Publication: 2025.
Author
Teixeira B.; Neves M.C.; Fonseca F.; Torres J.P.; Teixeira J.; Costa A.
Institution
(Teixeira, Neves, Costa) Gynecological Unit, Centro Hospitalar
Universitario de Sao Joao, Porto, Portugal
(Fonseca, Torres) Department of Cardiothoracic Surgery, Centro Hospitalar
Universitario de Sao Joao, Porto, Portugal
(Teixeira) Department of Vascular Surgery, Centro Hospitalar Universitario
de Sao Joao, Porto, Portugal
(Costa) Department of Obstetrics and Gynecology, Faculdade de Medicina da
Universidade do Porto, Porto, Portugal
Publisher
John Wiley and Sons Ltd
Abstract
In the present study, we report a case of intravenous leiomyomatosis with
intracardiac extension. A subsequent extensive literature review was
initiated in order to characterize this entity in terms of clinical
manifestations, diagnosis and treatment strategies. We performed a
literature search in PubMed, Webscience and Scopus using the MeSH term
"intravenous leiomyomatosis" and included case reports, case series and
retrospective studies published in the last 10 years. A total of 74
articles, with a total of 672 cases of intravenous leiomyomatosis were
included. The average age at diagnosis was 45.5 years and 92% of the cases
were reported in Asian countries. A total of 21% of the patients were
asymptomatic. The most frequent symptoms included perception of pelvic
mass, dyspnea, abnormal uterine bleeding and palpitations. In 55% of cases
there was a preoperative suspicion of the diagnosis. In 61%, the lesion
was confined to the pelvic cavity and in 35% there was extension beyond
the renal veins (including intracardiac extension). When there was a
preoperative diagnosis, the surgical team usually included elements from
gynecology, vascular surgery and/or cardiac surgery. The treatment
consisted of one-stage surgery in 86% of cases, with complete resection in
90%. The recurrence rate was 12%. Intravenous leiomyomatosis can have a
nonspecific presentation which, combined with its rarity, requires a high
degree of suspicion. The challenges in its treatment and follow-up arise
from its surgical complexity and the absence of guidelines. The objective
of this review was to compile the most recent cases reported to better
characterize this rare entity thereby achieving optimal
management.<br/>Copyright &#xa9; 2025 International Federation of
Gynecology and Obstetrics.

<92>
Accession Number
2038554008
Title
Surgical neuromodulation therapies to prevent postoperative atrial
fibrillation: A meta-analysis, meta-regression, and trial sequential
analysis of randomized controlled trials.
Source
Heart Rhythm. (no pagination), 2025. Date of Publication: 2025.
Author
Consoli L.N.; Cetinel E.; Lajczak P.; Koziakas I.G.; Majeed M.W.; Wijaya
P.; Salha I.; Samanidis G.
Institution
(Consoli) Federal University of Bahia, Salvador, Brazil
(Cetinel) San Raffaele University, Milan, Italy
(Lajczak) Medical University of Silesia, Katowice, Poland
(Koziakas, Samanidis) Department of Cardiac Surgery, Onassis Hospital,
Athens, Greece
(Majeed) Government Medical College Srinagar, Jammu and Kashmir, India
(Wijaya) Universitas Indonesia, Depok, Indonesia
(Salha) Trinity Centre for Global Health, Trinity College Dublin, Dublin,
Ireland
Publisher
Elsevier B.V.
Abstract
Background: Postoperative atrial fibrillation (POAF) occurs frequently
after cardiac surgery and is associated with increased mortality.
<br/>Objective(s): Surgical neuromodulation therapies (SNMTs) have been
explored as a preventive strategy, but their efficacy and safety remain
uncertain. <br/>Method(s): We searched PubMed, Embase, and the Cochrane
Library for eligible randomized controlled trials. Meta-analysis was
performed for primary (POAF) and secondary (hospital stay, complications,
atrial fibrillation at 1 year, operation time, POAF burden, intensive care
unit stay) end points. Subgroup analysis was conducted for each technique.
We compared end points using risk ratio for binary outcomes and mean
difference for continuous outcomes. We calculated 95% confidence intervals
for all outcomes. We carried out a trial sequential analysis for primary
(POAF) and secondary (hospital stay, complications) end points. We
conducted meta-regression for all covariates with at least 10
observations. <br/>Result(s): We included 20 trials (n = 3348): 7 studied
anterior fat pad (AFP) preservation; 5, pulmonary vein isolation (PVI); 2,
ganglionated plexus ablation; 1, partial cardiac denervation (PCD); and 5,
epicardial injections. POAF incidence was lower in the SNMT group (risk
ratio, 0.62 [0.48-0.79]; P < .001), driven by the AFP preservation, PCD,
and PVI subgroups. Epicardial injections were effective only in patients
undergoing coronary surgery. SNMTs also reduced hospital stay (P = .03).
All meta-regression analyses were insignificant. In the trial sequential
analysis, a positive effect for POAF was observed. <br/>Conclusion(s):
This meta-analysis found a significant reduction in POAF incidence with
implementation of AFP preservation, PCD, and PVI. Epicardial injections
were effective only for patients undergoing coronary bypass.<br/>Copyright
&#xa9; 2025 Heart Rhythm Society

<93>
Accession Number
2038547877
Title
Insights into the history and tendency of cardiac transplantation for
heart failure: A bibliometric-based visual analysis.
Source
IJC Heart and Vasculature. 59 (no pagination), 2025. Article Number:
101691. Date of Publication: 01 Aug 2025.
Author
Zhang W.; Shi H.; Feng J.; Pan R.; Jia C.; Fu Z.; Zhu H.; He Y.; Guo H.;
Liu B.
Institution
(Zhang, Feng, Pan, Fu, Zhu, He, Guo, Liu) Department of Anatomy, School of
Integrative Medicine, Shanghai University of Traditional Chinese Medicine,
Shanghai, China
(Shi) Department of Thoracic Surgery, Affiliated Qidong Hospital of
Nantong University, Qidong People's Hospital, Qidong Liver Cancer
Institute, 68 Minle Middle Road, Jiangsu, Qidong, China
(Jia) Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou,
China
Publisher
Elsevier Ireland Ltd
Abstract
Background: Heart transplantation (HT) remains the most effective
long-term treatment for end-stage heart failure (HF). As the field
continues to evolve, bibliometric analysis offers insights into historical
developments and emerging trends. <br/>Method(s): A comprehensive
bibliometric analysis was conducted using the Web of Science Core
Collection (WOSCC), covering HT-related publications from 1975 to 2023.
Extracted data included publication year, type, citation metrics,
contributing countries and institutions, journals, authors, keywords, and
references. <br/>Result(s): A total of 8414 publications were retrieved,
comprising 6356 original articles and 1018 reviews. Global research output
steadily increased over the study period. The United States led in
publication volume and citations, with significant contributions from
institutions in Europe and Asia. Core journals and prolific authors were
identified, highlighting the academic landscape. Research hotspots
included clinical immunosuppressive therapy, ventricular assist device
(VAD) technology, and donor allocation strategies. <br/>Conclusion(s): The
field of HT for HF has experienced substantial growth, with continued
focus on immunosuppression, mechanical circulatory support, and organ
allocation. These areas are likely to remain central in future research,
reflecting ongoing efforts to improve patient outcomes and expand
transplant accessibility.<br/>Copyright &#xa9; 2025

<94>
Accession Number
2034451415
Title
Reexploring the STRESS Trial: Subgroup Postoperative Outcomes Following
Methylprednisolone for Infant Heart Surgery.
Source
Pediatric Cardiology. (no pagination), 2025. Date of Publication: 2025.
Author
Sunthankar S.D.; Hill K.D.; Jacobs J.P.; Baldwin H.S.; Jacobs M.L.; Li
J.S.; Graham E.M.; Resheidat A.M.; Amula V.; Bleiweis M.S.; Wald E.L.;
Eghtesady P.; Scott J.P.; Anderson B.R.; Swartz M.F.; Benscoter A.;
Ravekes W.; Kannankeril P.J.
Institution
(Sunthankar, Baldwin, Kannankeril) Division of Pediatric Cardiology and
Center for Pediatric Precision Medicine, Department of Pediatrics,
Vanderbilt University Medical Center, 2220 Children's Way; Suite 5230,
Nashville, TN, United States
(Hill, Li) Division of Pediatric Cardiology, Duke University Medical
Center, Durham, NC, United States
(Jacobs, Bleiweis) Division of Cardiac Surgery, University of Florida,
Gainesville, FL, United States
(Jacobs) Division of Cardiac Surgery, Johns Hopkins School of Medicine,
Baltimore, MD, United States
(Graham) Division of Pediatric Cardiology, Medical University of South
Carolina, Charleston, SC, United States
(Resheidat) Division of Pediatric Cardiac Anesthesiology, Texas Children's
Hospital, Baylor College of Medicine, Houston, TX, United States
(Amula) Division of Critical Care, Department of Pediatrics, Primary
Children's Hospital, Salt Lake City, UT, United States
(Wald) Division of Pediatric Cardiology, Northwestern University Feinberg
School of Medicine, Chicago, IL, United States
(Eghtesady) Division of Cardiac Surgery, Washington University School of
Medicine, St. Louis, MO, United States
(Scott) Division of Pediatric Cardiology, Medical College of Wisconsin,
Madison, WI, United States
(Anderson) Division of Pediatric Cardiology, Icahn School of Medicine at
Mt Sinai, New York, NY, United States
(Swartz) Division of Cardiac Surgery, University of Rochester, Rochester,
NY, United States
(Benscoter) Division of Pediatric Cardiology, Cincinnati Children's
Hospital, Cincinnati, OH, United States
(Ravekes) Division of Pediatric Cardiology, Johns Hopkins School of
Medicine, Baltimore, MD, United States
Publisher
Springer
Abstract
Objective Assess the association between intraoperative methylprednisolone
and specific postoperative outcomes among subgroups undergoing infant
heart surgery. <br/>Design(s): Subpopulation analyses of The Steroids to
Reduce Systemic Inflammation after Infant Heart Surgery trial, a
double-blind randomized placebo-controlled trial. <br/>Setting(s): 24
congenital heart centers. <br/>Patient(s): Infants (< 1 year old)
undergoing heart surgery with cardiopulmonary bypass. Patients stratified
by Society of Thoracic Surgeons-European Association for Cardio-Thoracic
Surgery Congenital Heart Surgery (STAT) Mortality Category, age,
gestational age, and presence of chromosomal or syndromic diagnosis (CSD).
<br/>Intervention(s): Methylprednisolone (30 mg/kg) versus placebo
administered into cardiopulmonary bypass pump-priming fluid.
<br/>Measurements and Main Results: Outcomes included death, heart
transplantation, mechanical circulatory support, reinterventions, and
hospital length of stay. Ranked composite outcome (death, transplant, or
one of 13 major complications) was compared between placebo and
methylprednisolone for each subgroup using the win ratio.
Methylprednisolone did not reduce odds of death, transplant, or mechanical
circulatory support for any subgroup. Those receiving methylprednisolone
had fewer catheterization or surgical reinterventions after STAT Category
1-3 operations [OR 0.50 (0.29-0.86)]; and fewer reoperations for bleeding
among patients undergoing STAT Category 1-3 operations [OR 0.28
(0.09-0.87)], term infants [OR 0.30 (0.12-0.76)], and those without CSD
[OR 0.22 (0.07-0.68)]. Length of stay was no different between
methylprednisolone versus placebo. Those without chromosomal or syndromic
diagnosis demonstrated a favorable association for methylprednisolone [win
ratio 1.28 (1.01-1.61)] for the composite outcome. <br/>Conclusion(s):
Exploratory subpopulation analyses, although underpowered, suggest that
methylprednisolone is not associated with significant harm and may benefit
certain subpopulations<br/>Copyright &#xa9; The Author(s) 2025.

<95>
Accession Number
2038542926
Title
Perioperative dexmedetomidine for the prevention of postoperative delirium
after cardiac surgery: a systematic review, Bayesian meta-analysis, and
Bayesian re-analysis of the DECADE trial.
Source
British Journal of Anaesthesia. (no pagination), 2025. Date of
Publication: 2025.
Author
Hunt T.; Payne T.; Brophy J.M.; Irons J.; Wang A.Y.; Cartwright C.; Moran
B.; Loadsman J.A.; Sanders R.D.
Institution
(Hunt, Payne, Loadsman, Sanders) Central Clinical School, Faculty of
Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
(Hunt, Payne, Irons, Wang, Cartwright, Loadsman, Sanders) Department of
Anaesthetics, Royal Prince Alfred Hospital, Sydney Local Health District,
Camperdown, NSW, Australia
(Payne) Royal Melbourne Hospital, Melbourne Health, Parkville, VIC,
Australia
(Brophy) Department of Medicine, McGill University, Montreal, QC, Canada
(Brophy) Department of Epidemiology, McGill University, Montreal, QC,
Canada
(Brophy) Department of Biostatistics, McGill University, Montreal, QC,
Canada
(Moran) Department of Intensive Care, Gosford Hospital, Gosford, Australia
(Moran) Department of Anaesthesia and Pain Medicine, Gosford Hospital,
Gosford, Australia
(Moran) School of Medicine and Public Health, University of Newcastle,
Callaghan, NSW, Australia
(Sanders) Institute of Academic Surgery, Royal Prince Alfred Hospital,
Sydney Local Health District, NSW, Australia
(Sanders) NHMRC Clinical Trials Centre, The University of Sydney,
Camperdown, NSW, Australia
Publisher
Elsevier Ltd
Abstract
Background: Dexmedetomidine is seen as a promising agent for the
prevention of postoperative delirium after cardiac surgery, but the
largest study (DECADE) paradoxically suggested an increased risk of
delirium. <br/>Method(s): Studies were selected using inclusion/exclusion
criteria after conducting online database searches for randomised
controlled trials. The primary outcome was the incidence of postoperative
delirium with a minimum clinically important difference (MCID), defined as
an odds ratio >1.20 or <0.84. Publication bias was quantified using
Bayesian model averaging. A random-effects meta-analysis with weakly
informative priors was performed. Bayesian re-analysis of DECADE using
several different priors including a prior based on this meta-analysis
(excluding DECADE) was also performed. <br/>Result(s): We identified 12
eligible randomised controlled trials (3539 participants). The overall
pooled effect showed a mean benefit from dexmedetomidine in delirium
prevention (odds ratio 0.67 [95% credible interval 0.45, 0.92]), but any
definitive evidence of benefit disappeared after accounting for
publication bias (odds ratio 1.15 [95% credible interval 0.93, 2.51]).
Bayesian re-analysis of the DECADE trial under a vague prior showed a 1.5%
posterior probability of any benefit and only a 0.1% probability of an
MCID for benefit. Combining DECADE with the unadjusted
meta-analysis-derived prior increased the probability of an MCID for
benefit to 17.8%, which decreased to 0.2% using the meta-analysis-derived
prior adjusted for publication bias. <br/>Conclusion(s): Pooled evidence
suggests dexmedetomidine is associated with reduced incidence of
postoperative delirium; however, this is highly sensitive to the
possibility of publication bias. Bayesian re-analysis of the recently
published DECADE trial showed the effect of dexmedetomidine differs
markedly depending on the weight given to previous studies. Hence, any
true benefit from the use of dexmedetomidine over standard care in this
population cannot be definitively characterised at present. Systematic
review protocol: CRD42023401623 (PROSPERO).<br/>Copyright &#xa9; 2025
British Journal of Anaesthesia

<96>
Accession Number
2034437178
Title
Risk factors for postoperative hypothermia in non-cardiac surgery
patients: a systematic review and meta-analysis.
Source
BMC Anesthesiology. 25(1) (no pagination), 2025. Article Number: 223. Date
of Publication: 01 Dec 2025.
Author
Tan R.; Chen Y.; Yang D.; Long X.; Ma H.; Yang C.
Institution
(Tan, Yang, Ma, Yang) Anesthesiology Department, Chongqing University
Cancer Hospital, Chongqing, China
(Chen) School of Nursing, Guangxi University of Chinese Medicine, Nanning,
China
(Long) Nursing Department, Ruikang Hospital Affiliated to Guangxi
University of Chinese Medicine, Nanning, China
Publisher
BioMed Central Ltd
Abstract
Background: Postoperative hypothermia seems to be a common problem in
surgical patients but is easily ignored. This study aimed to identify risk
factors for postoperative hypothermia in non-cardiac surgery patients.
<br/>Method(s): We searched databases including PubMed, Embase, Web of
Science, Cochrane Library, CINAHL, VIP, Wan Fang, CNKI, and CBM from
inception to April 2025. The studies were selected using inclusion and
exclusion criteria. Two reviewers screened studies, extracted data, and
independently evaluated the risk of bias. The quality of the study was
assessed with the Newcastle-Ottawa Scale, and a meta-analysis was carried
out with Revman 5.4 software. <br/>Result(s): A total of 17 studies were
included. Age >= 60 (odds ratio [OR] = 1.80), BMI < 18.5 kg/m²
(OR = 1.83), ASA III-IV (OR = 1.87), endoscopic surgery (OR = 1.93),
intraoperative blood loss >= 100ml (OR = 2.35), intravenous fluid >=
1000ml (OR = 1.87), blood transfusion (OR = 1.80), duration of anesthesia
> 1 h (OR = 1.99) and duration of surgery > 1 h (OR = 2.34) were
significant risk factors that contributed to postoperative hypothermia in
non-cardiac surgery patients. <br/>Conclusion(s): There are many risk
factors for postoperative hypothermia in patients undergoing non-cardiac
surgery. The results of this research may improve clinician awareness,
risk stratification, and prevention of postoperative hypothermia in
non-cardiac surgery patients.<br/>Copyright &#xa9; The Author(s) 2025.

<97>
Accession Number
2038543148
Title
Economic Evaluations in Electrophysiology in the Last 15 Years: A
Systematic Review of the Literature.
Source
Reviews in Cardiovascular Medicine. 26(4) (no pagination), 2025. Article
Number: 36206. Date of Publication: 01 Apr 2025.
Author
Mei D.A.; Imberti J.F.; Vitolo M.; Bonini N.; Casali E.; Osoro L.;
Casado-Arroyo R.; Boriani G.
Institution
(Mei, Imberti, Vitolo, Bonini, Casali, Boriani) Cardiology Division,
Department of Biomedical, Metabolic and Neural Sciences, University of
Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
(Mei) Clinical and Experimental Medicine PhD Program, University of Modena
and Reggio Emilia, Modena, Italy
(Mei, Osoro, Casado-Arroyo) Advocacy, Quality Improvement and Health
Economics (AQIHEC) Committee, EHRA, Sophia Antipolis, France
(Osoro, Casado-Arroyo) Department of Cardiology, H.U.B.-Hopital Erasme,
Universite Libre de Bruxelles, Bruxelles, Belgium
Publisher
IMR Press Limited
Abstract
Background: Electrophysiology (EP) procedures, including cardiac
implantable electronic devices (CIEDs) and ablations, are widely used to
manage arrhythmias and heart failure. These interventions, though
effective, require substantial resources, prompting the need for
systematic economic evaluations to inform healthcare decision-making.
<br/>Method(s): A systematic review of studies from 2007 to 2024 was
conducted in two phases. Phase one assessed trends in economic evaluations
of EP procedures, analyzing 129 studies across regions and timeframes.
Phase two focused on cost-effectiveness analyses of implantable
cardioverter defibrillators (ICDs), cardiac resynchronization therapy
defibrillators (CRT-Ds), and atrial fibrillation (AF) ablation, examining
outcomes like quality-adjusted life years (QALYs) and incremental
cost-effectiveness ratios (ICERs), while identifying factors influencing
economic results. <br/>Result(s): EP procedures generally demonstrated
favorable cost-effectiveness, particularly in high-income regions. Studies
on ICDs and CRT-Ds consistently supported their economic value for
patients with arrhythmias or heart failure, while AF ablation showed
potential for long-term benefits, particularly when compared to medical
therapies. However, results varied by region, reflecting differences in
healthcare systems, costs, and patient populations. <br/>Conclusion(s):
The review highlights the overall cost-effectiveness of EP procedures in
many settings but underscores the need for tailored economic evaluations
in low- and middle-income countries. Simplified methodologies and greater
attention to regional contexts are recommended to guide resource
allocation and policy development globally.<br/>Copyright &#xa9; 2025 The
Author(s).

<98>
Accession Number
2038526117
Title
Infective endocarditis risk scores: a narrative review.
Source
Journal of Thoracic Disease. 17(4) (pp 2662-2678), 2025. Date of
Publication: 30 Apr 2025.
Author
Cho C.S.-Y.; Lim K.; Siu I.C.-H.; Ho J.Y.-K.; Chow S.C.-Y.; Fujikawa T.;
Kwok M.W.-T.; Wong R.H.-L.
Institution
(Cho, Lim, Siu, Ho, Chow, Fujikawa, Kwok, Wong) Division of Cardiothoracic
Surgery, Department of Surgery, Prince of Wales Hospital, Hong Kong
Publisher
AME Publishing Company
Abstract
Background and Objective: Despite modern advancements, infective
endocarditis remains a devastating disease with high mortality and
morbidity rates. Given the heterogeneous patient background and the
complexity of the condition, the decision for surgery is difficult.
Traditional general cardiac surgery risk models, including EuroSCORE and
Society of Thoracic Surgeons (STS) score, do not include disease-specific
factors that often impact both the operability and frailty of patients.
The aim of the study is to review the strength and limitations of current
risk scores designed specifically for patients with infective
endocarditis. <br/>Method(s): A search in PubMed and OVID databases was
conducted for articles and abstracts published from inception to
1^st June 2024 using the terms "infective endocarditis" AND
"risk score" or "surgical futility" or "operative mortality". Key Content
and Findings: Various risk scores have therefore been developed to help
stratify the operative risks of these patients by incorporating
endocarditis-specific features. This review aims to analyse the
applicability and usefulness of risk scores in the setting of surgical
management of infective endocarditis, which in turn helps to identify
patients who would benefit from interventions. From 2007, a total of 18
risk scores have been designed specifically for patients with infective
endocarditis. These scores however have low generalisability since
different patient characteristics, disease factors and validation
strategies are used. In various validation cohorts and comparative
studies, the discrimination performances of these scores are
unsatisfactory. Most of the studies focused on early, or in-patient
mortality, while the intermediate and long-term mortality was not well
studied. <br/>Conclusion(s): Risk stratification for the group of patients
who are indicated for surgery, but only received medical treatment due to
perceived futility or were too unstable to proceed to operation, is
pertinent. This population is not frequently recruited to current studies,
and more research is needed.<br/>Copyright &#xa9; AME Publishing Company.

<99>
Accession Number
2038543697
Title
Rationale and design of the anticoagulant therapy after left atrial
appendage closure (ATLAAC) trial.
Source
American Heart Journal. 287 (pp 86-93), 2025. Date of Publication: 01 Sep
2025.
Author
Gosvig K.; Goller J.; Hansson N.H.; Brandes A.; Modrau I.; Rasmussen L.F.;
Eskesen K.; Jensen A.K.G.; Belley-Cote E.; Whitlock R.; Riber L.P.S.
Institution
(Gosvig, Goller, Riber) Department of Cardiothoracic and Vascular Surgery,
Odense University Hospital, Odense, Denmark
(Gosvig, Goller, Riber) Department of Clinical Research, Research unit for
Cardiac Surgery, University of Southern Denmark, Odense, Denmark
(Hansson) Department of Cardiology, Odense University Hospital, Odense,
Denmark
(Brandes) Department of Cardiology, Esbjerg and Grindsted Hospital,
Esbjerg, Denmark
(Brandes) Department of Regional Health Research, University of Southern
Denmark, Esbjerg, Denmark
(Modrau) Department of Cardiothoracic and Vascular Surgery, Aarhus
University Hospital, Aarhus N, Denmark
(Modrau) Department of Clinical Medicine, Aarhus University, Aarhus C,
Denmark
(Rasmussen) Department of Cardiothoracic and Vascular Surgery, Aalborg
University Hospital, Aalborg, Denmark
(Eskesen) Department of Cardiology, Gentofte Hospital, Hellerup, Denmark
(Jensen) Department of Public Health, Section of Biostatistics, University
of Copenhagen, Copenhagen, Denmark
(Belley-Cote, Whitlock) Department of Surgery, McMaster University,
Hamilton, ON, Canada
(Belley-Cote, Whitlock) Population Health Research Institute, McMaster
University and Hamilton Health Sciences, Hamilton, ON, Canada
Publisher
Elsevier Inc.
Abstract
Introduction: Left atrial appendage closure (LAAC) has become a
recommended addition to oral anticoagulation for patients with atrial
fibrillation, who undergo cardiac surgery. The procedure significantly
reduces the risk of stroke and systemic arterial embolism, potentially
making oral anticoagulation (OAC) unnecessary or even harmful, when
considering the associated increased risk of bleeding. This publication
describes the rationale and design of a randomized trial, testing the
hypothesis that stopping OAC is noninferior to continuing OAC after
surgical LAAC in terms of the primary endpoint. <br/>Method(s): The ATLAAC
trial is a multicenter, randomized, controlled trial, aiming to enroll
1,220 patients with atrial fibrillation, who have undergone surgical LAAC
and remain on OAC. A cardiac CT scan is performed to confirm success of
the LAAC. Patients with successful closure are randomized to stop or
continue OAC. The primary endpoint is the first occurrence of ischemic
stroke, systemic arterial embolism, or major bleeding over an expected
mean follow-up of 4 years. Secondary endpoints include all-cause
mortality, cardiovascular mortality, any bleeding leading to
hospitalization, blood transfusion, venous thromboembolism, myocardial
infarction, and quality of life measures. Trial status: Enrollment for the
ATLAAC trial began in March 2024. As of January 18th, 2025, 554 patients
have been enrolled in the study and 319 patients have been randomized.
Recruitment is expected to continue for approximately 12 months. Follow-up
will be stopped once 128 primary endpoints have occurred.
<br/>Conclusion(s): The ATLAAC trial will evaluate the safety of stopping
OAC after surgical LAAC. Trial registration number: EU-CT:
2022-502986-92-00, clinicaltrials.gov ID: NCT06401616.<br/>Copyright
&#xa9; 2025 The Authors

<100>
Accession Number
647193754
Title
SINGLE PERCLOSE PLUS PLUG BASED DEVICE VERSUS DOUBLE PERCLOSE FOR
PERCUTANEOUS LARGE BORE ARTERIAL ACCESS: A SYSTEMATIC REVIEW AND META
ANALYSIS.
Source
Annals of vascular surgery. (no pagination), 2025. Date of Publication:
20 Apr 2025.
Author
Bertolino E.P.; Mastra Fontoura M.M.; Florencio de Mesquita C.; da Silva
Pimentel D.; Fernandez M.G.; Queiroz I.; Diaz Herrera B.A.; Moraes A.O.;
Millner R.; Mulatti G.C.
Institution
(Bertolino) Departamento de Medicina da Universidade Estadual de Maringa,
Parana, Brazil
(Mastra Fontoura) Faculdade de Medicina da Universidade Federal do Rio de
Janeiro, Rio de Janeiro, Brazil
(Florencio de Mesquita) Faculdade de Medicina da Universidade Federal de
Pernambuco, Recife, Brazil
(da Silva Pimentel) Faculdade de Medicina da Universidade Federal
Fluminense, Niteroi, Brazil
(Fernandez) Escola Bahiana de Medicina e Saude Publica, Bahia, Brazil
(Queiroz) Universidade Catolica de Pernambuco, Recife, Brazil
(Diaz Herrera) Universidad Autonoma del Estado de Hidalgo and Instituto
Nacional de Cardiologia "Ignacio Chavez", Mexico City, Mexico
(Moraes) IMV, Instituto de Molestias Vasculares, Maringa, Brazil
(Millner) Section of Vascular Surgery and Endovascular Therapy of the
University of Chicago, Chicago, IL, United States
(Mulatti) Departamento de Cirurgia Vascular e Endovascular do Hospital das
Clinicas da Universidade de Sao Paulo, Sao Paulo, Brazil
Abstract
OBJECTIVE: Vascular Closure primarily utilizing Suture Based Devices (SBD)
are frequently used for large bore percutaneous arterial access in
patients undergoing Transcatheter Aortic Valve Implantation (TAVR) and
Endovascular Aneurysm Repair (EVAR). Little is known about the intentional
combination of SBD with PBD. Main objective was to determine the efficacy
of adopting a combined SBD and PBD strategy compared to double SBD for
large bore arterial access. REVIEW METHODS: We searched randomized and
observational studies comparing both strategies and that reported the
outcomes of major vascular and vascular complications, major bleeding, all
bleeding events, need for surgical or endovascular interventions, device
failure, additional device and pseudoaneurysm. A meta-analysis was
conducted, with heterogeneity assessed using the I2 statistic and a
random-effects model applied to all outcomes. Additionally, trial
sequential analysis was performed. <br/>RESULT(S): We included 3
randomized trials and 4 observational studies with 2,064 access. Sheath
size ranged from 13 to 24 Fr. Vascular complications (RR 0.54; p<0.01),
major vascular complications (RR 0.55; p=0.04), major bleeding (RR 0.49;
p=0.02), need for surgical intervention (RR 0.25; p=0.01), and additional
device (RR 0.12; p<0.01) were significantly less common in patients
treated with the SBD and PBD technique. Pseudoaneurysm (RR 1.13; p=0.71),
all bleeding events (RR 0.59; p=0.1), and endovascular intervention (RR
0.65; p=0.26) were not significantly different between groups.
<br/>CONCLUSION(S): These findings suggest that one SBD, combined with
PBD, was associated with less femoral access complications when compared
to the exclusive double SBD as a vascular closure strategy in patients
with large bore arterial access.<br/>Copyright &#xa9; 2025 Elsevier Inc.
All rights reserved.

<101>
Accession Number
647197912
Title
Sex-Related Differences in Survival and Safety Outcomes After
Transcatheter Aortic Valve Replacement: A Meta-Analysis of Reconstructed
Time-to-Event Data.
Source
European heart journal. Quality of care & clinical outcomes. (no
pagination), 2025. Date of Publication: 22 Apr 2025.
Author
Tavakoli K.; Hosseini Mohammadi N.S.; Fallahtafti P.; Khamene S.S.; Taheri
M.; Ebrahimi P.; Bahiraie P.; Karimi E.; Alishahi M.M.; Pazoki M.; Anaraki
N.; Kazemian S.; Khanipour R.; Khalique O.K.; May H.T.; Thachil R.;
Iskander M.H.; Waheed A.; Hosseini K.
Institution
(Tavakoli, Hosseini Mohammadi, Fallahtafti, Khamene, Bahiraie, Karimi,
Pazoki, Anaraki, Kazemian, Hosseini) Tehran Heart Center, Cardiovascular
Diseases Research Institute, Tehran University of Medical Sciences,
Tehran, Iran, Islamic Republic of
(Taheri) Faculty of Medicine, Cardiology Research Center, Hamadan
University of Medical Sciences, Hamadan, Iran, Islamic Republic of
(Ebrahimi) Accident and Emergency Department (A&E), Royal Hampshire County
Hospital, Winchester, United Kingdom
(Alishahi) Islamic Azad University, Tehran Medical Branch, Tehran, Iran,
Islamic Republic of
(Khanipour) Department of Internal Medicine and Cardiology, University of
South Florida, HCA Florida Bayonet Point Hospital, United States
(Khalique) Francis Hospital & Heart Center, Closter, NJ, United States
(May) Intermountain Medical Center, Murray, UT, United States
(Thachil) Mount Sinai/Elmhurst Hospital Center, New York, NY, United
States
(Iskander) Department of Cardiovascular Medicine, Medical College of
Wisconsin, Milwaukee, WI, United States
(Waheed) Department of Family and Community Medicine, Pennsylvania State
University, Hershey, PA, United States
Abstract
AIMS: The impact of sex-related differences on outcomes following
transcatheter aortic valve replacement (TAVR) remains inconclusive. This
study investigates sex-related differences in survival and safety outcomes
in patients with aortic stenosis undergoing TAVR. METHODS AND RESULTS: We
systematically searched PubMed, Embase, Scopus, and Cochrane Library until
November 2024. Individual patient data (IPD) were reconstructed from
published Kaplan-Meier curves and compared using Cox-proportional hazards
model for overall survival and cardiovascular mortality. Pooled risk
ratios (RR) for safety outcomes at 30-days and one year were estimated
using a random-effects model. A total of 48 studies (69,355 women and
65,580 men) were included. Meta-analysis of reconstructed IPD showed that
men were at higher risk of all-cause mortality at five years (hazard ratio
[HR]: 1.24, 95% confidence interval [CI]: 1.20-1.28, P<0.001) and
cardiovascular mortality at four years (HR: 1.34, 95% CI: 1.21-1.49,
P<0.001) compared with women. In random-effects meta-analysis, men faced a
higher risk of permanent pacemaker implantation (RR: 1.29, 95% CI:
1.16-1.44, P<0.001) during the first year. Men experienced a lower risk of
stroke (RR: 0.75, 95% CI: 0.64-0.87, P<0.001) and major vascular
complications (RR: 0.58, 95% CI: 0.49-0.69, P<0.001) at 30 days, and a
lower risk of major bleeding (RR: 0.77, 95% CI: 0.70-0.84, P<0.001) as
well as major vascular complications (RR: 0.54, 95% CI: 0.43-0.68,
P<0.001) within the first year. <br/>CONCLUSION(S): Men demonstrated
poorer five-year overall survival and four-year cardiovascular survival
following TAVR compared with women. Future research with extended
follow-up is needed to understand the mechanism underlying sex-specific
TAVR outcomes.<br/>Copyright &#xa9; The Author(s) 2025. Published by
Oxford University Press on behalf of the European Society of Cardiology.
All rights reserved. For commercial re-use, please contact
reprints@oup.com for reprints and translation rights for reprints. All
other permissions can be obtained through our RightsLink service via the
Permissions link on the article page on our site-for further information
please contact

<102>
Accession Number
2034368399
Title
Vascular Closure Devices for Large Bore Femoral Access After Transfemoral
Transcatheter Aortic Valve Replacement: A Network Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. (no pagination), 2025.
Date of Publication: 2025.
Author
Upadhaya S.; Upreti A.; Gupta K.; Gonzalez-Perez B.; Ksayer R.; Cox-Alomar
P.; Sanina C.; Irimpen A.; Farhan S.; Wiley J.
Institution
(Upadhaya, Gonzalez-Perez, Ksayer, Sanina, Wiley) Department of Internal
Medicine, Section of Cardiology, Tulane University School of Medicine, New
Orleans, LA, United States
(Upreti) Department of Biomedical Sciences, Tulane University School of
Medicine, New Orleans, LA, United States
(Gupta, Irimpen) Department of Internal Medicine, Case Western Reserve
University, Cleveland, OH, United States
(Cox-Alomar) Department of Medicine, Section of Cardiology, University of
Miami, Miami, FL, United States
(Farhan) Department of Medicine, Division of Cardiology, Lenox Hill
Hospital, Northwell Health, New York, NY, United States
Publisher
John Wiley and Sons Inc
Abstract
Background and Aims: Large-bore femoral access is commonly required in
transfemoral transcatheter aortic valve replacement (TF-TAVR), but
vascular access complications remain prevalent, impacting patient
outcomes. Various vascular closure devices (VCDs) are used for hemostasis,
including the suture-based Prostar XL, Perclose ProGlide, and ProStyle,
and the plug-based MANTA device. However, comprehensive comparative
evidence on these VCDs, particularly single Perclose strategies, is
lacking. <br/>Method(s): A systematic review and network meta-analysis
were conducted according to PRISMA guidelines. We included randomized and
observational studies comparing the safety and efficacy of VCDs for
large-bore femoral access closure in TF-TAVR patients. Primary outcomes
included major vascular complications; secondary outcomes included major
and minor bleeding, minor vascular complications, VCD failure, and
all-cause mortality. Frequentist and Bayesian analyses were performed
using a random-effects model, with additional subgroup analyses of single
Perclose strategies. <br/>Result(s): Thirty-five studies comprising 16,503
patients met inclusion criteria. The single Perclose strategy, with or
without adjunct Angio-Seal or FemoSeal, significantly reduced major
vascular complications compared to dual Perclose (RR: 1.9, 95% CI
[1.2-3.01]), MANTA (RR: 1.89, 95% CI [1.03-3.48]), and Prostar XL (RR:
3.46, 95% CI [1.94-6.18]). Among secondary outcomes, single Perclose also
ranked highest in reducing minor complications and bleeding.
<br/>Conclusion(s): Single Perclose strategies, especially when combined
with Angio-Seal, demonstrated superior safety and efficacy for large-bore
femoral access closure following TF-TAVR. These findings support the need
for further randomized trials to validate single Perclose as a primary
approach in TF-TAVR vascular closure.<br/>Copyright &#xa9; 2025 Wiley
Periodicals LLC.

<103>
Accession Number
647193697
Title
Revascularization strategies for coronary artery aneurysms: A systematic
review.
Source
Cardiovascular revascularization medicine : including molecular
interventions. (no pagination), 2025. Date of Publication: 31 Mar 2025.
Author
Zordok M.; Buda K.G.; Etiwy M.; Basir M.B.; Alaswad K.; Beckmann E.;
Brilakis E.S.; Megaly M.
Institution
(Zordok) Department of Medicine, Catholic Medical Center, Manchester, NH,
United States of America
(Buda) Minneapolis Heart Institute at Abbott Northwestern Hospital, United
States of America; Cardiology Division, Department of Internal Medicine,
Hennepin Healthcare, United States of America
(Etiwy) Department of Medicine, Dartmouth Hitchcock, NH, United States
(Basir, Alaswad) Division of Cardiology, Henry Ford Hospital, Detroit, MI,
United States
(Beckmann, Brilakis) Minneapolis Heart Institute at Abbott Northwestern
Hospital, United States
(Megaly) Department of Cardiology, Ascension St John Medical Center,
United States of America. https://twitter.com/MichaelMegalyMD, Tulsa, OK,
United States

<104>
Accession Number
647179086
Title
Baseline right ventricular-pulmonary artery coupling and outcomes after
transcatheter aortic valve replacement: A systematic review and
meta-analysis.
Source
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
(no pagination), 2025. Date of Publication: 17 Apr 2025.
Author
Theofilis P.; Sakalidis A.; Vlachakis P.K.; Mantzouranis E.; Karakasis P.;
Pamporis K.; Dardas S.; Oikonomou E.; Drakopoulou M.; Dimitriadis K.;
Aggeli K.; Tsioufis K.; Tousoulis D.
Institution
(Theofilis, Sakalidis, Vlachakis, Mantzouranis, Pamporis, Drakopoulou,
Dimitriadis, Aggeli, Tsioufis, Tousoulis) 1(st) Department of Cardiology,
"Hippokration" General Hospital of Athens, Athens, Greece
(Karakasis) 2(nd) Department of Cardiology, Ippokrateio General Hospital
of Thessaloniki, Thessaloniki, Greece
(Dardas) London Health Sciences Center, ON, Canada
(Oikonomou) 3(rd) Department of Cardiology, Sotiria General Hospital,
Athens, Greece

<105>
Accession Number
647181546
Title
Enhanced recovery in cardiac surgery patients with frailty through
comprehensive perioperative nursing interventions: A randomized controlled
trial.
Source
Clinical rehabilitation. (pp 2692155251325618), 2025. Date of
Publication: 21 Apr 2025.
Author
Jin N.; Gu T.; Song S.; Yao J.; Pang X.
Institution
(Jin, Gu, Song, Yao, Pang) Department of Cardiac Surgery, First Hospital
of China Medical University, Shenyang, China
Abstract
ObjectiveTo evaluate the effects of comprehensive perioperative nursing
interventions on postoperative recovery in cardiac surgery patients with
frailty, with a focus on physical activity, nutritional status, and
cognitive function.DesignA prospective, randomized, single-blind,
parallel-group design with a 1:1 allocation ratio.SettingCardiac surgery
department in a tertiary care hospital.ParticipantsThis study included 300
patients with frailty after cardiac surgery. Using a computer-generated
random number table, patients were randomly assigned to the experimental
group (150 patients) and the control group (150 patients). The
intervention group received preoperative psychological counseling,
targeted nutritional support, skincare, and continuous hemodynamic
monitoring; the control group received routine care, including
postoperative vital sign monitoring, basic nutritional support, wound
care, and standard cardiovascular assessments (e.g., heart rate and blood
pressure).Primary outcomesPostoperative recovery was assessed through
improvements in physical activity (Barthel Index), nutritional status
(Mini Nutritional Assessment), cognitive function (Mini-Mental State
Examination), biostatistical data and cardiopulmonary function
indicators.ResultsThe intervention group showed significant improvements:
Barthel Index increased by 20 points (95% CI: 15-25, p < 0.01), Mini
Nutritional Assessment scores by 3 points (95% CI: 1-5, p < 0.05), and
Mini-Mental State Examination scores by 4 points (95% CI: 2-6, p < 0.05).
Hospital stay was reduced by 5 days (95% CI: 3-7, p < 0.01), and the
6-month survival rate was 10% higher (95% CI: 5-15%, p < 0.05) compared to
the control group.ConclusionsComprehensive perioperative nursing
interventions significantly improve postoperative recovery, self-care
ability, nutritional status, cognitive function, and short-term survival
in cardiac surgery patients with frailty.

<106>
Accession Number
647178819
Title
RETRACTION: Risk Factors Associated With Surgical Site Infections in
Patients Undergoing Cardiothoracic Surgery: A Systematic Review and
Meta-Analysis.
Source
International wound journal. 22(4) (pp e70526), 2025. Date of Publication:
01 Apr 2025.
Author
Anonymous
Abstract
RETRACTION: Y. Zhang, S. Tan, S. Chen, and X. Fan, "Risk Factors
Associated With Surgical Site Infections in Patients Undergoing
Cardiothoracic Surgery: A Systematic Review and Meta-Analysis,"
International Wound Journal 21, no. 4 (2024): e14573,
https://doi.org/10.1111/iwj.14573. The above article, published online on
15 December 2023, in Wiley Online Library
(http://onlinelibrary.wiley.com/), has been retracted by agreement between
the journal Editor in Chief, Professor Keith Harding; and John Wiley &
Sons Ltd. Following an investigation by the publisher, all parties have
concluded that this article was accepted solely on the basis of a
compromised peer review process. The editors have therefore decided to
retract the article. The authors did not respond to our notice regarding
the retraction.<br/>Copyright &#xa9; 2025 The Author(s). International
Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons
Ltd.

<107>
Accession Number
647183352
Title
SINGLE VERSUS DUAL ANTIPLATELET THERAPY FOLLOWING PERCUTANEOUS LEFT ATRIAL
APPENDAGE CLOSURE - A SYSTEMATIC REVIEW AND META-ANALYSIS.
Source
Giornale Italiano di Cardiologia. Conference: 43. Congresso Nazionale
della Societa Italiana di Cardiologia Interventistica - GIS. Milano Italy.
23(10 Supplement 1) (pp e48), 2022. Date of Publication: 01 Oct 2022.
Author
Continisio S.; Montonati C.; Angelini F.; Cardaioli F.; Scotti A.;
Sciarretta T.; Zuccarelli V.; Masiero G.; Fabris T.; Fraccaro C.; Napodano
M.; Fovino L.N.; Tarantini G.
Institution
(Continisio, Montonati, Cardaioli, Scotti, Sciarretta, Zuccarelli,
Masiero, Fabris, Fraccaro, Napodano, Fovino, Tarantini) Department of
Cardiac,Thoracic, Vascular Sciences and Public Health, University of
Padua, Italy
(Angelini) Department of Medical Sciences, University of Turin - Citta
della Salute e della Scienza, Italy
(Scotti) Montefiore-Einstein Center for Heart and Vascular Care,
Montefiore Medical Center, United States
Publisher
Il Pensiero Scientifico Editore s.r.l.
Abstract
Background. Atrial fibrillation (AF) is the most important cause of
cardioembolic stroke worldwide and most of stroke-causing clot derives
from the left atrial appendage (LAA). In the last few years, transcatheter
LAA occlusion (LAAO) has become a plausible alternative to oral
anticoagulation therapy (OAT) for AF patients with absolute
contraindications to anticoagulation therapy. Although post-procedure
antiplatelet therapy represents the only possible strategy in this subset,
few data are currently available about the best antiplatelet regimen. The
aim of this study was to assess clinical outcomes among patients treated
with single antiplatelet therapy (SAPT) and dual antiplatelet therapy
(DAPT) after LAAO. Methods. Published studies comparing single versus dual
antiplatelet regimens following LAAO were systematically searched and
screened. The outcomes of interest were ischemic stroke, major bleeding
and device-related thrombus (DRT). Random-effect meta-analysis was
performed comparing outcomes in both groups. The moderator effect of
baseline characteristics on outcomes were evaluated by univariate
metaregression analysis. Results. A total of 14 observational studies with
2931 patients treated with antiplatelet therapy (SAPT, n = 961; DAPT, n =
1970) after LAAO were included. The main indication to perform LAAO in the
overall population was previous bleeding during anticoagulation. In the
overall cohort, mean age was 74.4 +/- 8.6 years, while mean CHA2DS2-VASC
and HAS-BLED scores were 4.3 +/- 1.5 and 3.0 +/- 1.1, respectively. At a
weighted mean follow-up of 10.3 +/- 9.2 months, there were no
significative difference in the occurrence of stroke (RR 1.27; 95% CI 0.53
to 2.03; p=0.60), major bleeding (RR 1.18; 95% CI 0.52 to 2.69; p=0.70)
and DRT (RR 1.30; 95% CI 0.73 to 2.31; p=0.38) comparing SAPT versus DAPT
after LAAO. The occurrence of the composite outcome was also similar
between groups (7.5% vs. 7.1%, respectively; RR 1.16; 95% CI 0.50 to 2.71;
p=0.73). Conclusions. In patients treated with SAPT or DAPT after
percutaneous LAAO there were no differences with regards to stroke, major
bleeding, and DRT.

<108>
Accession Number
647183318
Title
COMPLETE OR INCOMPLETE REVASCULARIZATION AND INCIDENCE OF HEART FAILURE IN
PATIENTS WITH ACUTE CORONARY SYNDROME AND MULTIVESSEL DISEASE. A
SUB-ANALYSIS OF THE CORALYS REGISTRY.
Source
Giornale Italiano di Cardiologia. Conference: 43. Congresso Nazionale
della Societa Italiana di Cardiologia Interventistica - GIS. Milano Italy.
23(10 Supplement 1) (pp e11), 2022. Date of Publication: 01 Oct 2022.
Author
Bruno F.; Marengo G.; De Filippo O.; Wanha W.; Leonardi S.; Rubin S.R.;
Fabris E.; Truffa A.; Huczek Z.; Gaibazzi N.; Ielasi A.; Cortese B.; Gil
I.N.; Ugo F.; Bianco M.; Barbieri L.; Marchini F.; Desperak P.; Montalto
C.; Mancone M.; Morici N.; Scaglione M.; Tuttolomondo D.; Sardella G.;
Gasior M.; Gallone G.; Campo G.; Wojakowski W.; Abu Essi E.; Sinagra G.;
De Ferrari G.M.; D'Ascenzo F.
Institution
(Bruno, Marengo, De Filippo, Gallone, De Ferrari, D'Ascenzo)
Cardiology,Department of Medical Sciences, Citta della Salute e della
Scienza di Torino Hospital, University of Turin, Turin, Italy
(Wanha, Desperak, Gasior, Wojakowski) Department of Cardiology and
Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
(Leonardi, Montalto) Coronary Care Unit, Fondazione IRCCS Policlinico San
Matteo, Italy
(Rubin, Abu Essi) Hospital Universitario Alvaro Cunqueiro, Vigo, Spain
(Fabris, Sinagra) Cardiovascular Department, Azienda Sanitaria
Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy
(Truffa, Scaglione) Division of Cardiology, Ospedale Cardinal G. Massaia,
Asti, Italy
(Huczek) 1st Department of Cardiology, Medical University of Warsaw,
Warszawa, Poland
(Gaibazzi, Tuttolomondo) Cardiology Department, Parma University Hospital,
Parma, Italy
(Ielasi) UO Cardiologia Clinica ed Interventistica, Istituto Clinico
Sant'Ambrogio, Milan, Italy
(Cortese) Cardiovascular Research Team, San Carlo Clinic, Milano, Italy
(Gil) Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Spain
(Ugo) Department of Cardiology, Sant'Andrea Hospital, Vercelli, Italy
(Bianco) Division of Cardiology, San Luigi Gonzaga University Hospital,
Orbassano, Turin, Italy
(Barbieri) Division of Cardiology, Fondazione IRCCS Ca' Granda Ospedale
Maggiore Policlinico, Milan; University of Milan, Milan, Italy
(Marchini, Campo) Cardiovascular Institute, Azienda Ospedaliero
Universitaria di Ferrara, Cona, Italy
(Mancone, Sardella) Dipartimento di Scienze Cliniche Internistiche,
Anestesiologiche e Cardiovascolari, Sapienza Universita di Roma, Roma,
Italy
(Morici) IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS,
Milan, Italy
Publisher
Il Pensiero Scientifico Editore s.r.l.
Abstract
Introduction. Protective role of complete revascularization towards
development of HF after ACS remains to be elucidated. The main aim of this
subanalysis of the CORALYS registry is to evaluate the impact of CR on
adverse outcome at follow-up, including heart failure hospitalization in
patients with ACS and multivessel coronary artery disease undergoing PCI.
Methods. Consecutive ACS patients with multivessel disease from the
CORALYS registry were analyzed. Incidence of first hospitalization for HF
or CV death was the primary endpoint, while the single component and
all-cause death were the secondary ones. Patients were stratified
according to completeness of coronary revascularization. Results. Out of
14699 patients in the CORALYS registry, 5054 presented with multivessel
disease. 1473 (29.2%) underwent CR, while 3581 (70.8%) did not. Over 5
years follow-up, CR was associated with a reduced incidence of the primary
endpoint of HF hospitalization or CV death (adjusted HR 0.66, 95% CI
0.51-0.85), first HF hospitalization (adjusted HR 0.67, 95% CI 0.49-0.90)
along with all-cause death and CV death alone (adjusted HR 0.74, 95% CI
0.56-0.97 for all-cause death; and adjusted HR 0.56, 95% CI 0.38-0.84 for
CV death). The results were consistent also in the propensity-score
matching population and in IPTW analysis. The benefit of CR was consistent
across ACS presentations (HR 0.59, 95% CI 0.39-0.89 for STEMI and HR 0.71,
95% CI 0.50-0.99 for NSTE-ACS) and in patients with LVEF >40% (HR 0.52;
95% CI 0.37- 0.72), while no benefit was observed in patients with LVEF
<=40% (HR 0.77; 95% CI 0.37-1.10, p for interaction 0.04). Conclusions. In
patients with ACS (both STEMI and NSTE-ACS) and multivessel disease, CR
reduced the risk of the primary endpoint of first hospitalization for HF
and CV death, as well as first HF hospitalization, CV and overall death.
When feasible, CR should be performed in all patients with ACS to reduce
the incidence of HF and death at follow-up.

<109>
Accession Number
647183247
Title
AORTIC VALVE CALCIFICATION PATTERNS ON CT SCAN AND HEMODYNAMIC PERFORMANCE
OF THE SELF-EXPANDING INTRAANNULAR TRANSCATHETER PORTICO PROSTHESIS VALVE.
Source
Giornale Italiano di Cardiologia. Conference: 43. Congresso Nazionale
della Societa Italiana di Cardiologia Interventistica - GIS. Milano Italy.
23(10 Supplement 1) (pp e55), 2022. Date of Publication: 01 Oct 2022.
Author
Viscusi M.M.; Nusca A.; Circhetta S.; Nobile E.; Bernardini F.; De
Filippis A.; Paolucci L.; Mangiacapra F.; Ricottini E.; Melfi R.; Rinaldi
R.; Gallo P.; Cocco N.; Grigioni F.; Ussia G.P.
Institution
(Viscusi, Nusca, Circhetta, Nobile, Bernardini, De Filippis, Paolucci,
Mangiacapra, Ricottini, Melfi, Rinaldi, Gallo, Cocco, Grigioni, Ussia)
Campus Bio-Medico, Roma, Italy
Publisher
Il Pensiero Scientifico Editore s.r.l.
Abstract
Introduction. The burden of native aortic valve calcification (AVC)
represents a negative prognostic factor in patients undergoing
transcatheter aortic valve implantation (TAVI). Recent randomized clinical
trials comparing commercially available self-expanding (SE) supraannular
and balloon-expandable (BE) devices with second-generation SE
intra-annular devices demonstrated the clinical non-inferiority of the
latter in terms of procedural success. However, no current data are
available in vivo regarding the potential impact of the above-mentioned
calcification patterns on SE intra-annular device performance and clinical
outcomes. Purpose. To evaluate the potential impact of different AVC
patterns on SE intra-annular device performance in a consecutive cohort of
patients undergoing TAVI. Methods. This is an observational,
non-randomized, prospective, singlecenter study preliminarily enrolling 53
consecutive patients who underwent TAVI with a SE intra-annular device
(Portico - Abbott Structural Heart, St Paul, MN, USA) between 2019 and
2022 at our department. All patients underwent transthoracic
echocardiography, contrast-enhanced multidetector row computed tomography
(MDCT) with volumetric calcium score and coronary angiography before TAVI.
Patients with bicuspid aortic valve and previous surgical aortic valve
replacement eligible for valve-in-valve TAVI were excluded. AVC and left
ventricle outflow tract (LVOT) calcification (up to 15 mm below the basal
annular plane) were quantified in the contrast images by using a
Hounsfield unit threshold of 850. Results. Patients undergoing pacemaker
implantation post-TAVI (19% of the overall study population) because of
the occurrence of third degree atrio-ventricular block or advanced
atrio-ventricular block (implantation depth described as
ventricular/aortic stent extension ratio: 27.77+/-6.9%) had higher
calcification extension on all aortic cusps compared with those that did
not show this complication (overall AVA calcium score 270.6+/-409.6 vs
158.1+/-137.1, p=0.146; p significance of 0.048, 0.181 and 0.346 for left
cusp- LCC, right cusp - RCC- and non-coronary cusp-NCC, respectively).
Severe LVOT calcification was also associated with a higher incidence of
AV conduction abnormalities (37.9+/-44.5 vs 13.4+/-39.0 of patients
without AV defects, p=0.045). Moreover, post-procedural moderate/severe
aortic regurgitation occurred more frequently in patients with LCC
calcification (183.7+/-87.0 vs 64.2+/-99.6, p=0.018) and RCC calcification
(188.7+/-149.5 vs 58.7+/-120.8, p=0.019) rather than those with NCC or
LVOT calcification. Conclusions. Preliminary results of our observational
registry highlight the potential impact of AVC patterns on the occurrence
of aortic regurgitation and pacemaker implantation after a SE
intra-annular device implantation. A larger sample size is needed to
better understand the impact of calcium patterns on each single outcome in
order to identify patients at higher risk and to early manage these
complications, improving long-term outcomes.

<110>
Accession Number
647196669
Title
ELECTRO ACUPUNCTURE EXPEDITES RESPIRATORY WEANING FOLLOWING CARDIAC
SURGERY.
Source
Shock. Conference: 40th Annual Conference on Shock. Fort Lauderdale, FL
United States. 47(Supplement 1) (pp 73), 2017. Date of Publication: 01 Jun
2017.
Author
Asmussen S.; Maybauer D.M.; Przkora R.; Sanfilippo F.; Jennings K.; Fraser
J.F.; Adamzik M.; Maybauer M.O.
Institution
(Asmussen, Adamzik) Dept. of Anaesthesiology and Intensive Care,
University Hospital Knappschaft, Bochum, Germany
(Asmussen, Fraser, Maybauer) Critical Care Research Group, University of
Queensland and the Prince Charles Hospital, Brisbane, Australia
(Asmussen, Maybauer, Jennings, Maybauer) Depts. of Anesthesiology and
Epidemiology and Biostatistics, University of Texas Medical Branch,
Galveston, TX, United States
(Przkora) Dept. of Anesthesiology, University of Florida, Gainesville, FL,
United States
(Sanfilippo) Department of Cardiothoracic Anaesthesia and Critical Care,
St George's Hospital, London, United Kingdom
(Maybauer) Department of Anaesthesiology and Intensive Care, Philipps
University, Marburg, Germany
(Maybauer) Cardiothoracic Anaesthesia and Intensive Care, Manchester Royal
Infirmary, University of Manchester, Manchester, United Kingdom
Publisher
Lippincott Williams and Wilkins
Abstract
Objective: Acupuncture treatment is well known in China for over 2,500
years and is used worldwide as analgesic treatment in patients with acute
and chronic pain. Previous studies showed that acupuncture might be
beneficial as a supplement to general anesthesia (GA). Aim of this study
was to perform a systematic review and meta- analysis to assess the level
of evidence for the clinical use of electro acupuncture (EA) in addition
to GA in regard of inflammatory response in patients undergoing open-heart
surgery. <br/>Method(s): The systematic literature search in Medline,
Cochrane Library, and Web of Science yielded a total of 476 citations,
published between 1965 and November 30th, 2016. No systematic review or
meta-analyses on this topic matched our search criteria. Each article of
any language was assessed and rated for the methodological quality of the
studies, using the recommendation of the Oxford Centre for Evidence Based
Medicine. <br/>Result(s): Five prospective randomized controlled clinical
trials of evidence level 2 with a total of 251 patients matched our search
criteria. The total ventilation time in cardiac surgery patients was
significantly shorter in the group that received EA+GA vs. GA alone: EA+GA
125 patients, GA (Control) 126 patients, Standardized difference in means
0.381, SE 0.128, Variance 0.016, lower limit 0.130, upper limit 0.631,
Z-Value 2.979, P-Value 0.003. Three of these five prospective randomized
controlled clinical trials analysed additionally the length of stay on ICU
in hrs and showed concurring results. The time in the group that received
EA+GA was significantly reducedvs. GA alone: EA+GA 89 patients, Control 91
patients, Standardized difference in means 0.384, SE 0.153, Variance
0.024, lower limit 0.084, upper limit 0.685, Z-Value 2.506, P-Value 0.012.
Whereas the total length of hospital stay was investigated in two studies,
it showed only a tendency towards a quicker discharge in EA+GA vs GA, but
does not reach significant levels. (P-Value 0.176). <br/>Conclusion(s): We
conclude that electro-acupuncture in combination with general anesthesia
can be beneficial in regard of reducing ventilation time after cardiac
surgery and leads to an earlier discharge from ICU. Further prospective
investigations are needed to study these effects in regard of length of
hospital stay and potential additional economical benefits.

<111>
Accession Number
647173671
Title
Characteristics and Outcomes of Older Patients Undergoing Protected
Percutaneous Coronary Intervention With Impella.
Source
Journal of the American Heart Association. (pp e038509), 2025. Date of
Publication: 16 Apr 2025.
Author
Jakob P.; Lansky A.J.; Basir M.B.; Schonning M.J.; Falah B.; Zhou Z.;
Batchelor W.B.; Abu-Much A.; Grines C.L.; O'Neill W.W.; Stahli B.E.
Institution
(Jakob, Stahli) Department of Cardiology, University Heart Center,
University Hospital Zurich and the Center for Translational and
Experimental Cardiology (CTEC) University of Zurich Zurich Switzerland,
Switzerland
(Lansky) Department of Cardiology Yale University School of Medicine New
Haven CT USA
(Basir, O'Neill) Center for Structural Heart Disease, Division of
Cardiology Henry Ford Health System Detroit MI USA
(Schonning, Falah, Zhou, Abu-Much) Clinical Trials Center Cardiovascular
Research Foundation New York NY USA
(Batchelor) Inova Center of Outcomes Research Inova Heart and Vascular
Institute Falls Church VA USA
(Grines) Department of Cardiology Northside Hospital Cardiovascular
Institute Atlanta GA USA
Abstract
BACKGROUND: In patients undergoing high-risk percutaneous coronary
intervention, Impella has become an important adjunctive tool to support
revascularization. The impact of age on the outcomes of patients
undergoing high-risk percutaneous coronary intervention is limited. The
aim of this study is to describe the characteristics and outcomes of
patients >=75 years of age undergoing Impella-supported high-risk
percutaneous coronary intervention. METHODS AND RESULTS: Baseline
characteristics and outcomes of patients >=75 years of age versus those of
patients <75 years of age in patients enrolled in the cVAD PROTECT III
(Catheter-Based Ventricular Assist Device Prospective, Multi-Center,
Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus
Intra Aortic Balloon Pump in Patients Undergoing Non Emergent High Risk
Percutaneous Coronary Intervention) study (NCT04136392). Major adverse
cardiovascular and cerebral events (composite of all-cause death, nonfatal
myocardial infarction, stroke/transient ischemic attack, and repeat
revascularization) were assessed at 30 and 90 days and all-cause death at
1 year. Out of 1237 patients, 493 (39.9%) patients were >=75 years of age.
Patients >=75 years of age had less diabetes and prior myocardial
infarction, more hypertension and dyslipidemia, worse renal function, more
severe valvular heart disease, but higher left ventricular ejection
fraction (P<0.05 for all comparisons). Baseline Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery scores
were similar between groups. Older patients underwent more left main
percutaneous coronary intervention (58% versus 39%; P<0.0001), atherectomy
(32% versus 22%; P<0.0001), and femoral access (87% versus 79%, P=0.0003)
as compared with younger patients. In-hospital vascular complications did
not differ, but rates of respiratory failure, pericardial tamponade, and
cardiogenic shock were higher in older patients. Rates of all-cause death
and major adverse cardiovascular and cerebral events did not differ
between groups at 30 and 90 days. Rates of all-cause death at 1 year were
higher in patients >=75 years (adjusted hazard ratio, 1.99 [95% CI,
1.24-3.18], P=0.004). <br/>CONCLUSION(S): Impella-supported high-risk
percutaneous coronary intervention in older patients is feasible with an
acceptable safety profile. However, age >=75 years remained a
statistically significant predictor for all-cause death at 1 year.
REGISTRATION: URL: https://clinicaltrials.gov; Unique Identifier:
NCT04136392.

<112>
Accession Number
2036204960
Title
The Impact of Olfactory Dysfunction on Post-Operative Cognitive
Dysfunction and Delirium: A Systematic Review.
Source
Journal of Cellular and Molecular Anesthesia. 10(1) (no pagination), 2025.
Article Number: e158956. Date of Publication: 01 Mar 2025.
Author
Amirdosara M.; Hajiesmaeili M.; Goharani R.; Mokhtari M.; Vafaei A.; Zangi
M.
Institution
(Amirdosara, Hajiesmaeili, Goharani, Mokhtari, Vafaei, Zangi) Critical
Care Quality Improvement Research Center, Loghman Hakim Hospital, Shahid
Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of
Publisher
Brieflands
Abstract
Context: Post-operative cognitive dysfunction (POCD) and postoperative
delirium (POD) are common complications following major surgery,
particularly in older adults. Emerging evidence suggests that olfactory
dysfunction may significantly predispose individuals to these cognitive
disturbances, potentially serving as an early marker for post-surgical
cognitive decline. However, the relationship between olfactory impairment
and post-operative cognitive outcomes remains underexplored.
<br/>Objective(s): The present systematic review aims to synthesize
current evidence on the impact of olfactory dysfunction on POCD and POD.
<br/>Evidence Acquisition: The review adhered to the preferred reporting
items for systematic reviews and meta-analyses (PRISMA) guidelines. A
comprehensive search of PubMed, Scopus, and the Web of Science (WOS) was
conducted from inception until December 2024. Studies on patients
undergoing major operations that involved verified olfactory and cognitive
examinations and yielded quantitative data were included. Exclusion
criteria encompassed research focusing on non-surgical groups,
non-original studies, and studies lacking postoperative cognitive
assessments. <br/>Result(s): From an initial 389 articles, seven studies
met the inclusion criteria, comprising 1,038 participants. These studies,
conducted between 2004 and 2022, included patients undergoing major
surgeries such as cardiac, abdominal, and neurosurgery. Various olfactory
tests [e.g., sniffin' sticks, brief smell identification test (BSIT)] and
cognitive assessments [e.g., mini-mental state examination (MMSE), clock
drawing test (CDT)] were used. The findings across studies were
heterogeneous but suggested a potential link between olfactory dysfunction
and both POCD and POD. Specifically, several studies indicated that
impaired olfactory function was associated with an increased risk of
delirium (OR = 1.90; 95% CI = 1.17-3.09) and cognitive decline
post-surgery. Some studies identified olfactory impairment as an
independent predictor of worse cognitive outcomes, particularly among
frail or elderly populations. <br/>Conclusion(s): The evidence reviewed
supports the hypothesis that olfactory dysfunction may be a preoperative
marker for POCD, particularly delirium and delayed neurocognitive recovery
(dNCR). Based on the obtained results, olfactory testing could be a useful
preoperative screening tool, especially in populations at risk for
cognitive decline.<br/>Copyright &#xa9; 2025, Amirdosara et al.

<113>
Accession Number
2036204959
Title
Effect of Dexmedetomidine on Stress-Induced Changes in Hemodynamic and
Left Ventricular Function in Coronary Artery Bypass Grafting Surgery: A
Randomized Controlled Trial.
Source
Journal of Cellular and Molecular Anesthesia. 10(1) (no pagination), 2025.
Article Number: e160218. Date of Publication: 01 Mar 2025.
Author
Hussien R.M.; El Shafei M.N.; Ahmed M.M.; Abdelmoneim W.; Ghoneim M.A.-F.;
Tolba M.A.A.
Institution
(Hussien, El Shafei, Ahmed, Abdelmoneim, Tolba) Department of Anesthesia,
Ain Shams University, Cairo, Egypt
(Ghoneim) Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams
University, Cairo, Egypt
Publisher
Brieflands
Abstract
Background: Dexmedetomidine is a highly selective central adrenoceptor
agonist with a short half-life, making it an ideal intravenous drug for
blunting the stress response. <br/>Objective(s): The present study aimed
to determine the effect of dexmedetomidine on left ventricular function
and its ability to attenuate the hemodynamic response to skin incision,
sternotomy, and the postoperative period in coronary artery bypass graft
(CABG) surgery. <br/>Method(s): This randomized controlled clinical trial
included 64 patients of both sexes who underwent elective CABG surgery.
They were randomly assigned to two equal groups: Group D received a
continuous infusion of dexmedetomidine (0.5 microg/kg/h) one hour before
the induction of anesthesia until immediately before transfer to the
intensive care unit (ICU), while group C received a continuous infusion of
0.9% saline at a rate of 10 mL/h. <br/>Result(s): The heart rate (HR) and
mean arterial blood pressure in group D exhibited significant differences
starting 3 minutes following skin incision and continuing for 4 hours (P <
0.05). Although they changed postoperatively, the pre-and post-bypass
ejection fraction (EF) did not change significantly between the two
groups. The need for inotropic support was significantly higher in group
D. Additionally, the incidence of new-onset atrial fibrillation was
significantly lower in group D. Conversely, both groups showed no
significant differences in serum lactate levels, the incidence of bleeding
and reopening, pacemaker usage, mechanical ventilation, ventricular
fibrillation, and bradycardia. <br/>Conclusion(s): Using a 0.5 microg/kg/h
dexmedetomidine infusion as pretreatment is a secure and effective method
for decreasing stress-induced reactions and improving hemodynamic
stability, without any noticeable adverse effects.<br/>Copyright &#xa9;
2025, Maher Hussien et al.

<114>
Accession Number
2038509465
Title
Outcomes Evaluated By Transitional Pain Services: A Systematic Review.
Source
Journal of Pain. Conference: The Journal of Pain Abstracts of the 2025
USASP Annual Scientific Meeting. Chicago United States. 29(Supplement) (no
pagination), 2025. Article Number: 104823. Date of Publication: 01 Apr
2025.
Author
Sideris A.; Colamarino A.; Lok C.; Chan W.; Cho H.Y.; Jivanelli B.; Rim
F.; Manne J.; Doan L.
Institution
(Sideris, Colamarino, Lok, Chan, Cho, Jivanelli, Rim, Manne, Doan)
Hospital for Special Surgery, United States
Publisher
Elsevier B.V.
Abstract
Transitional Pain Services offer multidisciplinary programs that
incorporate preventative strategies and offer personalized, multimodal
treatments to ensure adequate postoperative pain control during
hospitalization, and continuity of care in surgical patients who are at
increased risk for experiencing opioid-related adverse events and
developing chronic post-surgical pain. To better understand how formal
Transitional Pain Services evaluate the effectiveness of their programs,
we conducted a systematic review of studies that quantified the impact of
their interventions in non-cancer surgical patients, and described
components of the programs, patient populations, and outcomes assessed. A
total of 1,373 abstracts from papers published through 2023 were screened,
and 20 manuscripts ultimately reviewed for data extraction. Differences
exist in the care delivery models and targeted outcomes. Most published
studies (18/20) were retrospective analyses of existing data between 2014
and 2022 from hospitals located in urban settings in five different
countries, primarily included patients who underwent elective surgeries
including orthopedic, cardiothoracic, obstetric and gynecological
procedures, included opioid-naive and opioid-experienced patients, and
compared patients in Transitional Pain Service programs against either
historical controls prior to program implementation or matched patients
who did not utilize the services. Outcomes assessed included opioids at
discharge in morphine milligram equivalents (n=6), and post-discharge
opioid use at 60 days (n=2), 3 (n=6), 6 (n=4), and 12 (n=2) months.
Patient- reported pain outcomes were assessed in 5 studies, and included
either pain intensity measures, pain interference, or pain
catastrophizing. Less frequently reported outcomes were postoperative
complications, quality of recovery and 30-day readmissions.
<br/>Funding(s): CV Starr Foundation.<br/>Copyright &#xa9; 2025

<115>
Accession Number
2034198882
Title
Comparison of the analgesic effects of liposomal bupivacaine in
ultrasound-guided erector spinae plane block and surgeon-administered
intercostal nerve block following video-assisted thoracoscopic lung
resection: protocol for a randomized controlled trial.
Source
Frontiers in Medicine. 12 (no pagination), 2025. Article Number: 1564738.
Date of Publication: 2025.
Author
Yan J.; Feng Y.-S.; Zheng X.-Y.; Zhang Y.; Liu H.-Y.; Yang Y.-F.; Wan
J.-J.; Peng K.; Liu H.; Ji F.-H.; Shan X.-S.
Institution
(Yan, Zheng, Zhang, Liu, Yang, Wan, Peng, Ji, Shan) Department of
Anesthesiology, First Affiliated Hospital of Soochow University, Jiangsu,
Suzhou, China
(Yan, Zheng, Zhang, Liu, Yang, Wan, Peng, Ji, Shan) Institute of
Anesthesiology, Soochow University, Jiangsu, Suzhou, China
(Feng) Suzhou Medical College, Soochow University, Jiangsu, Suzhou, China
(Liu) Ambulatory Surgery Centre, First Affiliated Hospital of Soochow
University, Jiangsu, Suzhou, China
(Liu) Department of Anesthesiology and Pain Medicine, University of
California, Davis, Sacramento, CA, United States
Publisher
Frontiers Media SA
Abstract
Background: The analgesic efficacy of liposomal bupivacaine (LB) for
ultrasound-guided erector spinae plane block (ESPB) and thoracoscopic
intercostal nerve block (ICNB) in thoracic surgery remains uncertain. This
study aims to evaluate the analgesic efficacy of
anesthesiologist-performed ESPB using LB versus surgeon-administrated ICNB
with LB in patients undergoing video-assisted thoracoscopic surgery (VATS)
lung resection. <br/>Method(s): This single-center, prospective,
randomized, double-blinded trial will include 120 adult patients scheduled
for VATS lung resection. Patients will be randomly assigned 1:1 to the
ESPB group or ICNB group. Each patient will receive either an ESPB or ICNB
at the end of the surgery, along with patients-controlled intravenous
analgesia (PCIA) as part of a postoperative multimodal analgesia. The
primary outcome is the average numeric rating scale (NRS) pain scores at
rest over 72 h postoperatively (average of three 24-h time points: 24, 48,
and 72 h). Secondary outcomes include NRS pain scores at rest and during
activity at 24, 48, and 72 h postoperatively, Quality of Recovery 15
scores at 24, 48, and 72 h postoperatively, time to first press on the
PCIA device, total opioid consumption within 72 h postoperatively, time to
initiate independent bedside mobilization, length of postoperative
hospital stay, and the incidence of chronic pain (defined as an NRS score
>= 1) at 3 months post-surgery. Analyses will be performed in the modified
intention-to-treat population. <br/>Discussion(s): We hypothesize that
anesthesiologist-performed ultrasound-guided ESPB with liposomal
bupivacaine will result in lower average numeric rating scale pain scores
over 72 h compared to surgeon-administrated thoracoscopic ICNB in patients
undergoing VATS lung resection. The findings of this study aim to provide
evidence to optimize postoperative analgesic regimens for patients
undergoing VATS lung resection. Clinical trial registration:
http://www.chictr.org.cn, identifier ChiCTR2400092927.<br/>Copyright
&#xa9; 2025 Yan, Feng, Zheng, Zhang, Liu, Yang, Wan, Peng, Liu, Ji and
Shan.

<116>
Accession Number
2038495686
Title
Effectiveness of intravenous administration of a combination of sufentanil
and esketamine on post-cardiac surgery pain management and depression: a
randomized controlled trial.
Source
Cardiovascular Diagnosis and Therapy. 15(2) (pp 291-301), 2025. Date of
Publication: 30 Apr 2025.
Author
Xu S.; Liang T.; Xu W.
Institution
(Xu, Xu) Center for Rehabilitation Medicine Center, Department of
Anesthesiology, Zhejiang Provincial People's Hospital, Affiliated People's
Hospital, Hangzhou Medical College, Hangzhou, China
(Xu) Second Clinical Medical School, Zhejiang Chinese Medical University,
Hangzhou, China
(Liang) Emergency and Critical Care Center, Intensive Care Unit, Zhejiang
Provincial People's Hospital, Affiliated People's Hospital, Hangzhou
Medical College, Hangzhou, China
Publisher
AME Publishing Company
Abstract
Background: Cardiac surgery often results in significant postoperative
pain, which can lead to complications and prolonged recovery. Pain and
depression are closely linked, with effective pain management potentially
reducing the risk of depression. Combining sufentanil, an opioid, with
esketamine, a medication with both analgesic and antidepressant effects,
may improve pain control and mood in postoperative patients. While
promising in other surgeries, their effects in cardiac surgery remain
unclear. This study explores how sufentanil and esketamine work together
to manage pain and reduce depression after cardiac surgery.
<br/>Method(s): A randomized controlled clinical trial was conducted from
January 2021 to December 2023, involving 104 patients who underwent
cardiac surgery. Patients [aged 61-64 years, body mass index (BMI) <30
kg/m², American Society of Anesthesiologists (ASA) I-II,
STOP-BANG score <3] were randomly assigned to a control group (n=52)
receiving 2.5 mug/kg sufentanil or an experimental group (n=52) receiving
2.0 mug/kg sufentanil with 2 mg/kg esketamine via a central venous
catheter for 48 h postoperatively. Exclusion criteria included allergies
to fentanyl or etomidate, central nervous system diseases, recent opioid
use, liver/kidney failure, or severe respiratory conditions. Outcome
measures included patient-controlled intravenous analgesia (PCIA) pump
usage, pain scores, clinical indicators, depressive symptoms, adverse
events, and satisfaction levels. <br/>Result(s): The experimental group
had significantly fewer PCIA pump button presses (2.41+/-0.72) than the
control group (6.20+/-1.31) (P<0.05). Visual analog pain scores were lower
in the experimental group at multiple postoperative time points (P<0.05).
Hamilton Depression Rating Scale (HAMD) scores were significantly lower in
the experimental group (7.52+/-4.24) compared to the control group
(13.84+/-2.76) (P<0.05), as were Hamilton Anxiety Rating Scale (HAMA)
scores (8.84+/-2.13 vs. 12.64+/-3.25, P<0.05). Heart rate and mean
arterial pressure were higher at postoperative time points T2, T3, and T4
in the experimental group (P<0.05), but no difference was observed at T1
(P>0.05) (T1 =4 h, T2 =8 h, T3 =24 h, T4 =48 h post-surgery). Oxygen
saturation showed no significant difference between groups (P>0.05).
Adverse reactions occurred in 13.46% of the experimental group and 19.23%
of the control group, with no statistically significant difference
(P>0.05). Patient and surgeon satisfaction scores were uniformly high on a
five-point scale (both groups had median =5). <br/>Conclusion(s): The
combined administration of sufentanil and esketamine effectively managed
pain and significantly reduced depressive symptoms in post-cardiac surgery
patients. The experimental group demonstrated reduced PCIA usage and
improved clinical indicators. These findings provide valuable insights for
enhancing postoperative recovery and addressing both pain management and
psychological well-being.<br/>Copyright &#xa9; AME Publishing Company.

<117>
Accession Number
2038499255
Title
Efficacy of enhanced recovery programmes for cardiac surgery: a systematic
review and meta-analysis.
Source
British Journal of Anaesthesia. (no pagination), 2025. Date of
Publication: 2025.
Author
Hoogma D.F.; Meeusen I.; Coppens S.; Verbrugghe P.; van den Eynde J.;
Engelman D.T.; Grant M.C.; Stoppe C.; Rex S.
Institution
(Hoogma, Coppens, Rex) Department of Anesthesiology, University Hospitals
Leuven, KU Leuven, Leuven, Belgium
(Hoogma, Coppens, Verbrugghe, van den Eynde, Rex) Biomedical Sciences
Group, Department of Cardiovascular Sciences, University of Leuven, KU
Leuven, Leuven, Belgium
(Meeusen) Biomedical Sciences, University of Leuven, KU Leuven, Leuven,
Belgium
(Verbrugghe) Department of Cardiac Surgery, University Hospitals Leuven,
KU Leuven, Leuven, Belgium
(Engelman) Heart and Vascular Program, Baystate Medical Center,
Springfield, MA, United States
(Grant) Department of Anesthesiology and Critical Care Medicine, Johns
Hopkins University School of Medicine, Baltimore, MD, United States
(Stoppe) Department of Anaesthesiology, Intensive Care, Emergency and Pain
Medicine, University Hospital Wurzburg, Wurzburg, Germany
(Stoppe) Department of Cardiac Anesthesiology and Intensive Care Medicine,
Charite Berlin, Berlin, Germany
Publisher
Elsevier Ltd
Abstract
Background: The terms fast-track (FT) and enhanced recovery after surgery
(ERAS) are often mistakenly used interchangeably. Fast-track cardiac
anaesthesia focuses on perioperative strategies, whereas ERAS (or enhanced
recovery programme [ERP]) encompasses a wider range of strategies designed
to enhance overall recovery. Evidence is needed to demonstrate the
additive value of ERP above FT in cardiac surgery. We conducted a
meta-analysis to investigate the comparative efficacy of ERP and FT
programmes in cardiac surgery. <br/>Method(s): We systematically searched
PubMed, Embase, and Web of Science for randomised trials and prospective
observational trials investigating ERP or FT programmes in cardiac surgery
(up to November 16, 2024). Following PRISMA guidelines, two reviewers
independently selected studies, extracted data, and assessed risk of bias.
Data were pooled using a random-effects model. The primary efficacy
outcome was hospital length of stay (LOS). <br/>Result(s): A total of 6368
articles were identified, of which 18 studies, with 2625 patients, were
included. Compared with control, a significant reduction in hospital LOS
(mean difference [95% confidence interval (CI)] -1.40 days [-2.19 to
-0.61], P=0.001), ICU LOS (-13.22 h [-21.75 to -4.68], P=0.006), and
ventilation time (-4.68 h [-7.85 to -1.52], P=0.008) was identified when
ERP or FT programmes were implemented. ERP demonstrated an additive value
above FT for hospital LOS (2.11 days [-3.52 to 0.71] vs -0.30 days [-0.88
to 0.27], respectively; P=0.003). <br/>Conclusion(s): In cardiac surgery,
ERP can reduce LOS in the ICU and hospital and ventilatory time. Moreover,
it is suggested that ERPs, including preoperative, intraoperative, and
postoperative interventions, are preferred above only intraoperative FT
strategies. Systematic review protocol: PROSPERO
(CRD42022382409).<br/>Copyright &#xa9; 2025 British Journal of Anaesthesia

<118>
Accession Number
2038500476
Title
Expanding Transcatheter Aortic Valve Replacement Use in Younger Patients
and Bicuspid Valves: Risks, Evidence Gaps, and Regulatory Action.
Source
Annals of Thoracic Surgery. (no pagination), 2025. Date of Publication:
2025.
Author
Miller D.C.
Institution
(Miller) Department of Cardiothoracic Surgery, Falk Cardiovascular
Research Center, Stanford University Medical School, Stanford, California,
United States
Publisher
Elsevier Inc.
Abstract
This expert review examines the expanding use of transcatheter aortic
valve replacement (TAVR) in younger patients with bicuspid aortic valves
(BAV), highlighting midterm outcomes, including elevated mortality,
stroke, and pacemaker dependency, compared with surgical aortic valve
replacement. The untested and unproven long-term effectiveness and
durability of TAVR in patients aged <70 years and the growing use of
"valve-in-valve" for surgical aortic valve replacement bioprosthetic
degeneration and TAVR failure are also highlighted. Summarizing recent
observational studies, registry data, and the limited randomized evidence
available, the author calls for new rigorous, long-term randomized
controlled trials before broader adoption of TAVR and valve-in-valve TAVR
in these populations, and urges the United States Food and Drug
Administration and Centers for Medicare and Medicaid Services to align
policy with evidence challenging the erosion of guideline-directed care
driven by market forces.<br/>Copyright &#xa9; 2025 The Society of Thoracic
Surgeons

<119>
Accession Number
2038495796
Title
Applications of multi-modality imaging in the diagnosis of infective
endocarditis: a real-life case based contemporary narrative review.
Source
Cardiovascular Diagnosis and Therapy. 15(2) (pp 465-479), 2025. Date of
Publication: 30 Apr 2025.
Author
Haouzi A.; Khayata M.; Jaber W.A.; Xu B.
Institution
(Haouzi, Khayata) Robert and Suzanne Tomsich Department of Cardiovascular
Medicine, Sydell and Arnold Family Heart, Vascular, and Thoracic
Institute, Cleveland Clinic, Cleveland, OH, United States
(Jaber, Xu) Section of Cardiovascular Imaging, Robert and Suzanne Tomsich
Department of Cardiovascular Medicine, Sydell and Arnold Family Heart,
Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH, United
States
Publisher
AME Publishing Company
Abstract
Background and Objective: Recent major international society guidelines
have highlighted the utility of multi-modality imaging in the evaluation
of infective endocarditis (IE). This article aims to discuss the
contemporary applications of multimodality imaging in IE through real-life
cases, demonstrating how emerging imaging modalities, including cardiac
computed tomography (CCT) and nuclear imaging techniques can be used.
<br/>Method(s): A literature search of the PubMed database was performed
between Jan 01, 2024 and Oct 01, 2024. Relevant articles on the subjects
of "infective endocarditis" and "multi-modality imaging" were used in our
review. Four clinical cases from the Cleveland Clinic Foundation were
incorporated to supplement this literature review with real-world
examples. Key Content and Findings: This literature review encompasses
international cardiology guidelines, as well as investigational studies,
meta-analyses, and dedicated reviews highlighting the specific roles,
strengths, and weaknesses of different imaging modalities in the
evaluation of IE, including transthoracic and transesophageal
echocardiography (TEE), CCT, ¹⁸F-fluorodeoxyglucose positron
emission tomography (¹⁸F-FDG PET), and white blood cell
single-photon emission computed tomography (WBC SPECT). This review
demonstrates the emerging role for these multi-modality imaging tools in
light of an increasingly complex patient population with growing numbers
of prosthetic valves and devices. <br/>Conclusion(s): The current
literature and guidelines are discussed with reference to complex clinical
cases, with the aim of illustrating the relative advantages and
disadvantages, and appropriate utility of multimodality cardiac imaging in
IE.<br/>Copyright &#xa9; AME Publishing Company.

<120>
Accession Number
2038497820
Title
Effect of PCSK9 inhibitor usage on coronary endothelial dysfunction in
patients with hypercholesterolemia after coronary stenting: The CuVIC-2
trial.
Source
Journal of Cardiology. (no pagination), 2025. Date of Publication: 2025.
Author
Akiyama Y.; Katsuki S.; Koga Y.; Yamamoto M.; Hironaga K.; Suematsu N.;
Miyata K.; Mukai Y.; Inoue S.; Nishi J.-I.; Tashiro H.; Nakano Y.;
Funakoshi K.; Tagawa K.; Ichi I.; Tsutsui H.; Abe K.; Matoba T.
Institution
(Akiyama, Koga) Department of Cardiovascular Medicine, Oita Prefectural
Hospital, Oita, Japan
(Akiyama, Katsuki, Nakano, Abe, Matoba) Department of Cardiovascular
Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka,
Japan
(Yamamoto) Department of Cardiovascular Medicine, Harasanshin Hospital,
Fukuoka, Japan
(Hironaga) Department of Cardiovascular Medicine, Fukuoka City Hospital,
Fukuoka, Japan
(Suematsu) Department of Cardiovascular Medicine, Saiseikai Fukuoka
General Hospital, Fukuoka, Japan
(Miyata) Department of Cardiovascular Medicine, Japan Community Health
Care Organization, Kyushu Hospital, Fukuoka, Japan
(Mukai) Department of Cardiovascular Medicine, Japanese Red Cross Fukuoka
Hospital, Fukuoka, Japan
(Inoue) Department of Cardiovascular Medicine, National Hospital
Organization Kyushu Medical Centre, Fukuoka, Japan
(Nishi) Department of Cardiovascular Medicine, Iizuka Hospital, Fukuoka,
Japan
(Tashiro) Department of Cardiovascular Medicine, St. Mary's Hospital,
Fukuoka, Japan
(Funakoshi, Tagawa) Center for Clinical and Translational Research of
Kyushu University Hospital, Fukuoka, Japan
(Ichi) of Humanities and Science, Ochanomizu University, Tokyo, Japan
(Tsutsui) School of Medicine and Graduate School, International University
of Health and Welfare, Fukuoka, Japan
Publisher
Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
Abstract
Background: The effects of evolocumab on coronary endothelial dysfunction
(CED), a hallmark of atherogenesis, are unknown. The aim of this study was
to investigate whether evolocumab, in combination with high-dose statins,
could ameliorate CED in patients who underwent coronary stenting.
<br/>Method(s): The CuVIC-2 trial was a multicenter randomized controlled
trial. CED was defined as intracoronary acetylcholine (ACh)-induced
contractile responses with signs of myocardial ischemia. We originally
intended to enroll 160 participants but altered the study design due to
the COVID-19 pandemic and then recruited 41 participants. The revised
primary endpoint was the coronary contraction rate in response to ACh
assessed in a core laboratory, ensuring a statistical power of over 80 %
using the mixed model for repeated measures. <br/>Result(s): The
evolocumab in combination with high-dose statins with or without ezetimibe
(EV + S) group included 19 males and 4 females aged 62 +/- 13 years. The
high-dose statins with or without ezetimibe (S) group included 13 males
and 5 females aged 64 +/- 11 years. Compared with the S group, the EV + S
group presented a significantly greater decrease in low-density
lipoprotein cholesterol at 28 weeks; 83 +/- 17 to 20 +/- 16 mg/dL (-76 %
from the baseline) in the EV + S group and 88 +/- 16 to 81 +/- 20 mg/dL
(-7 % from the baseline) in the S group (p < 0.0001). At 28 weeks, there
was no difference between the two groups in terms of the coronary artery
constriction rate across all doses [mean difference: 4.8 % (95 % CI: -13.6
to 23.2); p = 0.6]. <br/>Conclusion(s): Amelioration of CED by evolocumab
was not observed in this trial with several limitations.<br/>Copyright
&#xa9; 2025 The Authors

<121>
Accession Number
2038518911
Title
Trends in surgical stabilization of rib fractures: A contemporary
literature review.
Source
Journal of Clinical Orthopaedics and Trauma. 66 (no pagination), 2025.
Article Number: 103028. Date of Publication: 01 Jul 2025.
Author
Masoudi M.; Muchabaiwa R.; Wake E.; Patel B.
Institution
(Wake, Patel) Trauma Service, Gold Coast University Hospital, QLD,
Australia
(Masoudi, Muchabaiwa, Wake) School of Medicine, Griffith University, Gold
Coast, Australia
(Patel) Bond University, Gold Coast, Australia
Publisher
Elsevier B.V.
Abstract
Background: Blunt chest trauma leading to rib fractures is a common
injury, accounting for 20 % of thoracic trauma cases. Surgical
Stabilization of Rib Fractures (SSRF) has gained popularity due to
advancements in surgical techniques and multidisciplinary care, resulting
in improved patient outcomes. Despite a growing body of literature on
SSRF, inconsistencies in study design and outcome reporting limit the
synthesis of findings and the establishment of clear clinical guidelines.
This scoping review aims to provide an overview of the existing SSRF
literature, identifying prevalent trends and reported outcomes.
<br/>Method(s): A systematic scoping review was conducted following Arksey
and O'Malley's framework and the Preferred Reporting Items for Scoping
Reviews (PRISMA) guidelines. The study was registered with Open Science
Framework (8V9KN). A comprehensive search of MEDLINE, EMBASE, CINAHL, and
Cochrane CENTRAL was performed from inception to March 1, 2025. Studies
were included if they reported on SSRF for blunt chest trauma in human
patients. Data extraction focused on study characteristics, patient
demographics, reported outcomes, and methodological rigor. <br/>Result(s):
A total of 1462 articles were screened, with 185 studies meeting the
inclusion criteria. The majority (N = 162, 88 %) were published between
2015 and 2025, with the highest number in 2022. Most studies (N = 144, 78
%) employed a cohort study design, predominantly retrospective (N = 115,
80 %), while randomized controlled trials (RCTs) constituted only 8 % (N =
15). Hospital outcomes, including length of stay (N = 112) and ICU stay (N
= 97), were the most frequently reported measures. Complications were
documented in 124 studies, with pneumonia (N = 90) and mortality (N = 94)
being the most common. Patient-reported outcomes (PROMs) were included in
60 studies (32 %), with pain (N = 46, 78 %) and quality of life (N = 23,
39 %) as key measures. Device and procedural details were reported in 70
studies (38 %), with 62 using the same device. However, variations in
outcome measurement and a predominance of retrospective designs limit
comparability. <br/>Conclusion(s): SSRF literature has expanded
significantly over the past decade, yet inconsistencies in study design
and outcome reporting hinder the development of standardized clinical
guidelines. Future research should prioritize prospective, multi-center
trials with uniform reporting standards to enhance the reliability and
applicability of findings.<br/>Copyright &#xa9; 2025 The Authors

<122>
[Use Link to view the full text]
Accession Number
647153926
Title
Impact of Point-of-care allogeneic red blood cell washing on markers of
transfusion-related respiratory complications: A phase II randomized
clinical trial.
Source
Anesthesiology. (no pagination), 2025. Date of Publication: 14 Apr 2025.
Author
Kor D.J.; Warner M.A.; Norris P.J.; Armour S.; Wittwer E.D.; Santrach
P.J.; Meade L.A.; Conn C.M.; Schulte P.J.; Pendegraft R.S.; Di Germanio
C.; Podgoreanu M.; Welsby I.J.
Institution
(Kor) Professor of Anesthesiology, Department of Anesthesiology and
Perioperative Medicine, Mayo Clinic, Rochester, MN;
(Warner) Associate Professor of Anesthesiology, Division of Critical Care,
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic,
Rochester, MN;
(Norris) VP Research, Vitalant Research Institute, San Francisco, CA,
Professor of Laboratory Medicine, University of California, San Francisco;
(Armour) Assistant Professor of Anesthesiology, Department of
Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN;
(Wittwer) Associate Professor of Anesthesiology, Department of
Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN;
(Santrach) Associate Professor of Laboratory Medicine and Pathology,
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
MN;
(Meade) Registered Nurse, Department of Anesthesiology and Perioperative
Medicine, Mayo Clinic, Rochester, MN;
(Conn) Regulatory Affairs Coordinator, Department of Laboratory Medicine
and Pathology, Mayo Clinic, Rochester, MN;
(Schulte) Professor of Biostatistics, Department of Quantitative Health
Sciences, Mayo Clinic, Rochester, MN;
(Pendegraft) Senior Statistical Programmer, Department of Quantitative
Health Sciences, Mayo Clinic, Rochester, MN;
(Di Germanio) Director, Immunology Core, Vitalant Research Institute, San
Francisco, CA, Assistant Adjunct Professor, Laboratory Medicine,
University of California, San Francisco; cdigermanio@vitalant.org
(Podgoreanu) Associate Professor of Anesthesiology, Department of
Anesthesiology, Duke University Medical Center, Raleigh, NC;
(Welsby) Tenured Professor of Anesthesiology and Critical Care, Professor
of Medicine (Hematology), Co-Director Cardiothoracic Surgical ICU, Duke
University Medical Center, Erwin Road, Durham, NC 27710;
Abstract
BACKGROUND: Transfusion-related acute lung injury (TRALI) and
transfusion-associated circulatory overload (TACO) are leading causes of
transfusion-related morbidity and mortality. Soluble factors in red blood
cell (RBC) supernatant may increase risk for these complications. We
hypothesized that point-of-care allogeneic RBC washing may be an effective
intervention to mitigate elevations in soluble factors as well as
physiologic responses associated with transfusion-associated respiratory
complications in the setting of cardiac surgery. <br/>METHOD(S): This is a
two-center, non-blinded, randomized clinical trial evaluating
point-of-care washed versus standard-issue allogeneic RBC transfusions
administered during or on the day of cardiac surgery. The primary analysis
was performed via modified intention-to-treat. The primary outcomes
assessed were changes in intermediate markers of lung injury as well as
cardiopulmonary physiologic responses to RBC transfusion. Secondary
outcomes included the duration of intensive care unit and hospital stay,
durations of mechanical ventilation and oxygen supplementation, presence
of TRALI or TACO, and mortality. <br/>RESULT(S): Among 154 analyzed
patients (81 washed, 73 standard issue), median age was 66 years and 77
(50.0%) were women. The median (IQR) number of allogeneic RBC units
transfused on the day of surgery was 3.0 (2.0 - 5.0) in the washed RBC
group and 3.0 (2.0 - 4.0) in the standard issue group (p = 0.13). No
between-group differences were identified in any of the assessed recipient
lung injury biomarkers (all p-values > adjusted alpha). Durations of
intensive care unit stay (median [interquartile range]; 3.0 [2.0-5.0]
versus 3.0 [2.0-4.0] days; p = 0.117) and hospital length of stay (12.0
[9.0-17.0] versus 12.0 [9.0-17.0] days; p = 0.801) were similar, as were
the number of ventilator-free days at day 28 (27.0 [27.0-27.0] versus 27.0
[26.0-27.0]; p = 0.699) and oxygen free days at day 28 (24.0 [19.0-26.0]
versus 24.0 [22.0-26.0]; p = 0.400) . No significant differences were
noted in mortality rate nor in incidence rates for TRALI, TACO, and acute
kidney injury. <br/>CONCLUSION(S): Among patients undergoing
cardiovascular surgery with high risk of RBC transfusion, point-of-care
washing of allogeneic RBC transfusions did not mitigate changes in
intermediate markers of lung injury or cardiopulmonary physiologic
responses to RBC transfusion and was not associated with improved clinical
outcomes.<br/>Copyright &#xa9; 2025 American Society of Anesthesiologists.
All Rights Reserved.

<123>
Accession Number
647145649
Title
Statistical primer: An introduction into the principles of Bayesian
statistical analyses in clinical trials.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. (no pagination), 2025.
Date of Publication: 12 Apr 2025.
Author
Heuts S.; Kawczynski M.J.; Velders B.J.J.; Brophy J.M.; Hickey G.L.;
Kowalewski M.
Institution
(Heuts, Kawczynski, Kowalewski) Department of Cardiothoracic Surgery,
Maastricht University Medical Centre (MUMC+), Maastricht, Netherlands
(Heuts, Kawczynski) Cardiovascular Research Institute Maastricht (CARIM),
Maastricht University, Maastricht, Netherlands
(Velders) Department of Cardiothoracic Surgery, Leiden University Medical
Centre, Leiden, Netherlands
(Brophy) McGill University Health Centre, Centre for Health Outcome
Research (CORE), Montreal, QC, Canada
(Hickey) Structural Heart and Aortic, Medtronic, Minneapolis, MN, United
States
(Kowalewski) Department of Cardiac Surgery and Transplantology, National
Medical Institute of the Ministry of Interior and Administration, Warsaw,
Poland
Abstract
Trials in cardiac surgery are often hampered at the design level by small
sample sizes and ethical considerations. The conventional analytical
approach, combining frequentist statistics with null hypothesis
significance testing, has known limitations and its associated p-values
are often misinterpreted, leading to dichotomous conclusions of trial
results. The Bayesian statistical framework may overcome these limitations
through probabilistic reasoning, and is subsequently introduced in this
Primer. The Bayesian framework combines prior beliefs and currently
obtained data (the likelihood), resulting in updated beliefs, also known
as posterior distributions. These distributions subsequently facilitate
probabilistic interpretations. Several previous cardiac surgery trials
have been performed under a Bayesian framework and this Primer enhances
the understanding of their basic concepts by linking results to graphical
presentations. Furthermore, contemporary trials that were initially
analysed under a frequentist framework, are re-analysed within a Bayesian
framework to demonstrate several interpretative advantages.<br/>Copyright
&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf
of the European Association for Cardio-Thoracic Surgery.

<124>
Accession Number
2034340725
Title
Non-Severe Hypophosphatemia in Older Patients: A Systematic Review.
Source
Nutrients. 17(8) (no pagination), 2025. Article Number: 1354. Date of
Publication: 01 Apr 2025.
Author
Barbarossa L.; Zandona M.; Garo M.L.; Mjahed R.B.; D'Amelio P.
Institution
(Barbarossa) Geriatric Service, Clinica Luganese di Moncucco, Lugano,
Switzerland
(Zandona) Family Medicine Institute, Ente Ospedaliero Cantonale, Lugano,
Switzerland
(Garo) Biostatistic Unit, Mathsly Research, Rome, Italy
(Mjahed, D'Amelio) Service of Geriatric Medicine and Geriatric
Rehabilitation, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne,
Switzerland
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Phosphorus plays a fundamental role in cellular and
extracellular metabolism, contributing to nucleic acid synthesis,
enzymatic activity, neurologic function, and skeletal mineralization.
Despite its significance, non-severe hypophosphatemia (HP) remains largely
asymptomatic and underdiagnosed, with limited data on its prevalence in
the general population. Most studies focus on specific subgroups, such as
critically ill or dialysis patients, while the impact of mild HP in older
adults, a potentially vulnerable demographic, is not well understood. The
objective of this systematic review is to investigate the prevalence and
clinical implications of non-severe HP in older adults. <br/>Method(s):
The study followed PRISMA guidelines to assess HP in patients aged >= 65
years without critical illnesses or genetic disorders. A systematic search
was conducted in PubMed, Web of Science, and Scopus (March 2024). Eligible
studies included RCTs and prospective/retrospective studies, excluding
cancer-related studies or insufficient phosphate data. <br/>Result(s): We
identified 1350 articles, with 26 meeting eligibility criteria.
Ultimately, eight studies involving 26,548 patients were included, with an
HP prevalence of 12.5%. Studies reveal a higher prevalence of HP in frail
individuals, particularly those with increased frailty scores, and an
association between HP and cognitive decline, depressed mood, falls, and
chronic comorbidities. HP was also prevalent in infectious diseases,
especially bacterial pneumonia, with longer hospital stays and increased
mortality rates. Malnutrition was significantly more common in HP
patients, characterized by weight loss and poor nutritional status.
Furthermore, HP increased fall risk during hospitalization and worsened
outcomes after coronary artery bypass graft surgery, including higher
mortality and graft failure rates, underscoring its clinical importance.
<br/>Discussion(s): This review identified that non-severe
hypophosphatemia (HP) is associated with conditions such as frailty,
cognitive decline, and an increased risk of falls. The evidence suggests
that low phosphate levels may negatively impact health, increasing
mortality and the risk of adverse clinical outcomes. Despite limitations
in diagnostic criteria and sample variability, the findings indicate that
HP can be a useful marker for identifying patients at risk of health
deterioration. Further research is needed to clearly define the management
and treatment of HP in this vulnerable population.<br/>Copyright &#xa9;
2025 by the authors.

<125>
Accession Number
647160298
Title
Empagliflozin in Patients With Type 2 Diabetes Undergoing On-Pump CABG:
The POST-CABGDM Randomized Clinical Trial.
Source
Diabetes care. (no pagination), 2025. Date of Publication: 15 Apr 2025.
Author
Pitta F.G.; Lima E.G.; Tavares C.A.M.; Martins E.B.; Rached F.H.; Moreira
E.M.; Mioto B.M.; Lottenberg S.A.; Bolta P.M.P.; Justino L.G.; Favarato
D.; Carvalho L.N.S.; Pinesi H.T.; Barbosa C.T.M.; Dallan L.A.O.; Dallan
L.R.P.; Barbosa M.H.M.; Kalil Filho R.; de Lemos J.A.; Serrano C.V.
Institution
(Pitta, Lima, Tavares, Martins, Rached, Moreira, Mioto, Bolta, Justino,
Favarato, Carvalho, Pinesi, Barbosa, Dallan, Dallan, Barbosa, Kalil Filho,
Serrano) Instituto do coracao, Hospital das Clinicas Hospital das Clinicas
da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Faculdade
de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
(Pitta, Tavares, Martins, Rached, Mioto, Lottenberg, Pinesi, Barbosa,
Barbosa, Serrano) Hospital Israelita Albert Einstein, Sao Paulo, Brazil
(Lima) Hospital Nove de Julho, Sao Paulo, Brazil
(Lottenberg) Servico de endocrinologia e metabolismo, Hospital das
Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao
Paulo, Brazil
(de Lemos) Division of Cardiology, Department of Internal Medicine,
University of Texas Southwestern Medical Center, Dallas, TX, United States
Abstract
OBJECTIVE: To evaluate the efficacy and safety of empagliflozin in
patients with type 2 diabetes mellitus (T2DM) undergoing elective on-pump
coronary artery bypass grafting (CABG). RESEARCH DESIGN AND METHODS:
Investigator-initiated, pragmatic, single-center, randomized, open-label
trial with blinded outcome adjudication conducted in Brazil. A total of
145 patients with T2DM scheduled for elective on-pump CABG were randomized
to receive empagliflozin 25 mg daily plus standard care (n = 71) for at
least 3 months, which was discontinued 72 h before surgery, or to received
standard care alone (n = 74). The primary outcome was postoperative acute
kidney injury (AKI) within 7 days of surgery, defined by creatinine-based
criteria (namely, Acute Kidney Injury Network; Risk, Injury, Failure, Loss
of Kidney Function, and End-Stage Kidney Disease; or Kidney Disease:
Improving Global Outcomes). Secondary outcomes included 30-day
postoperative atrial fibrillation and type 5 myocardial infarction (MI).
Safety outcomes were ketoacidosis, urinary tract infection,
hospital-acquired pneumonia, and wound infection within 30 days after
CABG. <br/>RESULT(S): AKI occurred in 22.5% of the empagliflozin group vs.
39.1% in the control group (relative risk [RR] 0.57 [95% CI 0.34-0.96]; P
= 0.03). Rates of atrial fibrillation (15.4% vs. 13.5%; RR 1.15 [95% CI
0.52-2.53]; P = 0.73) and type 5 MI (1.4% vs. 4.1%; RR 0.35 [95% CI
0.04-3.26]; P = 0.62) were similar between groups. No statistically
significant differences between groups were observed for safety events.
Three deaths occurred, all in the control group. <br/>CONCLUSION(S):
Empagliflozin use before on-pump CABG in patients with T2DM was associated
with a reduced incidence of postoperative AKI without an increase in
safety events. These findings warrant confirmation in larger clinical
trials.<br/>Copyright &#xa9; 2025 by the American Diabetes Association.

<126>
Accession Number
2034333632
Title
Frailty in Cardiac Surgery-Assessment Tools, Impact on Outcomes, and
Optimisation Strategies: A Narrative Review.
Source
Journal of Cardiovascular Development and Disease. 12(4) (no pagination),
2025. Article Number: 127. Date of Publication: 01 Apr 2025.
Author
Chandiramani A.; Ali J.M.
Institution
(Chandiramani) Department of Cardiology, Royal Papworth Hospital,
Cambridge, United Kingdom
(Ali) Department of Cardiac Surgery, Royal Papworth Hospital, Cambridge,
United Kingdom
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Advancements in surgical care have made it possible to offer
cardiac surgery to an older and frailer patient cohort. Frailty has been
recognised as a prognostic indicator that impacts post-operative recovery
and patient outcomes. The aim of this study is to identify frailty
assessment tools, evaluate the impact of frailty on post-operative
outcomes, and explore strategies to optimise care for frail patients
undergoing cardiac surgery. <br/>Method(s): A comprehensive literature
search was performed across PubMed, MEDLINE, and SCOPUS to identify
articles reporting post-operative outcomes related to frail patients
undergoing cardiac surgery. <br/>Result(s): Measurement tools such as gait
speed, the Clinical Frailty Scale, Fried frailty phenotype, deficit
accumulation frailty index and the Short Physical Performance Battery can
be used to assess frailty. Frailty has been reported to increase the risk
of post-operative morbidity and mortality. Multiple studies have also
reported the association between frailty and an increased length of
intensive care unit and hospital stays, as well as an increased risk of
post-operative delirium. It is important to perform a comprehensive
frailty assessment and implement perioperative optimisation strategies to
improve outcomes in this patient population. Pre-operative strategies that
can be considered include adequate nutritional support, cardiac
prehabilitation, and assessing patients using a multidisciplinary team
approach with geriatric involvement. Post-operatively, interventions such
as early recognition and treatment of post-operative delirium, nutrition
optimisation, early planning for cardiac rehabilitation, and occupational
therapy can support patients' recovery and reintegration into daily
activities. <br/>Conclusion(s): The early identification of frail patients
during the perioperative period is essential for risk stratification and
tailored management strategies to minimise the impact of frailty on
outcomes following cardiac surgery.<br/>Copyright &#xa9; 2025 by the
authors.

<127>
Accession Number
647150694
Title
5th National Congress of Dematocosmetics Sciences and 4th Congress of
Portuguese Society of Science Cosmetological.
Source
Biomedical and Biopharmaceutical Research. Conference: 5th National
Congress of Dematocosmetics Sciences and 4th Congress of Portuguese
Society of Science Cosmetological. Lisboa Portugal. 12(1) (no pagination),
2015. Date of Publication: 2015.
Author
Anonymous
Publisher
ALIES
Abstract
The proceedings contain 35 papers. The topics discussed include: removal
of alpha-Gal xenogenic barrier from bioprosthetic heart valve substitutes
for improvement in cardiopathic patients life length and quality;
hemorheology and vascular diseases; galectin 3 levels after running - a
systematic review and perspective; physiological computing: using vascular
signals for something completely different; opportunities for direct
digital manufacturing in vascular research; identification of
differentially expressed proteins in atherosclerotic patients with type 2
diabetes; comparing the oscillatory properties of the LDF signal recorded
from subjects with different ages during a passive leg raising test; and
endothelium-dependent vasoactivity of the human internal mammary artery:
the influence of cardiovascular risk factors.